MICROBIAL CONSORTIA

Abstract

The present disclosure provides microbial consortia, and methods of making and using the same, comprising a complete microbiome replacement capable of stable engraftment in the gastrointestinal tract for the treatment of IBD, ulcerative colitis, and Crohn's disease.

Description

MICROBIAL CONSORTIA Cross-referencing related requests

[0001] This application claims priority to Provisional Patent Application No. US 63 / 451,442, filed March 10, 2023, and to Provisional Patent Application No. US 63 / 469,080, filed May 26, 2023, the content of which is incorporated in its entirety and for which priority is claimed. Sequence listing

[0002] This application contains a Sequence Listing that was submitted electronically in XML format and is incorporated herein by reference in its entirety. The XML copy, created on March 7, 2024, is named 0915920112.xml and is 393,216 bytes in size. Field of invention

[0003] This disclosure relates to microbial consortia for the treatment of intestinal dysbiosis and / or irritable bowel syndrome. Background

[0004] The gastrointestinal tract comprises several biological niches along its longitudinal length with different physical, chemical, and nutritional compositions. As a consequence of these diverse conditions, specific microbial communities are established in a specific biological niche. The microbial species that make up a specific microbial community are highly responsive to their local environment and produce a series of bioactive molecules that facilitate grafting onto the host, intermicrobial communication, nutrient metabolism, and the inclusion or exclusion of competing microbial species. To further increase the complexity, there is substantial diversity of microbial species and strains in the human gastrointestinal tract among individuals, which is attributed to several factors, including genetics, diet, antibiotic and antifungal use, and surgical intervention (e.g., bypass). Petition 870250102358, dated 07 / 11 / 2025, page 10 / 280 2 / 227 gastric / intestinal resection), presence of inflammatory bowel disease and / or irritable bowel syndrome, and other environmental influences. However, despite this interindividual diversity, the functional attributes of the variable human gut microbiota are relatively consistent among healthy adults and comprise the main metabolic pathways involved in carbohydrate metabolism, amino acid metabolism, fermentation, and oxidative phosphorylation.

[0005] The modulation of microbial species in the gastrointestinal tract through the use of antibiotics, antifungals, and, more recently, fecal microbial transplantation (FMT), has been a clinically investigated approach for the treatment and / or prevention of certain diseases and disorders. For example, Dodd et al. (N^alaiaree, 2007, 551: 648-652) proposed FMT as a therapy to modulate the levels of aromatic amino acid metabolites in the serum of gnotobiotic mice, which affect intestinal permeability and systemic immunity.

[0006] As a treatment modality for various diseases and / or conditions, there is a need for microbial compositions that include a plurality of microbial species with enhanced therapeutic efficacy and the ability to efficiently enter a host, grow, and metabolize pathogenic substrates into non-pathogenic metabolic products in the various biological niches of the gastrointestinal tract and in the diverse gastrointestinal environments of different individuals. Furthermore, there is an unmet need for disease treatment using a complex microbial community that can graft and function symbiotically in the human gastrointestinal tract for the degradation of a disease-associated metabolic substrate. Summary of the invention

[0007] This disclosure provides methods for preventing, reducing, and / or treating dysbiosis in an individual. In certain embodiments, the methods comprise the administration of a Petition 870250102358, dated 07 / 11 / 2025, page 11 / 280 3 / 227 effective quantity of a microbial consortium or pharmaceutical composition comprising: a) Clostridium citoniae, Bacteroides salyersiae, Blautia obeum, Parabacteroides merdae, Parabacteroides distasonis, Anaerostipes hadrus, Lachnospiraceae sp. FBI00033, Eubacterium eligens, Bifidobacterium dentium, Blautia wexlerae, Fusicatenibacter saccharivorans, Bacteroides nordii, Dorea formicigenerans, Dorea longicatena, Bacteroides stercorirosoris, Bifidobacterium longum, Bacteroides kribbi, Lachnospiraceae sp. FBI00071, Bacteroides thetaiotaomicron, Clostridium clostridioforme, Clostridium scindens, Roseburia hominis, Clostridium fessum, Coprococcus comes, Blautia faecis, Hungatella hathewayi, Bacteroides stercoris, Collinsella aerofaciens, Hungatella effluvii, Bifidobacterium adolescentis, Bifidobacterium catenulatum, Lactobacillus rogosae, Bacteroides faecis, Bacteroides finegoldii, Clostridiaceae sp.FBI00191, Ruminococcus faecis, Lachnoclostridium pacaense, Clostridium bolteae, Longicatena caecimuris, Eggerthella lenta, Blautia massiliensis, Bacteroides xylanisolvens, Bacteroides vulgatus, Megasphaera massiliensis, Butyricimonas faecihominis, Eisenbergiella tayi, Acidaminococcus intestini, Emergence timonensis, Bifidobacterium pseudocatenulatum, Eubacterium hallii, Anaerofustis stercorihominis, Eubacterium ventriosum, Blautia hydrogenotrophica and Lachnospiraceae sp. FBI00290, or a functional equivalent thereof; or. b) FBI00001, FBI00002, FBI00010, FBI00013, FBI00029, FBI00032, FBI00033, FBI00034, FBI00043, FBI00044, FBI00048, FBI00050, FBI00051, FBI00057, FBI00059, FBI00060, FBI00070, FBI00071, FBI00076, FBI00079, FBI00087, FBI00093, FBI00102, FBI00109, FBI00117, FBI00120, FBI00125, FBI00127, FBI00128, FBI00145, FBI00162, FBI00174, FBI00184, FBI00190, FBI00191, FBI00194, FBI00198, FBI00199, FBI00200, FBI00201, FBI00205, FBI00206, FBI00211, FBI00220, FBI00221, FBI00236, FBI00245, Petition 870250102358, dated 07 / 11 / 2025, page 12 / 280 4 / 227 FBI00248, FBI00251, FBI00254, FBI00267, FBI00278, FBI00288 and FBI00290, or a functional equivalent thereof.

[0008] In certain embodiments, the microbial consortium or a pharmaceutical composition thereof additionally comprises: a) Acutalibacter timonensis, Alistipes onderdonkii, Bacteroides uniformis, Eubacterium rectale, Alistipes timonensis, Bacteroides kribbi, Coprococcus eutactus, Bilophila wadsworthia, Bacteroides caccae, Alistipes shahii, Parasutterella excrementihominis, Paraprevotella clara, Sutterella wadsworthensis, Sutterella massiliensis, Porphyromonas asaccharolytica, Ruminococcus bromii, Monoglobus pectinolyticus, Ruminococcaceae sp. FBI00097, Gordonibacter pamelaeae, Bacteroides uniformis, Gordonibacter pamelaeae, Bacteroides fragilis, Phascolarctobacterium faecium, Monoglobus pectinolyticus, Clostridium aldenense, Ruthenibacterium lactatiformans, Bacteroides ovatus, Bifidobacterium bifidum, Anaerotruncus massiliensis, Clostridium aldenense, Sutterella wadsworthensis, Catabacter hongkongensis, Alistipes senegalensis, Ruminococcaceae sp.FBI00233, Alistipes shahii, Dielma fastidiosa, Eubacterium siraeum, Faecalibacterium prausnitzii, Turicibacter sanguinis, Eubacterium rectale, Bacteroides caccae, Methanobrevibacter smithii, Barnesiella intestinihominis, Alistipes onderdonkii and Methanobrevibacter smithii, or a functional equivalent thereof;. b) Bifidobacterium adolescentis, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Bacteroides thetaiotaomicron, Coprococcus comes, Fusicatenibacter saccharivorans, Eggerthella lenta, Eubacterium eligens, Bacteroides xylanisolvens, Lactobacillus rogosae, Clostridium citroniae, Collinsella aerofaciens, Blautia obeum, Eggerthella lenta, Blautia wexlerae, Lachnoclostridium pacaense, Bacteroides vulgatus, Parabacteroides merdae, Dorea formicigenerans, Petition 870250102358, dated 07 / 11 / 2025, p. 13 / 280 5 / 227 Ruminococcus faecis, Roseburia hominis, Anaerostipes hadrus, Bifidobacterium adolescentis, Bifidobacterium pseudocatenulatum, Clostridium bolteae, Eisenbergiella tayi, Dorea longicatena, Eggerthella lenta, Bacteroides stercoris, Hungatella hathewayi, and Bacteroides xylanisolvens, or a functional equivalent thereof; and / or c) Alistipes putredinis, Dialister succinatiphilus, Akkermansia muciniphila, Ruminococcus bromii, Dialister invisus, Bacteroides massiliensis, Bilophila wadsworthia, Holdemanella biformis, Parasutterella excrementihominis, Alistipes sp. FBI00180, Bacteroides coprocola, Alistipes sp. FBI00238, Alistipes putredinis, Eubacterium xylanophilum, and Senegalmassilia anaerobia, or a functional equivalent thereof.

[0009] Em determinadas modalities, o consórcio microbialo ou uma composizione farmacêutica do mesmo comprède additionally: a) FBI00004, FBI00012, FBI00015, FBI00018, FBI00019, FBI00021, FBI00038, FBI00040, FBI00046, FBI00061, FBI00066, FBI00075, FBI00077, FBI00080, FBI00081, FBI00085, FBI00092, FBI00097, FBI00099, FBI00112, FBI00132, FBI00137, FBI00140, FBI00149, FBI00151, FBI00176, FBI00189, FBI00197, FBI00208, FBI00212, FBI00224, FBI00226, FBI00229, FBI00233, FBI00235, FBI00237, FBI00243, FBI00244, FBI00258, FBI00260, FBI00263, FBI00270, FBI00273, FBI00277, and FBI00292, or a functional equivalent thereof; b) FBI00009, FBI00011, FBI00016, FBI00020, FBI00025, FBI00027, FBI00030, FBI00047, FBI00052, FBI00053, FBI00056, FBI00062, FBI00078, FBI00096, FBI00104, FBI00110, FBI00111, FBI00113, FBI00115, FBI00116, FBI00123, FBI00124, FBI00126, FBI00135, FBI00147, FBI00159, FBI00167, FBI00170, FBI00232, FBI00255 and FBI00271 or one or a functional equivalent thereof; and / or Petition 870250102358, dated 07 / 11 / 2025, page 14 / 280 6 / 227 c) FBI00022, FBI00049, FBI00068, FBI00069, FBI00152, FBI00165, FBI00171, FBI00175, FBI00177, FBI00180, FBI00182, FBI00238, FBI00269, FBI00274 and FBI00281, or a functional equivalent thereof.

[0010] In certain embodiments, the microbial consortium or a pharmaceutical composition thereof further comprises a first strain of Oxalobacter formigenes or FBI00067. In certain embodiments, the microbial consortium or a pharmaceutical composition thereof further comprises a second strain of Oxalobacter formigenes or FBI00133. In certain embodiments, the microbial consortium or a pharmaceutical composition thereof further comprises a third strain of Oxalobacter formigenes or FBI00289.

[0011] In certain embodiments, the microbial consortium or a pharmaceutical composition thereof comprises: a) Clostridium citoniae, Bacteroides salyersiae, Blautia obeum, Parabacteroides merdae, Parabacteroides distasonis, Anaerostipes hadrus, Lachnospiraceae sp. FBI00033, Eubacterium eligens, Bifidobacterium dentium, Blautia wexlerae, Fusicatenibacter saccharivorans, Bacteroides nordii, Dorea formicigenerans, Dorea longicatena, Bacteroides stercorirosoris, Bifidobacterium longum, Bacteroides kribbi, Lachnospiraceae sp. FBI00071, Bacteroides thetaiotaomicron, Clostridium clostridioforme, Clostridium scindens, Roseburia hominis, Clostridium fessum, Coprococcus comes, Blautia faecis, Hungatella hathewayi, Bacteroides stercoris, Collinsella aerofaciens, Hungatella effluvii, Bifidobacterium adolescentis, Bifidobacterium catenulatum, Lactobacillus rogosae, Bacteroides faecis, Bacteroides finegoldii, Clostridiaceae sp.FBI00191, Ruminococcus faecis, Lachnoclostridium pacaense, Clostridium bolteae, Longicatena caecimuris, Eggerthella lenta, Blautia massiliensis, Bacteroides xylanisolvens, Bacteroides vulgatus, Megasphaera massiliensis, Butyricimonas faecihominis,. Petition 870250102358, dated 07 / 11 / 2025, p. 15 / 280 7 / 227 Eisenbergiella tayi , Acidaminococcus intestini, Emergence timonensis, Bifidobacterium pseudocatenulatum, Eubacterium hallii, Anaerofustis stercorihominis, Eubacterium ventriosum, Blautia hydrogenotrophica and Lachnospiraceae sp. FBI00290, or a functional equivalent thereof; b) Acutalibacter timonensis, Alistipes onderdonkii, Bacteroides uniformis, Eubacterium rectale, Alistipes timonensis, Bacteroides kribbi, Coprococcus eutactus, Bilophila wadsworthia, Bacteroides caccae, Alistipes shahii, Parasutterella excrementihominis, Paraprevotella clara, Sutterella wadsworthensis, Sutterella massiliensis, Porphyromonas asaccharolytica, Ruminococcus bromii, Monoglobus pectinolyticus, Ruminococcaceae sp. FBI00097, Gordonibacter pamelaeae, Bacteroides uniformis, Gordonibacter pamelaeae, Bacteroides fragilis, Phascolarctobacterium faecium, Monoglobus pectinolyticus, Clostridium aldenense, Ruthenibacterium lactatiformans, Bacteroides ovatus, Bifidobacterium bifidum, Anaerotruncus massiliensis, Clostridium aldenense, Sutterella wadsworthensis, Catabacter hongkongensis, Alistipes senegalensis, Ruminococcaceae sp.FBI00233, Alistipes shahii, Dielma fastidiosa, Eubacterium siraeum, Faecalibacterium prausnitzii, Turicibacter sanguinis, Eubacterium rectale, Bacteroides caccae, Methanobrevibacter smithii, Barnesiella intestinihominis, Alistipes onderdonkii and Methanobrevibacter smithii, or a functional equivalent thereof;. c) Bifidobacterium adolescentis, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Bacteroides thetaiotaomicron, Coprococcus comes, Fusicatenibacter saccharivorans, Eggerthella lenta, Eubacterium eligens, Bacteroides xylanisolvens, Lactobacillus rogosae, Clostridium citroniae, Collinsella aerofaciens, Blautia obeum, Eggerthella lenta, Blautia wexlerae, Lachnoclostridium pacaense, Bacteroides vulgatus, Parabacteroides merdae, Dorea formicigenerans, Petition 870250102358, dated 07 / 11 / 2025, p. 16 / 280 8 / 227 Ruminococcus faecis, Roseburia hominis, Anaerostipes hadrus, Bifidobacterium adolescentis, Bifidobacterium pseudocatenulatum, Clostridium bolteae, Eisenbergiella tayi, Dorea longicatena, Eggerthella lenta, Bacteroides stercoris, Hungatella hathewayi, and Bacteroides xylanisolvens, or a functional equivalent thereof; and d) Alistipes putredinis, Dialister succinatiphilus, Akkermansia muciniphila, Ruminococcus bromii, Dialister invisus, Bacteroides massiliensis, Bilophila wadsworthia, Holdemanella biformis, Parasutterella excrementihominis, Alistipes sp. FBI00180, Bacteroides coprocola, Alistipes sp. FBI00238, Alistipes putredinis, Eubacterium xylanophilum and Senegalmassilia anaerobia, or a functional equivalent thereof.

[0012] Em determinadas modalities, o consórcio microbialo ou uma composizione farmacêutica do mesmo comprèze: a) FBI00001, FBI00002, FBI00010, FBI00013, FBI00029, FBI00032, FBI00033, FBI00034, FBI00043, FBI00044, FBI00048, FBI00050, FBI00051, FBI00057, FBI00059, FBI00060, FBI00070, FBI00071, FBI00076, FBI00079, FBI00087, FBI00093, FBI00102, FBI00109, FBI00117, FBI00120, FBI00125, FBI00127, FBI00128, FBI00145, FBI00162, FBI00174, FBI00184, FBI00190, FBI00191, FBI00194, FBI00198, FBI00199, FBI00200, FBI00201, FBI00205, FBI00206, FBI00211, FBI00220, FBI00221, FBI00236, FBI00245, FBI00248, FBI00251, FBI00254, FBI00267, FBI00278, FBI00288 e FBI00290, ou um equivalente funcional dos mesmos; b) FBI00004, FBI00012, FBI00015, FBI00018, FBI00019, FBI00021, FBI00038, FBI00040, FBI00046, FBI00061, FBI00066, FBI00075, FBI00077, FBI00080, FBI00081, FBI00085, FBI00092, FBI00097, FBI00099, FBI00112, FBI00132, FBI00137, FBI00140, FBI00149, FBI00151, FBI00176, FBI00189, FBI00197, FBI00208, FBI00212, FBI00224, FBI00226, FBI00229, FBI00233, FBI00235, FBI00237, FBI00243, FBI00244, FBI00258, FBI00260, FBI00263, Petition 870250102358, dated 07 / 11 / 2025, page 17 / 280 9 / 227 FBI00270, FBI00273, FBI00277 and FBI00292, or a functional equivalent thereof; c) FBI00009, FBI00011, FBI00016, FBI00020, FBI00025, FBI00027, FBI00030, FBI00047, FBI00052, FBI00053, FBI00056, FBI00062, FBI00078, FBI00096, FBI00104, FBI00110, FBI00111, FBI00113, FBI00115, FBI00116, FBI00123, FBI00124, FBI00126, FBI00135, FBI00147, FBI00159, FBI00167, FBI00170, FBI00232, FBI00255 and FBI00271, or a functional equivalent thereof; ed) FBI00022, FBI00049, FBI00068, FBI00069, FBI00152, FBI00165, FBI00171, FBI00175, FBI00177, FBI00180, FBI00182, FBI00238, FBI00269, FBI00274 and FBI00281, or a functional equivalent thereof.

[0013] In certain embodiments, the microbial consortium or a pharmaceutical composition thereof further comprises a first strain of Oxalobacter formigenes or FBI00067, a second strain of Oxalobacter formigenes or FBI00133, and a third strain of Oxalobacter formigenes or FBI00289. In certain embodiments, the microbial consortium or a pharmaceutical composition thereof further comprises a first strain of Oxalobacter formigenes or FBI00067, a second strain of Oxalobacter formigenes or FBI00133, and a third strain of Oxalobacter formigenes or FBI00289. In certain embodiments, the microbial consortium or a pharmaceutical composition thereof is FB-001 or a functional equivalent thereof. In certain embodiments, the microbial consortium or a pharmaceutical composition thereof is FB-003 or a functional equivalent thereof.

[0014] In certain embodiments, the microbial consortium or a pharmaceutical composition thereof increases the microbial diversity of the gastrointestinal tract. In certain embodiments, the microbial consortium or a pharmaceutical composition thereof increases short-chain fatty acids (SCFAs). In certain embodiments, the microbial consortium or Petition 870250102358, dated 07 / 11 / 2025, page 18 / 280 10 / 227 a pharmaceutical composition thereof increases secondary bile acids. In certain embodiments, the microbial consortium or a pharmaceutical composition thereof decreases bacterial pathogens in the individual's gastrointestinal tract.

[0015] In certain embodiments, the microbial consortium or a pharmaceutical composition thereof comprises between approximately 5 x 10⁹ and approximately 5 x 10¹² viable cells. In certain embodiments, the microbial consortium or a pharmaceutical composition thereof comprises between approximately 5 x 10⁹ and approximately 5 x 10¹⁰ viable cells. In certain embodiments, the microbial consortium or a pharmaceutical composition thereof comprises between approximately 5 x 10¹⁰ and approximately 5 x 10¹¹ viable cells. In certain embodiments, the microbial consortium or a pharmaceutical composition thereof comprises between approximately 5 x 10¹¹ and approximately 5 x 10¹² viable cells. In certain embodiments, the microbial consortium or a pharmaceutical composition thereof comprises up to approximately 10¹¹ viable cells. In certain embodiments, the microbial consortium or a pharmaceutical composition thereof comprises up to approximately 1012 viable cells.

[0016] In certain embodiments, the methods comprise the administration of a loading dose and one or more maintenance doses. In certain embodiments, the loading dose is administered for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, or 10 days. In certain embodiments, the loading dose is administered for 2 to 3 days, 3 to 5 days, 4 to 6 days, or 5 to 7 days. In certain embodiments, one or more maintenance doses are administered for at least 21 days after the last loading dose.

[0017] In certain embodiments, the methods additionally comprise the administration of an antibacterial agent, an antiviral agent, an antifungal agent, an anti-inflammatory agent, an immunosuppressive agent and / or a prebiotic. In Petition 870250102358, dated 07 / 11 / 2025, page 19 / 280 11 / 227 In certain modalities, the antibacterial agent is selected from the group consisting of ciprofloxacin, levaquin, floxin, tequin, avelox, norflox, cephalexin, cefuroxime, cefadroxil, cefazolin, cephalothin, cefaclor, cefamandole, cefoxitin, cefprozil, ceftobiprole, amoxicillin, ampicillin, penicillin V, dicloxacillin, carbenicillin, vancomycin and methicillin, tetracycline, minocycline, oxytetracycline, doxycycline, ertapenem, doripenem, imipenem / cilastatin and meropenem.In certain modalities, the antiviral agent is selected from the group consisting of abacavir, acyclovir, adefovir, amprenavir, atazanavir, cidofovir, darunavir, delavirdine, didanosine, docosanol, efavirenz, elvitegravir, emtricitabine, enfuvirtide, etravirine, famciclovir, foscamet, fomivirsen, ganciclovir, indinavir, idoxuridine, lamivudine, lopinavir, maraviroc, MK-2048, nelfinavir, nevirapine, nirmatrelvir, penciclovir, raltegravir, rilpivirine, ritonavir, saquinavir, stavudine, tenofovir, trifluridine, valacyclovir, valganciclovir, vidarabine, ibacitabine, amantadine, oseltamivir, rimantidine, tipranavir, zalcitabine, zanamivir and zidovudine.In certain embodiments, the antifungal agent is selected from the group consisting of miconazole, ketoconazole, clotrimazole, econazole, omoconazole, bifonazole, butoconazole, fenticonazole, isoconazole, oxiconazole, sertaconazole, sulconazole, tioconazole, fluconazole, itraconazole, isavuconazole, ravuconazole, posaconazole, voriconazole, terconazole, albaconazole, abafungin, terbinafine, naftifine, butenafine, anidulafungin, caspofungin, micafungin, poligodial, benzoic acid, ciclopirox, tolnaftate, undecylenic acid, flucytosine or 5-fluorocytosine, griseofulvin, and haloprogin. In certain modalities, the anti-inflammatory and / or immunosuppressive agent is selected from the group consisting of cyclophosphamide, mycophenolate mofetil, corticosteroids, mesalazine, mesalamine, sulfasalazine, sulfasalazine derivatives. Petition 870250102358, dated 07 / 11 / 2025, page 20 / 280 12 / 227 Cyclosporine A, mercaptopurine, azathiopurine, prednisone, methotrexate, antihistamines, glucocorticoids, epinephrine, theophylline, sodium cromoglycate, antileukotrienes, anticholinergics, anti-IgE monoclonal antibodies, immunomodulatory peptides, small immunomodulatory molecules, immunomodulatory cytokines, immunomodulatory antibodies, and vaccines. In certain embodiments, the prebiotic is selected from the group consisting of amino acids, biotin, fructooligosaccharides, galacto-oligosaccharides, inulin, lactulose, mannan-oligosaccharides, oligofructose-enriched inulin, oligofructose, oligodextrose, tagatose, transgalactooligosaccharide, and xylo-oligosaccharides.

[0018] In certain embodiments, the microbial consortium or its pharmaceutical composition is present in a food product.

[0019] This disclosure also offers methods for restoring the microbiome and / or recovering a healthy microbiome in an individual. In certain embodiments, the methods comprise administering an effective amount of a microbial consortium or pharmaceutical composition comprising: a) Clostridium citoniae, Bacteroides salyersiae, Blautia obeum, Parabacteroides merdae, Parabacteroides distasonis, Anaerostipes hadrus, Lachnospiraceae sp. FBI00033, Eubacterium eligens, Bifidobacterium dentium, Blautia wexlerae, Fusicatenibacter saccharivorans, Bacteroides nordii, Dorea formicigenerans, Dorea longicatena, Bacteroides stercorirosoris, Bifidobacterium longum, Bacteroides kribbi, Lachnospiraceae sp. FBI00071, Bacteroides thetaiotaomicron, Clostridium clostridioforme, Clostridium scindens, Roseburia hominis, Clostridium fessum, Coprococcus comes, Blautia faecis, Hungatella hathewayi, Bacteroides stercoris, Collinsella aerofaciens, Hungatella effluvii, Bifidobacterium adolescentis, Petition 870250102358, dated 07 / 11 / 2025, p. 21 / 280 13 / 227 Bifidobacterium catenulatum, Lactobacillus rogosae, Bacteroides faecis, Bacteroides finegoldii, Clostridiaceae sp. FBI00191, Ruminococcus faecis, Lachnoclostridium pacaense, Clostridium bolteae, Longicatena caecimuris, Eggerthella lenta, Blautia massiliensis, Bacteroides xylanisolvens, Bacteroides vulgatus, Megasphaera massiliensis, Butyricimonas faecihominis, Eisenbergiella tayi, Acidaminococcus intestini, Emergence timonensis, Bifidobacterium pseudocatenulatum, Eubacterium hallii, Anaerofustis stercorihominis, Eubacterium ventriosum, Blautia hydrogenotrophica and Lachnospiraceae sp. FBI00290, or a functional equivalent thereof; or b) FBI00001, FBI00002, FBI00010, FBI00013, FBI00029, FBI00032, FBI00033, FBI00034, FBI00043, FBI00044, FBI00048, FBI00050, FBI00051, FBI00057, FBI00059, FBI00060, FBI00070, FBI00071, FBI00076, FBI00079, FBI00087, FBI00093, FBI00102, FBI00109, FBI00117, FBI00120, FBI00125, FBI00127, FBI00128, FBI00145, FBI00162, FBI00174, FBI00184, FBI00190, FBI00191, FBI00194, FBI00198, FBI00199, FBI00200, FBI00201, FBI00205, FBI00206, FBI00211, FBI00220, FBI00221, FBI00236, FBI00245, FBI00248, FBI00251, FBI00254, FBI00267, FBI00278, FBI00288 and FBI00290, or a functional equivalent thereof.

[0020] In certain embodiments, the microbial consortium or a pharmaceutical composition thereof additionally comprises: a) Acutalibacter timonensis, Alistipes onderdonkii, Bacteroides uniformis, Eubacterium rectale, Alistipes timonensis, Bacteroides kribbi, Coprococcus eutactus, Bilophila wadsworthia, Bacteroides caccae, Alistipes shahii, Parasutterella excrementihominis, Paraprevotella clara, Sutterella wadsworthensis, Sutterella massiliensis, Porphyromonas asaccharolytica, Ruminococcus bromii, Monoglobus pectinolyticus, Ruminococcaceae sp. FBI00097, Gordonibacter pamelaeae, Bacteroides uniformis, Gordonibacter pamelaeae, Petition 870250102358, dated 07 / 11 / 2025, p. 22 / 280 14 / 227 Bacteroides fragilis, Phascolarctobacterium faecium, Monoglobus pectinolyticus, Clostridium aldenense, Ruthenibacterium lactatiformans, Bacteroides ovatus, Bifidobacterium bifidum, Anaerotruncus massiliensis, Clostridium aldenense, Sutterella wadsworthensis, Catabacter hongkongensis, Alistipes senegalensis, Ruminococcaceae sp. FBI00233, Alistipes shahii, Dielma fastidiosa, Eubacterium siraeum, Faecalibacterium prausnitzii, Turicibacter sanguinis, Eubacterium rectale, Bacteroides caccae, Methanobrevibacter smithii, Barnesiella intestinihominis, Alistipes onderdonkii and Methanobrevibacter smithii, or a functional equivalent thereof; b) Bifidobacterium adolescentis, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Bacteroides thetaiotaomicron, Coprococcus comes, Fusicatenibacter saccharivorans, Eggerthella lenta, Eubacterium eligens, Bacteroides xylanisolvens, Lactobacillus rogosae, Clostridium citoniae, Collinsella aerofaciens, Blautia obeum, Eggerthella lenta, Blautia wexlerae, Lachnoclostridium pacaense, Bacteroides vulgatus, Parabacteroides merdae, Dorea formicigenerans, Ruminococcus faecis, Roseburia hominis, Anaerostipes hadrus, Bifidobacterium adolescentis, Bifidobacterium pseudocatenulatum, Clostridium bolteae, Eisenbergiella tayi, Dorea longicatena, Eggerthella lenta, Bacteroides stercoris, Hungatella hathawayi, and Bacteroides xylanisolvens, or a functional equivalent thereof; and / or c) Alistipes putredinis, Dialister succinatiphilus, Akkermansia muciniphila, Ruminococcus bromii, Dialister invisus, Bacteroides massiliensis, Bilophila wadsworthia, Holdemanella biformis, Parasutterella excrementihominis, Alistipes sp. FBI00180, Bacteroides coprocola, Alistipes sp. FBI00238, Alistipes putredinis, Eubacterium xylanophilum and Senegalimassilia anaerobia, or a functional equivalent thereof. Petition 870250102358, dated 07 / 11 / 2025, page 23 / 280 15 / 227

[0021] In certain embodiments, the microbial consortium or a pharmaceutical composition thereof additionally comprises: a) FBI00004, FBI00012, FBI00015, FBI00018, FBI00019, FBI00021, FBI00038, FBI00040, FBI00046, FBI00061, FBI00066, FBI00075, FBI00077, FBI00080, FBI00081, FBI00085, FBI00092, FBI00097, FBI00099, FBI00112, FBI00132, FBI00137, FBI00140, FBI00149, FBI00151, FBI00176, FBI00189, FBI00197, FBI00208, FBI00212, FBI00224, FBI00226, FBI00229, FBI00233, FBI00235, FBI00237, FBI00243, FBI00244, FBI00258, FBI00260, FBI00263, FBI00270, FBI00273, FBI00277, e FBI00292, ou um equivalente funcional dos mesmos; b) FBI00009, FBI00011, FBI00016, FBI00020, FBI00025, FBI00027, FBI00030, FBI00047, FBI00052, FBI00053, FBI00056, FBI00062, FBI00078, FBI00096, FBI00104, FBI00110, FBI00111, FBI00113, FBI00115, FBI00116, FBI00123, FBI00124, FBI00126, FBI00135, FBI00147, FBI00159, FBI00167, FBI00170, FBI00232, FBI00255 e FBI00271 ou um ou um equivalente funcional dos mesmos; e / ou c) FBI00022, FBI00049, FBI00068, FBI00069, FBI00152, FBI00165, FBI00171, FBI00175, FBI00177, FBI00180, FBI00182, FBI00238, FBI00269, FBI00274 and FBI00281, or a functional equivalent thereof.

[0022] In certain embodiments, the microbial consortium or a pharmaceutical composition thereof further comprises a first strain of Oxalobacter formigenes or FBI00067. In certain embodiments, the microbial consortium or a pharmaceutical composition thereof further comprises a second strain of Oxalobacter formigenes or FBI00133. In certain embodiments, the microbial consortium or a pharmaceutical composition thereof further comprises a third strain of Oxalobacter formigenes or FBI00289.

[0023] In certain modalities, the microbial consortium Petition 870250102358, dated 07 / 11 / 2025, page 24 / 280 16 / 227 or a pharmaceutical composition thereof comprises: a) Clostridium citoniae, Bacteroides salyersiae, Blautia obeum, Parabacteroides merdae, Parabacteroides distasonis, Anaerostipes hadrus, Lachnospiraceae sp. FBI00033, Eubacterium eligens, Bifidobacterium dentium, Blautia wexlerae, Fusicatenibacter saccharivorans, Bacteroides nordii, Dorea formicigenerans, Dorea longicatena, Bacteroides stercorirosoris, Bifidobacterium longum, Bacteroides kribbi, Lachnospiraceae sp. FBI00071, Bacteroides thetaiotaomicron, Clostridium clostridioforme, Clostridium scindens, Roseburia hominis, Clostridium fessum, Coprococcus comes, Blautia faecis, Hungatella hathewayi, Bacteroides stercoris, Collinsella aerofaciens, Hungatella effluvii, Bifidobacterium adolescentis, Bifidobacterium catenulatum, Lactobacillus rogosae, Bacteroides faecis, Bacteroides finegoldii, Clostridiaceae sp.FBI00191, Ruminococcus faecis, Lachnoclostridium pacaense, Clostridium bolteae, Longicatena caecimuris, Eggerthella lenta, Blautia massiliensis, Bacteroides xylanisolvens, Bacteroides vulgatus, Megasphaera massiliensis, Butyricimonas faecihominis, Eisenbergiella tayi, Acidaminococcus intestini, Emergence timonensis, Bifidobacterium pseudocatenulatum, Eubacterium hallii, Anaerofustis stercorihominis, Eubacterium ventriosum, Blautia hydrogenotrophica and Lachnospiraceae sp. FBI00290, or a functional equivalent thereof;. b) Acutalibacter timonensis, Alistipes onderdonkii, Bacteroides uniformis, Eubacterium rectale, Alistipes timonensis, Bacteroides kribbi, Coprococcus eutactus, Bilophila wadsworthia, Bacteroides caccae, Alistipes shahii, Parasutterella excrementihominis, Paraprevotella clara, Sutterella wadsworthensis, Sutterella massiliensis, Porphyromonas asaccharolytica, Ruminococcus bromii, Monoglobus pectinolyticus, Ruminococcaceae sp. FBI00097, Gordonibacter pamelaeae, Bacteroides uniformis, Gordonibacter pamelaeae, Petition 870250102358, dated 07 / 11 / 2025, p. 25 / 280 17 / 227 Bacteroides fragilis, Phascolarctobacterium faecium, Monoglobus pectinolyticus, Clostridium aldenense, Ruthenibacterium lactatiformans, Bacteroides ovatus, Bifidobacterium bifidum, Anaerotruncus massiliensis, Clostridium aldenense, Sutterella wadsworthensis, Catabacter hongkongensis, Alistipes senegalensis, Ruminococcaceae sp. FBI00233, Alistipes shahii, Dielma fastidiosa, Eubacterium siraeum, Faecalibacterium prausnitzii, Turicibacter sanguinis, Eubacterium rectale, Bacteroides caccae, Methanobrevibacter smithii, Barnesiella intestinihominis, Alistipes onderdonkii and Methanobrevibacter smithii, or a functional equivalent thereof; c) Bifidobacterium adolescentis, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Bacteroides thetaiotaomicron, Coprococcus comes, Fusicatenibacter saccharivorans, Eggerthella lenta, Eubacterium eligens, Bacteroides xylanisolvens, Lactobacillus rogosae, Clostridium citoniae, Collinsella aerofaciens, Blautia obeum, Eggerthella lenta, Blautia wexlerae, Lachnoclostridium pacaense, Bacteroides vulgatus, Parabacteroides merdae, Dorea formicigenerans, Ruminococcus faecis, Roseburia hominis, Anaerostipes hadrus, Bifidobacterium adolescentis, Bifidobacterium pseudocatenulatum, Clostridium bolteae, Eisenbergiella tayi, Dorea longicatena, Eggerthella lenta, Bacteroides stercoris, Hungatella hathawayi, and Bacteroides xylanisolvens, or a functional equivalent thereof; and d) Alistipes putredinis, Dialister succinatiphilus, Akkermansia muciniphila, Ruminococcus bromii, Dialister invisus, Bacteroides massiliensis, Bilophila wadsworthia, Holdemanella biformis, Parasutterella excrementihominis, Alistipes sp. FBI00180, Bacteroides coprocola, Alistipes sp. FBI00238, Alistipes putredinis, Eubacterium xylanophilum and Senegalimassilia anaerobia, or a functional equivalent thereof. Petition 870250102358, dated 07 / 11 / 2025, page 26 / 280 18 / 227

[0024] In certain embodiments, the microbial consortium or a pharmaceutical composition thereof comprises: a) FBI00001, FBI00002, FBI00010, FBI00013, FBI00029, FBI00032, FBI00033, FBI00034, FBI00043, FBI00044, FBI00048, FBI00050, FBI00051, FBI00057, FBI00059, FBI00060, FBI00070, FBI00071, FBI00076, FBI00079, FBI00087, FBI00093, FBI00102, FBI00109, FBI00117, FBI00120, FBI00125, FBI00127, FBI00128, FBI00145, FBI00162, FBI00174, FBI00184, FBI00190, FBI00191, FBI00194, FBI00198, FBI00199, FBI00200, FBI00201, FBI00205, FBI00206, FBI00211, FBI00220, FBI00221, FBI00236, FBI00245, FBI00248, FBI00251, FBI00254, FBI00267, FBI00278, FBI00288 e FBI00290, ou um equivalente funcional dos mesmos; b) FBI00004, FBI00012, FBI00015, FBI00018, FBI00019, FBI00021, FBI00038, FBI00040, FBI00046, FBI00061, FBI00066, FBI00075, FBI00077, FBI00080, FBI00081, FBI00085, FBI00092, FBI00097, FBI00099, FBI00112, FBI00132, FBI00137, FBI00140, FBI00149, FBI00151, FBI00176, FBI00189, FBI00197, FBI00208, FBI00212, FBI00224, FBI00226, FBI00229, FBI00233, FBI00235, FBI00237, FBI00243, FBI00244, FBI00258, FBI00260, FBI00263, FBI00270, FBI00273, FBI00277 e FBI00292, ou um equivalente funcional dos mesmos; c) FBI00009, FBI00011, FBI00016, FBI00020, FBI00025, FBI00027, FBI00030, FBI00047, FBI00052, FBI00053, FBI00056, FBI00062, FBI00078, FBI00096, FBI00104, FBI00110, FBI00111, FBI00113, FBI00115, FBI00116, FBI00123, FBI00124, FBI00126, FBI00135, FBI00147, FBI00159, FBI00167, FBI00170, FBI00232, FBI00255 e FBI00271, ou um equivalente funcional dos mesmos; e d) FBI00022, FBI00049, FBI00068, FBI00069, FBI00152, FBI00165, FBI00171, FBI00175, FBI00177, FBI00180, FBI00182, FBI00238, FBI00269, FBI00274 and FBI00281, or a functional equivalent thereof.

[0025] In certain embodiments, the microbial consortium or a pharmaceutical composition thereof comprises Petition 870250102358, dated 07 / 11 / 2025, page 27 / 280 19 / 227 additionally comprises a first strain of Oxalobacter formigenes or FBI00067, a second strain of Oxalobacter formigenes or FBI00133, and a third strain of Oxalobacter formigenes or FBI00289. In certain embodiments, the microbial consortium or a pharmaceutical composition thereof additionally comprises a first strain of Oxalobacter formigenes or FBI00067, a second strain of Oxalobacter formigenes or FBI00133, and a third strain of Oxalobacter formigenes or FBI00289. In certain embodiments, the microbial consortium or a pharmaceutical composition thereof is FB-001 or a functional equivalent thereof. In certain embodiments, the microbial consortium or a pharmaceutical composition thereof is FB-003 or a functional equivalent thereof.

[0026] In certain embodiments, the microbial consortium or a pharmaceutical composition thereof increases the microbial diversity of the gastrointestinal tract. In certain embodiments, the microbial consortium or a pharmaceutical composition thereof increases short-chain fatty acids (SCFAs). In certain embodiments, the microbial consortium or a pharmaceutical composition thereof increases secondary bile acids. In certain embodiments, the microbial consortium or a pharmaceutical composition thereof decreases bacterial pathogens in the individual's gastrointestinal tract.

[0027] In certain embodiments, the microbial consortium or a pharmaceutical composition thereof comprises between approximately 5 x 10⁹ and approximately 5 x 10¹² viable cells. In certain embodiments, the microbial consortium or a pharmaceutical composition thereof comprises between approximately 5 x 10⁹ and approximately 5 x 10¹⁰ viable cells. In certain embodiments, the microbial consortium or a pharmaceutical composition thereof comprises between approximately 5 x 10¹⁰ and approximately 5 x 10¹¹ viable cells. In certain embodiments, the microbial consortium or a pharmaceutical composition thereof comprises between approximately Petition 870250102358, dated 07 / 11 / 2025, pages 28 / 280 20 / 227 x10¹¹ and approximately 5 x 10¹² viable cells. In certain embodiments, the microbial consortium or a pharmaceutical composition thereof comprises up to approximately 10¹¹ viable cells. In certain embodiments, the method comprises administering a loading dose and one or more maintenance doses. In certain embodiments, the loading dose is administered for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, or 10 days. In certain embodiments, the loading dose is administered for 2 to 3 days, 3 to 5 days, 4 to 6 days, or 5 to 7 days. In certain embodiments, one or more maintenance doses are administered for at least 21 days after the last loading dose.

[0028] In certain embodiments, the methods additionally comprise the administration of an antibacterial agent, an antiviral agent, an antifungal agent, an anti-inflammatory agent, an immunosuppressive agent and / or a prebiotic. In certain embodiments, the antibacterial agent is selected from the group consisting of ciprofloxacin, levaquin, floxin, tequin, avelox, norflox, cephalexin, cefuroxime, cefadroxil, cefazolin, cephalothin, cefaclor, cefamandole, cefoxitin, cefprozil, ceftobiprole, amoxicillin, ampicillin, penicillin V, dicloxacillin, carbenicillin, vancomycin and methicillin, tetracycline, minocycline, oxytetracycline, doxycycline, ertapenem, doripenem, imipenem / cilastatin and meropenem.In certain modalities, the antiviral agent is selected from the group consisting of abacavir, acyclovir, adefovir, amprenavir, atazanavir, cidofovir, darunavir, delavirdine, didanosine, docosanol, efavirenz, elvitegravir, emtricitabine, enfuvirtide, etravirine, famciclovir, foscamet, fomivirsen, ganciclovir, indinavir, idoxuridine, lamivudine, lopinavir, maraviroc, MK-2048, nelfinavir, nevirapine, nirmatrelvir. Petition 870250102358, dated 07 / 11 / 2025, p. 29 / 280 21 / 227 penciclovir, raltegravir, rilpivirine, ritonavir, saquinavir, stavudine, tenofovir, trifluridine, valaciclovir, valganciclovir, vidarabine, ibacitabine, amantadine, oseltamivir, rimantidine, tipranavir, zalcitabine, zanamivir and zidovudine. In certain embodiments, the antifungal agent is selected from the group consisting of miconazole, ketoconazole, clotrimazole, econazole, omoconazole, bifonazole, butoconazole, fenticonazole, isoconazole, oxiconazole, sertaconazole, sulconazole, tioconazole, fluconazole, itraconazole, isavuconazole, ravuconazole, posaconazole, voriconazole, terconazole, albaconazole, abafungin, terbinafine, naftifine, butenafine, anidulafungin, caspofungin, micafungin, poligodial, benzoic acid, ciclopirox, tolnaftate, undecylenic acid, flucytosine or 5-fluorocytosine, griseofulvin, and haloprogin.In certain modalities, the anti-inflammatory and / or immunosuppressive agent is selected from the group consisting of cyclophosphamide, mycophenolate mofetil, corticosteroids, mesalazine, mesalamine, sulfasalazine, sulfasalazine derivatives, cyclosporine A, mercaptopurine, azathiopurine, prednisone, methotrexate, antihistamines, glucocorticoids, epinephrine, theophylline, sodium cromoglycate, leukotriene antagonists, anticholinergics, monoclonal anti-IgE, immunomodulatory peptides, small immunomodulatory molecules, immunomodulatory cytokines, immunomodulatory antibodies, and vaccines. In certain formulations, the prebiotic is selected from the group consisting of amino acids, biotin, fructooligosaccharides, galacto-oligosaccharides, inulin, lactulose, mannan-oligosaccharides, inulin enriched with oligofructose, oligofructose, oligodextrose, tagatose, transgalactooligosaccharide, and xylo-oligosaccharides.

[0029] In certain embodiments, the microbial consortium or its pharmaceutical composition is present in a food product. Petition 870250102358, dated 07 / 11 / 2025, page 30 / 280 22 / 227

[0030] In addition, the present disclosure offers methods for treating a disease in an individual. In certain embodiments, the methods comprise administering an effective amount of a microbial consortium or a pharmaceutical composition comprising: a) Clostridium citoniae, Bacteroides salyersiae, Blautia obeum, Parabacteroides merdae, Parabacteroides distasonis, Anaerostipes hadrus, Lachnospiraceae sp. FBI00033, Eubacterium eligens, Bifidobacterium dentium, Blautia wexlerae, Fusicatenibacter saccharivorans, Bacteroides nordii, Dorea formicigenerans, Dorea longicatena, Bacteroides stercorirosoris, Bifidobacterium longum, Bacteroides kribbi, Lachnospiraceae sp. FBI00071, Bacteroides thetaiotaomicron, Clostridium clostridioforme, Clostridium scindens, Roseburia hominis, Clostridium fessum, Coprococcus comes, Blautia faecis, Hungatella hathewayi, Bacteroides stercoris, Collinsella aerofaciens, Hungatella effluvii, Bifidobacterium adolescentis, Bifidobacterium catenulatum, Lactobacillus rogosae, Bacteroides faecis, Bacteroides finegoldii, Clostridiaceae sp.FBI00191, Ruminococcus faecis, Lachnoclostridium pacaense, Clostridium bolteae, Longicatena caecimuris, Eggerthella lenta, Blautia massiliensis, Bacteroides xylanisolvens, Bacteroides vulgatus, Megasphaera massiliensis, Butyricimonas faecihominis, Eisenbergiella tayi, Acidaminococcus intestini, Emergence timonensis, Bifidobacterium pseudocatenulatum, Eubacterium hallii, Anaerofustis stercorihominis, Eubacterium ventriosum, Blautia hydrogenotrophica and Lachnospiraceae sp. FBI00290, or a functional equivalent thereof; or. b) FBI00001, FBI00002, FBI00010, FBI00013, FBI00029, FBI00032, FBI00033, FBI00034, FBI00043, FBI00044, FBI00048, FBI00050, FBI00051, FBI00057, FBI00059, FBI00060, FBI00070, FBI00071, FBI00076, FBI00079, FBI00087, FBI00093, FBI00102, FBI00109, FBI00117, FBI00120, FBI00125, FBI00127, FBI00128, Petition 870250102358, dated 07 / 11 / 2025, p. 31 / 280 23 / 227 FBI00145, FBI00162, FBI00174, FBI00184, FBI00190, FBI00191, FBI00194, FBI00198, FBI00199, FBI00200, FBI00201, FBI00205, FBI00206, FBI00211, FBI00220, FBI00221, FBI00236, FBI00245, FBI00248, FBI00251, FBI00254, FBI00267, FBI00278, FBI00288 and FBI00290, or a functional equivalent thereof.

[0031] In certain forms, the disease is irritable bowel syndrome, diarrhea, constipation, celiac disease and leaky gut syndrome, colitis, ulcerative colitis or Crohn's disease.

[0032] In certain embodiments, the microbial consortium or a pharmaceutical composition thereof additionally comprises: a) Acutalibacter timonensis, Alistipes onderdonkii, Bacteroides uniformis, Eubacterium rectale, Alistipes timonensis, Bacteroides kribbi, Coprococcus eutactus, Bilophila wadsworthia, Bacteroides caccae, Alistipes shahii, Parasutterella excrementihominis, Paraprevotella clara, Sutterella wadsworthensis, Sutterella massiliensis, Porphyromonas asaccharolytica, Ruminococcus bromii, Monoglobus pectinolyticus, Ruminococcaceae sp. FBI00097, Gordonibacter pamelaeae, Bacteroides uniformis, Gordonibacter pamelaeae, Bacteroides fragilis, Phascolarctobacterium faecium, Monoglobus pectinolyticus, Clostridium aldenense, Ruthenibacterium lactatiformans, Bacteroides ovatus, Bifidobacterium bifidum, Anaerotruncus massiliensis, Clostridium aldenense, Sutterella wadsworthensis, Catabacter hongkongensis, Alistipes senegalensis, Ruminococcaceae sp.FBI00233, Alistipes shahii, Dielma fastidiosa, Eubacterium siraeum, Faecalibacterium prausnitzii, Turicibacter sanguinis, Eubacterium rectale, Bacteroides caccae, Methanobrevibacter smithii, Barnesiella intestinihominis, Alistipes onderdonkii and Methanobrevibacter smithii, or a functional equivalent thereof;. b) Bifidobacterium adolescentis, Bifidobacterium longum, Petition 870250102358, dated 07 / 11 / 2025, p. 32 / 280 24 / 227 Bifidobacterium pseudocatenulatum, Bacteroides thetaiotaomicron, Coprococcus comes, Fusicatenibacter saccharivorans, Eggerthella lenta, Eubacterium eligens, Bacteroides xylanisolvens, Lactobacillus rogosae, Clostridium citoniae, Collinsella aerofaciens, Blautia obeum, Eggerthella lenta, Blautia wexlerae, Lachnoclostridium pacaense, Bacteroides vulgatus, Parabacteroides merdae, Dorea formicigenerans, Ruminococcus faecis, Roseburia hominis, Anaerostipes hadrus, Bifidobacterium adolescentis, Bifidobacterium pseudocatenulatum, Clostridium bolteae, Eisenbergiella tayi, Dorea longicatena, Eggerthella lenta, Bacteroides stercoris, Hungatella hathewayi, and Bacteroides xylanisolvens, or a functional equivalent thereof; and / or c) Alistipes putredinis, Dialister succinatiphilus, Akkermansia muciniphila, Ruminococcus bromii, Dialister invisus, Bacteroides massiliensis, Bilophila wadsworthia, Holdemanella biformis, Parasutterella excrementihominis, Alistipes sp. FBI00180, Bacteroides coprocola, Alistipes sp. FBI00238, Alistipes putredinis, Eubacterium xylanophilum and Senegalmassilia anaerobia, or a functional equivalent thereof.

[0033] Em determinadas modalities, o consórcio microbialo ou uma composizione farmacêutica do mesmo comprendre additionally: a) FBI00004, FBI00012, FBI00015, FBI00018, FBI00019, FBI00021, FBI00038, FBI00040, FBI00046, FBI00061, FBI00066, FBI00075, FBI00077, FBI00080, FBI00081, FBI00085, FBI00092, FBI00097, FBI00099, FBI00112, FBI00132, FBI00137, FBI00140, FBI00149, FBI00151, FBI00176, FBI00189, FBI00197, FBI00208, FBI00212, FBI00224, FBI00226, FBI00229, FBI00233, FBI00235, FBI00237, FBI00243, FBI00244, FBI00258, FBI00260, FBI00263, FBI00270, FBI00273, FBI00277, and FBI00292, or a functional equivalent thereof; Petition 870250102358, dated 07 / 11 / 2025, page 33 / 280 25 / 227 b) FBI00009, FBI00011, FBI00016, FBI00020, FBI00025, FBI00027, FBI00030, FBI00047, FBI00052, FBI00053, FBI00056, FBI00062, FBI00078, FBI00096, FBI00104, FBI00110, FBI00111, FBI00113, FBI00115, FBI00116, FBI00123, FBI00124, FBI00126, FBI00135, FBI00147, FBI00159, FBI00167, FBI00170, FBI00232, FBI00255 and FBI00271 or one or a functional equivalent thereof; and / or c) FBI00022, FBI00049, FBI00068, FBI00069, FBI00152, FBI00165, FBI00171, FBI00175, FBI00177, FBI00180, FBI00182, FBI00238, FBI00269, FBI00274 and FBI00281, or a functional equivalent thereof.

[0034] In certain embodiments, the microbial consortium or a pharmaceutical composition thereof additionally comprises a first strain of Oxalobacter formigenes or FBI00067.

[0035] In certain embodiments, the microbial consortium or a pharmaceutical composition thereof additionally comprises a second strain of Oxalobacter formigenes or FBI00133.

[0036] In certain embodiments, the microbial consortium or a pharmaceutical composition thereof additionally comprises a third strain of Oxalobacter formigenes or FBI00289.

[0037] In certain embodiments, the microbial consortium or a pharmaceutical composition thereof comprises: a) Clostridium citoniae, Bacteroides salyersiae, Blautia obeum, Parabacteroides merdae, Parabacteroides distasonis, Anaerostipes hadrus, Lachnospiraceae sp. FBI00033, Eubacterium eligens, Bifidobacterium dentium, Blautia wexlerae, Fusicatenibacter saccharivorans, Bacteroides nordii, Dorea formicigenerans, Dorea longicatena, Bacteroides stercorirosoris, Bifidobacterium longum, Bacteroides kribbi, Lachnospiraceae sp. FBI00071, Bacteroides thetaiotaomicron, Petition 870250102358, dated 07 / 11 / 2025, p. 34 / 280 26 / 227 Clostridium clostridioforme , Clostridium scindens, Roseburia hominis, Clostridium fessum, Coprococcus comes, Blautia faecis, Hungatella hathewayi, Bacteroides stercoris, Collinsella aerofaciens, Hungatella effluvii, Bifidobacterium adolescentis, Bifidobacterium catenulatum, Lactobacillus rogosae, Bacteroides faecis, Bacteroides finegoldii, Clostridiaceae sp. FBI00191, Ruminococcus faecis, Lachnoclostridium pacaense, Clostridium bolteae, Longicatena caecimuris, Eggerthella lenta, Blautia massiliensis, Bacteroides xylanisolvens, Bacteroides vulgatus, Megasphaera massiliensis, Butyricimonas faecihominis, Eisenbergiella tayi, Acidaminococcus intestini, Emergence timonensis, Bifidobacterium pseudocatenulatum, Eubacterium hallii, Anaerofustis stercorihominis, Eubacterium ventriosum, Blautia hydrogenotrophica and Lachnospiraceae sp. FBI00290, ou um equivalent funcional do mesmo; b) Acutalibacter timonensis, Alistipes onderdonkii, Bacteroides uniformis, Eubacterium rectale, Alistipes timonensis, Bacteroides kribbi, Coprococcus eutactus, Bilophila wadsworthia, Bacteroides caccae, Alistipes shahii, Parasutterella excrementihominis, Paraprevotella clara, Sutterella wadsworthensis, Sutterella massiliensis, Porphyromonas asaccharolytica, Ruminococcus bromii, Monoglobus pectinolyticus, Ruminococcaceae sp. FBI00097, Gordonibacter pamelaeae, Bacteroides uniformis, Gordonibacter pamelaeae, Bacteroides fragilis, Phascolarctobacterium faecium, Monoglobus pectinolyticus, Clostridium aldenense, Ruthenibacterium lactatiformans, Bacteroides ovatus, Bifidobacterium bifidum, Anaerotruncus massiliensis, Clostridium aldenense, Sutterella wadsworthensis, Catabacter hongkongensis, Alistipes senegalensis, Ruminococcaceae sp.FBI00233, Alistipes shahii, Dielma fastidiosa, Eubacterium siraeum, Faecalibacterium prausnitzii, Turicibacter sanguinis, Eubacterium rectale, Bacteroides caccae, Methanobrevibacter smithii, Barnesiella. Petition 870250102358, dated 07 / 11 / 2025, p. 35 / 280 27 / 227 intestinihominis, Alistipes onderdonkii and Methanobrevibacter smithii, or a functional equivalent thereof; c) Bifidobacterium adolescentis, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Bacteroides thetaiotaomicron, Coprococcus comes, Fusicatenibacter saccharivorans, Eggerthella lenta, Eubacterium eligens, Bacteroides xylanisolvens, Lactobacillus rogosae, Clostridium citoniae, Collinsella aerofaciens, Blautia obeum, Eggerthella lenta, Blautia wexlerae, Lachnoclostridium pacaense, Bacteroides vulgatus, Parabacteroides merdae, Dorea formicigenerans, Ruminococcus faecis, Roseburia hominis, Anaerostipes hadrus, Bifidobacterium adolescentis, Bifidobacterium pseudocatenulatum, Clostridium bolteae, Eisenbergiella tayi, Dorea longicatena, Eggerthella lenta, Bacteroides stercoris, Hungatella hathawayi, and Bacteroides xylanisolvens, or a functional equivalent thereof; and d) Alistipes putredinis, Dialister succinatiphilus, Akkermansia muciniphila, Ruminococcus bromii, Dialister invisus, Bacteroides massiliensis, Bilophila wadsworthia, Holdemanella biformis, Parasutterella excrementihominis, Alistipes sp. FBI00180, Bacteroides coprocola, Alistipes sp. FBI00238, Alistipes putredinis, Eubacterium xylanophilum and Senegalmassilia anaerobia, or a functional equivalent thereof.

[0038] Em determined modalities, o consórcio microbialo ou uma composizione farmacêutica do mesmo comprèze: a) FBI00001, FBI00002, FBI00010, FBI00013, FBI00029, FBI00032, FBI00033, FBI00034, FBI00043, FBI00044, FBI00048, FBI00050, FBI00051, FBI00057, FBI00059, FBI00060, FBI00070, FBI00071, FBI00076, FBI00079, FBI00087, FBI00093, FBI00102, FBI00109, FBI00117, FBI00120, FBI00125, FBI00127, FBI00128, FBI00145, FBI00162, FBI00174, FBI00184, FBI00190, FBI00191, FBI00194, FBI00198, FBI00199, FBI00200, FBI00201, FBI00205, Petition 870250102358, dated 07 / 11 / 2025, page 36 / 280 28 / 227 FBI00206, FBI00211, FBI00220, FBI00221, FBI00236, FBI00245, FBI00248, FBI00251, FBI00254, FBI00267, FBI00278, FBI00288 and FBI00290, or a functional equivalent thereof; b) FBI00004, FBI00012, FBI00015, FBI00018, FBI00019, FBI00021, FBI00038, FBI00040, FBI00046, FBI00061, FBI00066, FBI00075, FBI00077, FBI00080, FBI00081, FBI00085, FBI00092, FBI00097, FBI00099, FBI00112, FBI00132, FBI00137, FBI00140, FBI00149, FBI00151, FBI00176, FBI00189, FBI00197, FBI00208, FBI00212, FBI00224, FBI00226, FBI00229, FBI00233, FBI00235, FBI00237, FBI00243, FBI00244, FBI00258, FBI00260, FBI00263, FBI00270, FBI00273, FBI00277 and FBI00292, or a functional equivalent thereof; c) FBI00009, FBI00011, FBI00016, FBI00020, FBI00025, FBI00027, FBI00030, FBI00047, FBI00052, FBI00053, FBI00056, FBI00062, FBI00078, FBI00096, FBI00104, FBI00110, FBI00111, FBI00113, FBI00115, FBI00116, FBI00123, FBI00124, FBI00126, FBI00135, FBI00147, FBI00159, FBI00167, FBI00170, FBI00232, FBI00255 e FBI00271, ou um equivalente funcional dos mesmos; e d) FBI00022, FBI00049, FBI00068, FBI00069, FBI00152, FBI00165, FBI00171, FBI00175, FBI00177, FBI00180, FBI00182, FBI00238, FBI00269, FBI00274 e FBI00281, ou um equivalente funcional dos mesmos.

[0039] In certain embodiments, the microbial consortium or a pharmaceutical composition thereof further comprises a first strain of Oxalobacter formigenes or FBI00067, a second strain of Oxalobacter formigenes or FBI00133, and a third strain of Oxalobacter formigenes or FBI00289. In certain embodiments, the microbial consortium or a pharmaceutical composition thereof further comprises a first strain of Oxalobacter formigenes or FBI00067, a second strain of Oxalobacter formigenes or FBI00133, and a third strain of Oxalobacter formigenes or FBI00289. In certain embodiments, the microbial consortium or a composition Petition 870250102358, dated 07 / 11 / 2025, p. 37 / 280 29 / 227 The pharmaceutical composition thereof is FB-001 or a functional equivalent thereof. In certain embodiments, the microbial consortium or a pharmaceutical composition thereof is FB-003 or a functional equivalent thereof. In certain embodiments, the microbial consortium or a pharmaceutical composition thereof increases the microbial diversity of the gastrointestinal tract. In certain embodiments, the microbial consortium or a pharmaceutical composition thereof increases short-chain fatty acids (SCFAs). In certain embodiments, the microbial consortium or a pharmaceutical composition thereof increases secondary bile acids. In certain embodiments, the microbial consortium or a pharmaceutical composition thereof decreases bacterial pathogens in the individual's gastrointestinal tract.

[0040] In certain embodiments, the microbial consortium or a pharmaceutical composition thereof comprises between about 5 x 10⁹ and about 5 χ 10¹² viable cells. In certain embodiments, the microbial consortium or a pharmaceutical composition thereof comprises between about 5 χ 10⁹ and about 5 χ 10¹⁰ viable cells. In certain embodiments, the microbial consortium or a pharmaceutical composition thereof comprises between about 5 χ 10¹⁰ and about 5 χ 10¹¹ viable cells. In certain embodiments, the microbial consortium or a pharmaceutical composition thereof comprises between about 5 χ 10¹¹ and about 5 χ 10¹² viable cells. In certain embodiments, the microbial consortium or a pharmaceutical composition thereof comprises up to about 10¹¹ viable cells. In certain embodiments, the microbial consortium or a pharmaceutical composition thereof comprises up to approximately 1012 viable cells.In certain modalities, the method involves administering a loading dose and one or more maintenance doses. In certain modalities, the loading dose is administered for 1 day, 2 days, 3 days, 4 days, 5 days, etc. Petition 870250102358, dated 07 / 11 / 2025, page 38 / 280 30 / 227 days, 7 days, 8 days, 9 days, or 10 days. In certain modalities, the loading dose is administered for 2 to 3 days, 3 to 5 days, 4 to 6 days, or 5 to 7 days. In certain modalities, one or more maintenance doses are administered for at least 21 days after the last loading dose.

[0041] In certain embodiments, the methods additionally comprise the administration of an antibacterial agent, an antiviral agent, an antifungal agent, an anti-inflammatory agent, an immunosuppressive agent and / or a prebiotic. In certain embodiments, the antibacterial agent is selected from the group consisting of ciprofloxacin, levaquin, floxin, tequin, avelox, norflox, cephalexin, cefuroxime, cefadroxil, cefazolin, cephalothin, cefaclor, cefamandole, cefoxitin, cefprozil, ceftobiprole, amoxicillin, ampicillin, penicillin V, dicloxacillin, carbenicillin, vancomycin and methicillin, tetracycline, minocycline, oxytetracycline, doxycycline, ertapenem, doripenem, imipenem / cilastatin and meropenem.In certain modalities, the antiviral agent is selected from the group consisting of abacavir, acyclovir, adefovir, amprenavir, atazanavir, cidofovir, darunavir, delavirdine, didanosine, docosanol, efavirenz, elvitegravir, emtricitabine, enfuvirtide, etravirine, famciclovir, foscamet, fomivirsen, ganciclovir, indinavir, idoxuridine, lamivudine, lopinavir, maraviroc, MK-2048, nelfinavir, nevirapine, nirmatrelvir, penciclovir, raltegravir, rilpivirine, ritonavir, saquinavir, stavudine, tenofovir, trifluridine, valacyclovir, valganciclovir, vidarabine, ibacitabine, amantadine, oseltamivir, rimantidine, tipranavir, zalcitabine, zanamivir and zidovudine. In certain embodiments, the antifungal agent is selected from the group consisting of miconazole, ketoconazole, clotrimazole, econazole, omoconazole, bifonazole, butoconazole, fenticonazole, isoconazole, oxiconazole, sertaconazole, sulconazole, tioconazole, fluconazole, itraconazole, isavuconazole, ravuconazole. Petition 870250102358, dated 07 / 11 / 2025, p. 39 / 280 31 / 227 posaconazole, voriconazole, terconazole, albaconazole, abafungin, terbinafine, naftifine, butenafine, anidulafungin, caspofungin, micafungin, polygodial, benzoic acid, ciclopirox, tolnaftate, undecylenic acid, flucytosine or 5fluorocytosine, griseofulvin and haloprogin. In certain modalities, the anti-inflammatory and / or immunosuppressive agent is selected from the group consisting of cyclophosphamide, mycophenolate mofetil, corticosteroids, mesalazine, mesalamine, sulfasalazine, sulfasalazine derivatives, cyclosporine A, mercaptopurine, azathiopurine, prednisone, methotrexate, antihistamines, glucocorticoids, epinephrine, theophylline, sodium cromoglycate, leukotriene antagonists, anticholinergics, monoclonal anti-IgE, immunomodulatory peptides, small immunomodulatory molecules, immunomodulatory cytokines, immunomodulatory antibodies, and vaccines.In certain formulations, the prebiotic is selected from the group consisting of amino acids, biotin, fructooligosaccharides, galacto-oligosaccharides, inulin, lactulose, mannan-oligosaccharides, inulin enriched with oligofructose, oligofructose, oligodextrose, tagatose, transgalactooligosaccharide, and xylo-oligosaccharides.

[0042] In certain embodiments, the microbial consortium or its pharmaceutical composition is present in a food product. In certain embodiments, the methods disclosed in this document additionally comprise the diagnosis of IBD in the individual prior to administration of the microbial consortium or its pharmaceutical composition.

[0043] This disclosure also provides a method for reducing dysbiosis in an individual, wherein the method comprises administering to a patient a therapeutically effective amount of a pharmaceutical composition comprising a consortium to reduce dysbiosis of the gastrointestinal tract in the patient. In certain embodiments, the reduction of dysbiosis Petition 870250102358, dated 07 / 11 / 2025, page 40 / 280 32 / 227 includes the grafting of microbial consortia, increased microbial diversity of the gastrointestinal tract, increased short-chain fatty acids (SCFAs), increased secondary bile acids, and / or reduced bacterial pathogens. In certain embodiments, the Consortium is FB-001 or a functional equivalent thereof. In certain embodiments, the Consortium is FB-003 or a functional equivalent thereof.

[0044] In addition, the present disclosure provides a method for restoring the microbiome in a patient, wherein the method comprises administering to the patient a therapeutically effective amount of a pharmaceutical composition comprising a Consortium. In certain embodiments, microbiome restoration comprises grafting microbes from the Consortia, increasing microbial diversity of the gastrointestinal tract, increasing short-chain fatty acids (SCFAs), increasing secondary bile acids, and / or decreasing bacterial pathogens. In certain embodiments, the Consortium is FB-001 or a functional equivalent thereof. In certain embodiments, the Consortium is FB-003 or a functional equivalent thereof.

[0045] This disclosure provides a method for enhancing the recovery of a healthy microbiome in a patient following a dysbiosis-inducing event, wherein the method comprises administering to the individual a therapeutically effective amount of a pharmaceutical composition comprising a Consortium. In certain embodiments, the recovery of a healthy microbiome comprises the grafting of microbes from the consortia, increased microbial diversity of the gastrointestinal tract, increased short-chain fatty acids (SCFAs), increased secondary bile acids, and / or decreased bacterial pathogens. In certain embodiments, the Consortium is FB-001 or a functional equivalent thereof. In certain embodiments, the Consortium is FB-003 or a Petition 870250102358, dated 07 / 11 / 2025, page 41 / 280 33 / 227 functional equivalent of the same. In certain modalities, the dysbiosis-inducing event is treatment with one or more antibiotics, an infectious disease, or an underlying disease. In certain modalities, the underlying disease is IBD, colitis, ulcerative colitis, or Crohn's disease.

[0046] This disclosure provides a composition for treating or reducing the severity of at least one symptom of a gastrointestinal disease, disorder, or condition associated with dysbiosis in a patient, wherein the composition comprises a Consortium in an amount effective to populate and optionally graft into a patient's gastrointestinal tract. In certain embodiments, the gastrointestinal disease is selected from the group consisting of IBD, colitis, ulcerative colitis, and Crohn's disease. In certain embodiments, the dysbiosis is associated with a decrease in microbial diversity of the gastrointestinal tract, a decrease in short-chain fatty acids (SCFAs), a decrease in secondary bile acids, and / or an increase in bacterial pathogens. In certain embodiments, the Consortium is FB-001 or a functional equivalent thereof. In certain embodiments, the Consortium is FB-003 or a functional equivalent thereof.

[0047] This disclosure also offers a method for treating or reducing the severity of at least one symptom of a gastrointestinal disease associated with dysbiosis, wherein the method comprises administering an effective amount of a pharmaceutical composition comprising a Consortium. In certain embodiments, the Consortium is FB-001 or a functional equivalent thereof. In certain embodiments, the Consortium is FB-003 or a functional equivalent thereof.

[0048] This disclosure offers a composition comprising FB-003 or a functional equivalent thereof. This disclosure offers a method of manufacturing FB-003 or Petition 870250102358, dated 07 / 11 / 2025, page 42 / 280 34 / 227 of a functional equivalent of the same.

[0049] This disclosure offers a method for treating IBD, colitis, ulcerative colitis, or Crohn's disease through the administration of a Consortium. In certain embodiments, the Consortium is FB-003 or FB-001. This disclosure offers a method for reducing the symptoms associated with IBD, colitis, ulcerative colitis, or Crohn's disease through the administration of a Consortium. In certain embodiments, the Consortium is FB-003 or FB-001. This disclosure provides any method or composition described herein. Brief description of the drawings

[0050] Figures 1A and 1B. Figure 1A shows an exemplary co-culture experiment and Figure 1B shows an exemplary co-culture experiment that has been modified to produce 100% strain detection after co-culture.

[0051] Figures 2A and 2B. Figure 2A shows the design of the DS buckets for a consortium and Figure 2B shows the yield of the strains after co-culture, depending on the inoculum seed.

[0052] Figures 3A and 3B. Figures 3A and 3B show examples of different excipients for lyophilization.

[0053] Figures 4A and 4B. Figures 4A and 4B show examples of different lyophilization excipients and reducing agents.

[0054] Figures 5A and 5B. Figures 5A and 5B show examples of different excipients for lyophilization.

[0055] Figures 6A and 6B. Figure 6A is a Venn diagram showing the overlap of microbes from five representative consortia designed and disclosed in this document. Figure 6B shows the breakdown of the microbe type in each of the five representative consortia.

[0056] Figures 7A and 7B. Figures 7A and 7B show the schematic designs of the experimental studies described in Example 5.

[0057] Figure 8. Figure 8 shows that YCFAC + GalNAc does not Petition 870250102358, dated 07 / 11 / 2025, page 43 / 280 35 / 227 has the capacity to support the growth of Akkermansia.

[0058] Figure 9. Figure 9 shows that threonine supports the growth of Akkermansia in the absence of GalNAc.

[0059] Figure 10. Figure 10 shows a diagram of the co-culture method for manufacturing FB-001 and FB-003.

[0060] Figure 11. Figure 11 shows an overview of the strain isolation and purification process, the RCB bank, and the RCB identity / purity test.

[0061] Figure 12. Figure 12 shows a method for generating master cell banks (MCBs).

[0062] Figure 13. Figure 13 shows a phylogenetic tree indicating the taxonomic composition of some of the consortia disclosed in this document, including consortia FB-001 and FB003.

[0063] Figures 14A to 14C. Figures 14A to 14C show a table summarizing the strains and species of the microbial consortia disclosed in this document.

[0064] Figures 15A and 15B. Figure 15A shows the effect of FB-001 on reducing intestinal permeability, and Figure 15B shows the ability of FB-001 to produce short-chain fatty acids (SCFAs) at a level comparable to that of a normal, healthy intestine. Butyrate, an SCFA, is important because it supports the health of gastrointestinal epithelial cells, energy metabolism, and cell signaling to improve barrier function. In this experiment, O. formigenes did not show activity and / or viability, and therefore the drug used in these experiments is a research version of FB-003 (i.e., the FB-001 strains without O. formigenes).

[0065] Figure 16. Figure 16 shows the manufacturing process used for O. formigenes in the production of the consortia described in this document. In addition, the DS5-DS7 (i.e., the three medicinal substances of O. formigenes) of FB-001 used this manufacturing process for both GMP and non-GMP manufacturing. Petition 870250102358, dated 07 / 11 / 2025, page 44 / 280 36 / 227

[0066] Figure 17. Figure 17 shows the manufacturing process used for DS1 in the production of the consortia described in this document. Furthermore, DS1 from FB-001 used this manufacturing process for both GMP and non-GMP production.

[0067] Figure 18. Figure 18 shows the manufacturing process used for DS2 in the production of the consortia described in this document. Additionally, DS2 from FB-001 used this manufacturing process for both GMP and non-GMP production.

[0068] Figure 19. Figure 19 shows the manufacturing process used for DS3 in the production of the consortia described in this document. Additionally, DS3 from FB-001 used this manufacturing process for both GMP and non-GMP production.

[0069] Figure 20. Figure 20 shows the manufacturing process used for DS4 in the production of the consortia described in this document. Additionally, DS4 from FB-001 used this manufacturing process for both GMP and non-GMP production.

[0070] Figures 21A to 21D. Figure 21A shows the experimental design for the in vivo evaluation of the graft and metabolic function of FB-003 after antibiotic treatment in mice. Figure 21B shows that FB-003 has a stable graft for more than 60 days in SPF mice. The veh or vehicle used in this experiment was simple medium (the term "Medium" is used for simplification in Figure 21A. "abx" means antibiotics). The antibiotics (antibiotics in Figure 21A and abx in Figure 21B) used in this experiment were 0.575 mg / ml enrofloxacin and 1 mg / ml ampicillin, which were provided in the drinking water for 11 days. Figure 21C shows the diverse colonization of FB-003 based on the genera-level graft. Figure 21D shows the diverse colonization of FB-003 based on the strain-level graft.The FB-003 graft shown in Figures 21C and 21D is from 1 day to 60 days after FB-003 dosing in SPF mice and shows that the graft stabilizes approximately after 1 week of dosing. Petition 870250102358, dated 07 / 11 / 2025, page 45 / 280 37 / 227

[0071] Figures 22A to 22C. Figures 22A to 22C show that treatment with FB-004 can rapidly produce a modified SCFA profile in mice. Specifically, the total recovery of SCFA after treatment with microbiome-ablating antibiotic (0.575 mg / ml enrofloxacin and 1 mg / ml ampicillin) is faster with FB-003 than with a vehicle control, that FB-003 can control the SCFA profile of SPF mice, and that mice treated with vehicle (i.e., medium) exhibit a dysbiotic community dominated by butyrate producers. Figure 22A shows the total SCFA concentrations (acetate not included) after antibiotic treatment in mice + / - treatment with FB-003. Figure 22B shows the SCFA levels after antibiotic and FB-003 treatment. Figure 22C shows the SCFA levels after treatment with antibiotic and vehicle (i.e., control medium).A comparison of Figures 22B and 22C shows that the proportion of SCFAs differs between the FB-003 treatment group and the control group, such that butyrate is dominant over propionate in the control group, which is a sign of dysbiosis.

[0072] Figures 23A and 23B. Figure 23A shows that antibiotics drastically alter the bile acid pool in the intestine. Figure 23B shows that FB-003 rapidly restores the balance of the bile acid pool after antibiotic treatment induces dysbiosis.

[0073] Figures 24A to 24G. Figures 24A to 24F show the design and results of a mouse model experiment with DSS colitis. Figure 24A shows a schematic of the experimental design of the DSS colitis model. Figure 24B shows the experimental design for sample collection and analysis. Figure 24C shows the body weight results of DSS 5% + / - FB-003 in the presence of antibiotic pretreatment. Figure 24D shows the body weight results of DSS 5% + / - FB-003 in the absence of antibiotic pretreatment. Petition 870250102358, dated 07 / 11 / 2025, page 46 / 280 38 / 227 Figure 24E shows that antibiotics are necessary to displace a native microbiome of mice, that antibiotic treatment increases the severity of DSS colitis, and that treatment with FB-003 dramatically improves clinical scores in mice (and the experiment also showed reduced weight loss). Figure 24F shows that, in the antibiotic-free setting, FB-003 still shows improvement in clinical score (reduced weight loss was also observed). For Figures 24E and 24F, the Total Clinical Score was calculated as Area Under the Curve (AUC). Data are presented as mean ± SEM (n=2 or Naive, n=10 per treatment group). Data were analyzed by one-way ordinary ANOVA followed by Sidak's multiple comparisons test; the mean of the Abx + FB-003 group was compared to the Abx + vehicle group, and the FB-003-treated group was compared to the vehicle group. Figure 24G shows the stool consistency score after ulcerative colitis induced by 5% DSS.Specifically, the Stool Consistency Score was calculated as Area Under the Curve (AUC). Data are presented as mean ± SEM (n=2 or Naive, n=10 per treatment group). Data were analyzed by one-way ordinary ANOVA followed by Sidak's multiple comparisons test; the mean of the Abx + FB-003 group was compared to the Abx + vehicle group, and the FB003-treated group was compared to the vehicle group.

[0074] Figure 25. Figure 25 shows that FB-003 improves survival in the DSS colitis model.

[0075] Figure 26. Figure 26 presents a graph that provides references disclosing the function of certain species within the consortia disclosed in this document, including FB-003, Consortium A and Consortium B.

[0076] Figures 27A to 27C. Figure 27A shows the clinical scores of the mouse colon in the DSS study described in the examples. Figures 27B and 27C show images of the colon of mice treated with FB-003 in contrast to the control. Petition 870250102358, dated 07 / 11 / 2025, p. 47 / 280 39 / 227 vehicle. Detailed description

[0077] This disclosure relates to compositions and methods for grafting a microbial consortium disclosed in this document. This disclosure is based, in part, on the disclosure that the currently disclosed microbial consortia have the ability to effectively graft onto an individual and reduce dysbiosis, restore the microbiome, and recover an individual's microbiome. Furthermore, this disclosure relates to methods for treating IBD, colitis, ulcerative colitis, and Crohn's disease that include the administration of the microbial consortia disclosed in this document. For clarity of description, and not as a limitation, this section is divided into the subsections described below. Definitions

[0078] Unless defined otherwise, all technical and scientific terms used in this document have the meaning commonly understood by one skilled in the art. The following references furnish to one skilled in the art a general definition of many of the terms currently used in the disclosed subject matter: Singleton et al., Dictionary of Microbiology and Molecular Biology (2nd ed. 1994); The Cambridge Dictionary of Science and Technology (Walker ed., 1988); The Glossary of Genetics, 5th ed., R. Rieger et al. (eds.), Springer Verlag (1991); and Hale & Marham, The Harper Collins Dictionary of Biology (1991). As used in this document, the following terms have the meanings assigned to them below, unless otherwise specified.

[0079] It is understood that the aspects and modalities of this disclosure described in this document include comprising, consisting of, and “consisting essentially of” aspects and modalities. The terms comprising and comprising shall have the broad meaning ascribed to them in the U.S. Patent Law and may mean includes, include, and the like. For Petition 870250102358, dated 07 / 11 / 2025, p. 48 / 280 40 / 227 To facilitate understanding of this disclosure, several terms and expressions are defined below.

[0080] The terms a and um, as used in this document, mean one or more and include the plural, unless the context appropriates.

[0081] As used in this document, the term microbe or microbiota refers to a microbial organism, including, but not limited to, bacteria, archaea, protozoa, and single-celled fungi.

[0082] As used in this document, the term active microbes refers to microbes that express sufficient amounts of one or more metabolic enzymes to metabolize a substrate that causes or contributes to disease in an animal.

[0083] As used in this document, the term supporting community refers to one or more microbial strains that, when administered with an active microbe, enhance one or more characteristics of the active microbe, selected from the group consisting of gastrointestinal graft, biomass, metabolic substrate metabolism, and longitudinal stability.

[0084] As used in this document, the term synthesizing microbe refers to a microbe that expresses sufficient quantities of one or more enzymes to catalyze the combination of one or more metabolites produced by an active microbe and one or more fermentation products produced by a fermenting microbe in a gastrointestinal niche.

[0085] As used in this document, the term fermenting microbe refers to a microbe that expresses sufficient quantities of one or more enzymes to catalyze a fermentation reaction in a gastrointestinal niche.

[0086] As used in this document, the term longitudinal stability refers to the ability of one or more microbes, or microbial consortia, to remain grafted and metabolically active in one or more niches of the tract. Petition 870250102358, dated 07 / 11 / 2025, page 49 / 280 41 / 227 gastrointestinal, despite transient or long-term environmental changes in the gastrointestinal niche.

[0087] As used in this document, the term metabolism, metabolize, metabolization, or variants thereof refers to the biochemical conversion of a metabolic substrate into a metabolic product. In certain embodiments, metabolization includes isomerization.

[0088] As used in this document, the term biomass refers to the total mass of one or more microbes, or consortia, in a given area or volume.

[0089] As used in this document, the terms microbial consortia and microbial consortium are used interchangeably and refer to a mixture of two or more isolated microbial strains that are expanded in culture, wherein one microbial strain in the mixture has a beneficial or desired effect on another microbial strain in the mixture.

[0090] As used in this document, the term Consortia is used as a capitalized term to refer to one or more of the microbial consortia described in this document.

[0091] As used in this document, dysbiosis refers to an imbalance in the homeostasis of the microbiome in an individual's internal organs and tissues (e.g., gut) or in the individual's external organs, tissues, and surfaces (e.g., skin).

[0092] As used in this document, the term gastrointestinal graft, graft, or graft refers to the establishment of one or more microbes or microbial consortia into one or more niches of the gastrointestinal tract that, prior to the administration of one or more microbes or microbial consortia, did not contain one or more microbes or microbial consortia. For clarity, grafting refers to the grafting of one or more microbes administered to an individual. In certain embodiments, gastrointestinal grafting may be Petition 870250102358, dated 07 / 11 / 2025, page 50 / 280 42 / 227 transient. In certain modalities, the gastrointestinal graft may be persistent.

[0093] As used in this document, the term “pharmaceutical composition” refers to the combination of an active agent with a carrier, inert or active, making the composition especially suitable for therapeutic use in vivo or ex vivo.

[0094] As used in this document, the term “pharmaceutically acceptable carrier” refers to any of the standard pharmaceutical vehicles, such as phosphate-buffered saline, water, emulsions (e.g., oil-in-water or water-in-oil emulsions), and various types of wetting agents. Compositions may also include stabilizers and preservatives. For examples of carriers, stabilizers, and adjuvants, see, for example, Martin, Remington's Pharmaceutical Sciences, 15th Ed. Mack Publ. Co., Easton, PA

[1975] .

[0095] As used in this document, the term “effective amount” refers to an amount sufficient to achieve a beneficial or desired outcome. In certain non-limiting embodiments, an effective amount may be an amount that results in improved gastrointestinal grafting (e.g., grafting of one or more active microbes), increased biomass (e.g., of one or more active microbes), increased metabolism, or improved longitudinal stability.

[0096] As used in this document, “significantly” or “significant” refers to a change or alteration in a measurable parameter to a statistically significant degree, as determined according to an appropriate statistically relevant test. For example, in certain non-limiting modalities, a change or alteration is significant if it is statistically significant according to, for example, a Student’s t-test, chi-square test, or Mann-Whitney test.

[0097] As used in this document, the term “standardized substrate metabolization assay” refers to an assay Petition 870250102358, dated 07 / 11 / 2025, page 51 / 280 43 / 227 experimental known to those skilled in the art, used to quantify the amount of substrate converted into a metabolic product.

[0098] As used in this document, the term individual refers to an organism to be treated by the microbial consortium and compositions described in this document. These organisms preferably include, without limitation, mammals (e.g., mice, monkeys, horses, cattle, pigs, canines, cats and the like) and, more preferably, humans.

[0099] The term percentage identity or sequence identity, in the context of two or more nucleic acid or polypeptide sequences, refers to two or more sequences or subsequences that have a specified percentage of nucleotides or amino acid residues that are identical when compared and aligned for maximum match, as measured using one of the sequence comparison algorithms described below (e.g., BLASTP and BLASTN or other algorithms available to trained personnel) or by visual inspection. Depending on the application, the percentage identity may exist in a region of the sequence being compared, for example, in a functional domain, or alternatively, exist over the entire length of the two sequences being compared.

[0100] For sequence comparison, one sequence typically acts as a reference sequence against which the test sequences are compared. When using a sequence comparison algorithm, the test and reference sequences are entered into a computer, the subsequence coordinates are assigned if necessary, and the sequence algorithm program parameters are assigned. The sequence comparison algorithm then calculates the percentage of sequence identity for the test sequence(s) with respect to the reference sequence, based on the assigned program parameters. Petition 870250102358, dated 07 / 11 / 2025, page 52 / 280 44 / 227

[0101] The ideal alignment of sequences for comparison can be conducted, for example, by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the similarity search method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by visual inspection (see generally Ausubel et al., infra).

[0102] An example of a suitable algorithm for determining sequence identity and similarity percentage is the BLAST algorithm, described in Altschul et al., J. Mol. Biol. 215:403-410 (1990). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov / ).

[0103] When used in reference to 16S rRNA sequences, a “sequence identity” of at least 97% indicates that two microbial strains likely belong to the same species, while 16S rRNA sequences with less than 97% sequence identity indicate that two microbial strains likely belong to different species, and 16S rRNA sequences with less than 95% sequence identity indicate that two microbial strains likely belong to distinct genera (Stackebrandt E. and Goebel, BM, Int J Syst Bact, 44 (1994) 846849).

[0104] As used in this document, the terms “functional equivalent” or “functionally equivalent” refer to microbes, microbial consortia, and compositions that share similar or identical functions (e.g., oxalate metabolism). For example, without limitation, two different microbial consortia that can catalyze high concentrations of oxalate are functionally equivalent to each other. Petition 870250102358, dated 07 / 11 / 2025, page 53 / 280 45 / 227 In certain non-limiting embodiments, a microbe, a microbial consortium, and a functionally equivalent composition may be based on the characteristic described in Table 3 (see Example section).

[0105] Throughout the description, when compositions are described as having, including or comprising specific components, or when processes and methods are described as having, including or comprising specific steps, it is contemplated that, additionally, there are compositions of this disclosure that consist essentially of, or consist of, the aforementioned components, and that there are processes and methods according to this disclosure that consist essentially of, or consist of, the aforementioned processing steps.

[0106] As a general rule, compositions that specify a percentage are by weight, unless otherwise specified. Furthermore, if a variable is not accompanied by a definition, the previous definition of the variable prevails. Dysbiosis

[0107] Microbiomes are present in various species (e.g., mammals) and include bacteria, archaea, protists, fungi, and viruses. Traditionally, a microbiome (e.g., a human microbiome) includes several trillion microbes (e.g., bacteria) of thousands of species and performs functions that may benefit the host organism (e.g., a human being). For example, the species present in a microbiome benefit the host (e.g., a human individual) by performing useful or necessary functions, such as assisting in the digestion of food in the individual's intestinal tract, protecting the body against the penetration of pathogenic microbes, and promoting immune development. In certain embodiments, the organisms that perform these functions may be called symbiotic or commensal organisms because they exist within the host (e.g., a human being). Petition 870250102358, dated 07 / 11 / 2025, page 54 / 280 46 / 227 human) without harming, and in some cases actually benefiting, the host. In certain modalities, in dysbiosis, the physiological / normal microbiome of the host (e.g., a human individual) is disrupted or damaged, which can lead to a variety of diseases and / or disorders. In certain modalities, dysbiosis can result, for example, from the loss of beneficial species, the loss of microbial diversity, the increase in pathogenic organisms, and / or the alteration of metabolic capacity. In certain modalities, species that normally dominate the microbiome become underrepresented (e.g., commensal or symbiotic species) and species that are normally underrepresented (e.g., opportunistic species) become overrepresented. See Petersen et al., "Defining dysbiosis and its influence on host immunity and disease." Cell Microbiol 2014, July 16(7), 1024-1033.

[0108] In certain embodiments, the compositions and methods described in this document reduce dysbiosis. In certain embodiments, the compositions and methods provide an increase in the abundance of beneficial bacterial species for the microbiome. In certain embodiments, the compositions and methods provide a decrease in the abundance of pathogenic bacterial species. In certain embodiments, the compositions and methods described in this document do not reduce all features of dysbiosis. In certain embodiments, the compositions and methods provide an increase in the abundance of beneficial bacterial species for the microbiome. In certain embodiments, the compositions and methods provide an increase in the abundance of beneficial bacterial species for the microbiome, but do not increase microbiome diversity.In certain modalities, the term "dysbiosis reduction" refers to the restoration of the composition and homeostasis of the microbiota community. In certain modalities, disruptions in the microbiome may allow for... Petition 870250102358, dated 07 / 11 / 2025, page 55 / 280 47 / 227 pathogens within the microbiome or from other sources colonize, overpopulate, and / or cause disease in the individual. In certain modalities, dysbiosis is associated with many diseases and / or disorders, including inflammatory bowel disease (IBD), colitis, ulcerative colitis, and Crohn's disease.

[0109] In certain modalities, dysbiosis can be detected and / or monitored by various methods, such as stool tests (e.g., identification and / or quantification of microbial populations, enzyme assays, metabolite assays, immune function) and / or hydrogen / methane breath tests. Other dysbiosis detection methods covered by this disclosure can be found in Wei et al., Applied and Environmental Microbiology 87, No. 11 (2021): e00395-21, the contents of which are incorporated by reference in their entirety.

[0110] In certain embodiments, the reduction of dysbiosis involves a change (e.g., an increase or a decrease) in the abundance of one or more bacterial populations. In certain embodiments, bacterial abundance, including the abundance of specific species or strains of bacteria and the abundance of a bacterial population (e.g., bacteria belonging to a specific phylum), can be assessed by any method known to one skilled in the art. In certain embodiments, bacterial abundance can be assessed directly or indirectly. In certain embodiments, methods for directly assessing bacterial abundance in a sample (e.g., a microbiome or a sample thereof) include the identification and quantification of bacterial strains in a fecal sample from the individual.In certain modalities, methods for indirectly assessing the abundance of bacteria in a sample (e.g., a microbiome or a sample thereof) include sequencing nucleic acid samples (e.g., 16S rRNA gene for a given bacterial species). Petition 870250102358, dated 07 / 11 / 2025, page 56 / 280 48 / 227 or other bacterial genes) obtained from a fecal sample or biopsy sample and the detection and quantification of metabolites associated with specific bacteria (e.g., phospholipid fatty acid metabolism, microbial biomass carbon analysis) in an individual's fecal sample.

[0111] In certain embodiments, the abundance of one or more bacterial populations in a sample from an individual can be compared to the abundance of bacterial populations in a sample from the same individual obtained at another time (e.g., obtained earlier or later). In certain embodiments, the abundance of one or more bacterial populations in a sample from an individual can be compared to the abundance of bacterial populations in a sample from a different individual (e.g., a reference individual).

[0112] In certain modalities, dysbiosis is distinguished by an increase in the abundance of microorganisms associated with inflammation and / or disease. In certain modalities, dysbiosis is characterized by an increase in the abundance of Proteobacteria. In certain modalities, the increase in the abundance of microorganisms associated with inflammation and / or disease is relative to the abundance of microorganisms associated with inflammation before exposure to an event, called the dysbiosis-inducing event.

[0113] In some modalities, an individual's dysbiosis is distinguished by a decrease in the abundance of microorganisms considered to have the capacity to provide one or more beneficial effects to the individual. In certain modalities, dysbiosis is distinguished by a decrease in the abundance of bacteria of the phylum Bacteroidetes. In certain modalities, an individual's microbiota dysbiosis is distinguished by a decrease in the abundance of bacteria of the phylum Firmicutes. In certain modalities, dysbiosis is distinguished by a decrease in the abundance of bacteria belonging to Clostridium groups IV and / or Clostridium XIVa. In certain Petition 870250102358, dated 07 / 11 / 2025, page 57 / 280 In 49 / 227 modalities, dysbiosis is distinguished by a decrease in the abundance of bacteria belonging to Clostridium group XVII. In certain modalities, the decrease in the abundance of beneficial microorganisms is relative to the abundance of microorganisms associated with inflammation prior to exposure to an event, termed a dysbiosis-inducing event, as described in this document.

[0114] In certain modalities, dysbiosis is a dysbiosis of the gastrointestinal microbiota. In certain modalities, dysbiosis of the gastrointestinal microbiota is distinguished by an increase in the abundance of microorganisms associated with inflammation and / or disease. In certain modalities, dysbiosis of the gastrointestinal microbiota is distinguished by an increase in the abundance of proteobacteria. In certain modalities, the increase in the abundance of microorganisms associated with inflammation and / or disease is relative to the abundance of microorganisms associated with inflammation before exposure to an event (e.g., a dysbiosis-inducing event).

[0115] In certain modalities, gastrointestinal microbiota dysbiosis is distinguished by a decrease in the abundance of microorganisms considered capable of providing one or more beneficial effects to the individual. In certain modalities, gastrointestinal microbiota dysbiosis is distinguished by a decrease in the abundance of bacteria of the phylum Bacteroidetes. In certain modalities, gastrointestinal microbiota dysbiosis is distinguished by a decrease in the abundance of bacteria of the phylum Firmicutes. In certain modalities, gastrointestinal microbiota dysbiosis is distinguished by a decrease in the abundance of bacteria belonging to Clostridium groups IV and / or Clostridium XIVa. In certain modalities, gastrointestinal microbiota dysbiosis is distinguished by a decrease in the abundance of bacteria Petition 870250102358, dated 07 / 11 / 2025, page 58 / 280 50 / 227 belong to Clostridium group XVII. In certain modalities, the decrease in the abundance of beneficial microorganisms is relative to the abundance of microorganisms associated with inflammation before exposure to an event (e.g., a dysbiosis-inducing event).

[0116] In certain embodiments, the reduction of dysbiosis results in an increase in the abundance of bacteria of the phylum Bacteroidetes (e.g., bacteria of the genus Bacteroides) relative to the abundance of Bacteroides in the host (e.g., a human individual) (or in their microbiome) prior to administration of the pharmaceutical composition. In certain embodiments, the reduction of dysbiosis results in an increase in the abundance of bacteria of the phylum Bacteroidetes (e.g., bacteria of the genus Bacteroides) relative to the abundance of Bacteroides in a reference host (e.g., a human individual) (or their microbiome) that has not received the pharmaceutical composition. In certain embodiments, the reduction of dysbiosis results in an increase in the abundance of one or more bacterial species belonging to the genus Bacteroides.In certain modalities, the reduction of dysbiosis results in an increase in the overall abundance of bacterial species belonging to the genus Bacteroides. Biological niches.

[0117] This document presents microbial consortia for administration to an animal (e.g., a human individual), comprising a plurality of active microbes that metabolize a primary metabolic substrate. In certain embodiments, the primary metabolic substrate causes or contributes to disease in the animal. The microbial consortia disclosed in this document also include an effective quantity of a supporting community of microbes that metabolize one or more metabolites produced by the plurality of active microbes, wherein one or more metabolites inhibit the metabolism of Petition 870250102358, dated 07 / 11 / 2025, page 59 / 280 51 / 227 plurality of active microbes. These microbial consortia are advantageous because they have enhanced characteristics when administered to an animal, compared to administering the plurality of active microbes in isolation. The enhanced characteristics of microbial consortia include, for example, and without limitation, improved gastrointestinal grafting, increased biomass, increased metabolism of the first metabolic substrate, and improved longitudinal stability.

[0118] This disclosure provides microbial consortia capable of grafting into one or more niches of a gastrointestinal tract. In certain embodiments, the grafted microbial consortia have the ability to metabolize a substrate that causes or contributes to disease in an animal. These niches comprise specific microbial communities whose composition varies according to several environmental factors, including, but not limited to, the specific physical compartment of the gastrointestinal tract inhabited by a microbial community, the chemical and physicochemical properties of the inhabited environment, the composition of the metabolic substrate of the inhabited environment, and other cohabiting microbial species. Consortia

[0119] This disclosure provides consortia comprising a plurality of active microbes and an effective amount of a supporting community of microbes.

[0120] In certain embodiments, the Consortium comprises a plurality of microbes (e.g., active microbes and supporting community microbes) designated as “Consortium I”. In certain embodiments, Consortium I comprises Acidaminococcus intestini, Bacteroides stercoris, Blautia hydrogenotrophica, Coprococcus eutactus, Holdemanella biformis, Akkermansia muciniphila, Bacteroides stercoris, Blautia luti, Coprococcus eutactus, Holdemanella biformis, Alistipes finegoldii, Bacteroides thetaiotaomicron, Blautia luti, Petition 870250102358, dated 07 / 11 / 2025, page 60 / 280 52 / 227 Desulfovibrio desulfuricans, Hungatella hathewayi, Alistipes onderdonkii, Bacteroides thetaiotaomicron, Blautia luti, Desulfovibrio desulfuricans, Hungatella hathewayi, Alistipes onderdonkii, Bacteroides thetaiotaomicron, Blautia obeum, Dialister invisus, Neglecta timonensis, Alistipes onderdonkii, Bacteroides uniformis, Blautia obeum, Dorea formicigenerans, Oxalobacter formigenes, Alistipes putredinis, Bacteroides uniformis, Blautia obeum, Dorea formicigenerans, Oxalobacter formigenes, Alistipes putredinis, Bacteroides uniformis, Blautia obeum, Dorea formicigenerans, Oxalobacter formigenes, Alistipes putredinis, Bacteroides uniformis, Blautia obeum, Dorea formicigenerans, Oxalobacter formigenes, Alistipes senegalensis, Bacteroides uniformis, Blautia wexlerae, Dorea longicatena, Parabacteroides distasonis, Alistipes senegalensis, Bacteroides vulgatus, Blautia wexlerae, Dorea longicatena, Parabacteroides distasonis, Alistipes shahii, Bacteroides vulgatus, Blautia wexlerae, Dorea longicatena, Parabacteroides distasonis, Alistipes shahii, Bacteroides vulgatus, Clostridium aldenense,Eggerthella lenta, Parabacteroides merdae, Alistipes shahii, Bacteroides vulgatus, Clostridium aldenense, Eggerthella lenta, Parabacteroides merdae, Alistipes timonensis, Bacteroides xylanisolvens, Clostridium amygdalinum, Eggerthella lenta, Parabacteroides merdae, Anaerofustis stercorihominis, Bacteroides xylanisolvens, Clostridium bolteae, Eggerthella lenta, Paraprevotella clara, Anaerostipes hadrus, Bacteroides xylanisolvens, Clostridium bolteae, Eubacterium eligens, Parasutterella excrementihominis, Anaerostipes hadrus, Bifidobacterium adolescentis, Clostridium citroniae, Eubacterium eligens, Parasutterella excrementihominis, Anaerotruncus colihominis, Bifidobacterium adolescentis, Clostridium citroniae, Eubacterium eligens, Roseburia hominis, Bacteroides caccae, Bifidobacterium catenulatum, Clostridium scindens, Eubacterium eligens, Roseburia hominis, Bacteroides caccae, Bifidobacterium dentium, Clostridium symbiosum, Petition 870250102358, dated 07 / 11 / 2025, p. 61 / 280 53 / 227 Eubacterium hallii, Roseburia hominis, Bacteroides cellulosilyticus, Bifidobacterium longum, Clostridium symbiosum, Eubacterium rectale, Roseburia hominis, Bacteroides coprocola, Bifidobacterium longum, Clostridium symbiosum, Eubacterium rectale, Ruminococcus bromii, Bacteroides finegoldii, Bifidobacterium longum, Collinsella aerofaciens, Eubacterium rectale, Ruminococcus bromii, Bacteroides fragilis, Bifidobacterium longum, Collinsella aerofaciens, Eubacterium rectale, Ruminococcus bromii, Bacteroides massiliensis, Bifidobacterium pseudocatenulatum, Collinsella aerofaciens, Eubacterium siraeum, Ruminococcus bromii, Bacteroides massiliensis, Bifidobacterium pseudocatenulatum, Collinsella aerofaciens, Eubacterium ventriosum, Ruminococcus faecis, Bacteroides nordii, Bifidobacterium pseudocatenulatum, Coprococcus comes, Eubacterium xylanophilum, Ruminococcus faecis, Bacteroides oleiciplenus, Blautia faecis, Coprococcus comet, Faecalibacterium prausnitzii, Turicibacter sanguinis,Bacteroides ovatus, Blautia faecis, Coprococcus comes, Faecalibacterium prausnitzii, Bacteroides salyersiae, Blautia faecis, Coprococcus comes, Gordonibacter pamelaeae, Bacteroides stercoris, Blautia faecis, Coprococcus eutactus and Gordonibacter pamelaeae.,

[0121] In certain embodiments, the Consorcio comprises a plurality of microbes (for example, active microbes and microbiomes from the community of apoio) designated as "Consórcio II" In certain embodiments, the Consorcio II comprises Akkermansia muciniphila, Bacteroides vulgatus, Clostridium amygdalinum, Eggerthella lenta, Oxalobacter formigenes, Alistipes onderdonkii, Bifidobacterium dentium, Clostridium citroniae, Eubacterium eligens, Parabacteroides distasonis, Alistipes putredinis, Bifidobacterium faecale, Clostridium citroniae, Eubacterium eligens, Parabacteroides distasonis, Alistipes shahii, Bifidobacterium longum, Clostridium scindens, Petition 870250102358, dated 07 / 11 / 2025, p. 62 / 280 54 / 227 Eubacterium rectale, Parabacteroides merdae, Alistipes timonensis, Bifidobacterium longum, Clostridium symbiosum, Eubacterium rectale, Paraprevotella clara, Bacteroides caccae, Bifidobacterium pseudocatenulatum, Collinsella aerofaciens, Faecalibacterium prausnitzii, Parasutterella excrementihominis, Bacteroides koreensis, Bifidobacterium pseudocatenulatum, Coprococcus comes, Fusicatenibacter saccharivorans, Phascolarctobacterium faecium, Bacteroides kribbi, Bifidobacterium pseudocatenulatum, Coprococcus eutactus, Fusicatenibacter saccharivorans, Phascolarctobacterium faecium, Bacteroides kribbi, Blautia faecis, Desulfovibrio desulfuricans, Gordonibacter pamelaeae, Phascolarctobacterium faecium, Bacteroides nordii, Blautia faecis, Dialister succinatiphilus, Lachnoclostridium pacaense, Roseburia hominis, Bacteroides ovatus, Blautia obeum, Dorea formicigenerans, Lachnospira pectinoschiza, Ruminococcus bromii, Bacteroides salyersiae, Blautia obeum, Dorea longicatena,Monoglobus pectinilyticus, Ruminococcus bromii, Bacteroides thetaiotaomicron, Blautia obeum, Eggerthella lenta, Neglecta timonensis, Ruminococcus faecis, Bacteroides thetaiotaomicron, Blautia wexlerae, Eggerthella lenta, Oxalobacter formigenes, Sutterella massiliensis, Bacteroides uniformis, Blautia wexlerae, Eggerthella lenta, Oxalobacter formigenes from Sutterella wadsworthensis.

[0122] In certain embodiments, the Consorcio comprises a plurality of microbes (for example, active microbes and microbes from the community of support) designated as "Consórcio III" In certain embodiments, the Consorcio III comprises Akkermansia muciniphila, Bacteroides vulgatus, Clostridium scindens, Eubacterium rectale, Parabacteroides merdae, Anaerotruncus colihominis, Bacteroides vulgatus, Clostridium symbiosum, Eubacterium rectal, Ruminococcus bromii, Bacteroides caccae, Bacteroides vulgatus, Clostridium symbiosum, Eubacterium Petition 870250102358, dated 07 / 11 / 2025, p. 63 / 280 55 / 227 rectale, Ruminococcus bromii, Bacteroides caccae, Bifidobacterium adolescentis, Clostridium symbiosum, Eubacterium rectale, Ruminococcus bromii, Bacteroides cellulosilyticus, Bifidobacterium adolescentis, Collinsella aerofaciens, Eubacterium siraeum, Ruminococcus bromii, Bacteroides fragilis, Bifidobacterium bifidum, Collinsella aerofaciens, Faecalibacterium prausnitzii, Sutterella wadsworthensis, Bacteroides massiliensis, Bifidobacterium bifidum, Collinsella aerofaciens, Gordonibacter pamelaeae, Sutterella wadsworthensis, Bacteroides massiliensis, Bifidobacterium catenulatum, Collinsella aerofaciens, Gordonibacter pamelaeae, Sutterella wadsworthensis, Bacteroides salyersiae, Bifidobacterium dentium, Coprococcus comes, Hydrogenoanaerobacterium saccharovorans, Bacteroides vulgatus, Bacteroides stercoris, Bifidobacterium longum, Coprococcus comes, Lachnospiraceae sp., Clostridium citroniae, Bacteroides stercoris, Bifidobacterium longum, Coprococcus comes, Lactonifactor longoviformis, Eggerthella lenta, Bacteroides stercoris, Bifidobacterium longum, Desulfovibrio desulfuricans, Neglecta timonensis, Parabacteroides merdae, Bacteroides thetaiotaomicron, Bifidobacterium longum, Desulfovibrio desulfuricans, Oxalobacter formigenes, Parabacteroides merdae, Bacteroides thetaiotaomicron, Bifidobacterium pseudocatenulatum, Dorea longicatena, Oxalobacter formigenes, Eggerthella lenta, Bacteroides thetaiotaomicron, Bifidobacterium pseudocatenulatum, Dorea longicatena, Oxalobacter formigenes, Clostridium citroniae, Bacteroides uniformis, Bifidobacterium pseudocatenulatum, Dorea longicatena, Parabacteroides distasonis, Bacteroides uniformis, Bacteroides uniformis, Citrobacter freundii, Eggerthella lenta, Parabacteroides distasonis, Bacteroides uniformis, Clostridium amygdalinum, Eggerthella lenta from Parabacteroides distasonis.

[0123] In certain modalities, the Consortium comprises Petition 870250102358, dated 07 / 11 / 2025, page 64 / 280 56 / 227 a plurality of microbes (e.g., active microbes and community support microbes) designated as “Consortium IV” In certain embodiments, Consortium IV comprises Alistipes finegoldii, Bacteroides vulgatus, Clostridium bolteae, Dorea longicatena, Oxalobacter formigenes, Alistipes putredinis, Bacteroides vulgatus, Clostridium bolteae, Eggerthella lenta, Parabacteroides merdae Alistipes putredinis, Bacteroides xylanisolvens, Clostridium citroniae, Eggerthella lenta, Parabacteroides merdae, Anaerotruncus colihominis, Bacteroides xylanisolvens, Clostridium citroniae, Eggerthella lenta, Parabacteroides merdae, Bacteroides caccae, Bacteroides xylanisolvens, Clostridium scindens, Eggerthella lenta, Ruminococcus bromii, Bacteroides cellulosilyticus, Bifidobacterium bifidum, Clostridium symbiosum, Eubacterium eligens, Ruminococcus bromii, Bacteroides coprocola, Bifidobacterium bifidum, Clostridium symbiosum, Eubacterium eligens, Ruminococcus bromii,Bacteroides fragilis, Bifidobacterium catenulatum, Clostridium symbiosum, Eubacterium eligens, Ruminococcus bromii, Bacteroides ovatus, Bifidobacterium dentium, Collinsella aerofaciens, Eubacterium eligens, Sutterella wadsworthensis, Bacteroides salyersiae, Bifidobacterium longum, Collinsella aerofaciens, Eubacterium hallii, Bacteroides stercoris, Bifidobacterium longum, Collinsella aerofaciens, Eubacterium rectale, Bacteroides stercoris, Bifidobacterium longum, Collinsella aerofaciens, Eubacterium siraeum, Bacteroides stercoris, Bifidobacterium longum, Coprococcus comes, Eubacterium ventriosum, Bacteroides thetaiotaomicron, Bifidobacterium pseudocatenulatum, Coprococcus eutactus, Faecalibacterium prausnitzii, Bacteroides thetaiotaomicron, Bifidobacterium pseudocatenulatum, Coprococcus eutactus, Faecalibacterium prausnitzii, Bacteroides thetaiotaomicron, Bifidobacterium pseudocatenulatum, Coprococcus eutactus, Hungatella hathewayi, Bacteroides, Petition 870250102358, dated 07 / 11 / 2025, p. 65 / 280 57 / 227 uniformis, Blautia hydrogenotrophica, Desulfovibrio desulfuricans, Hungatella hathewayi, Bacteroides uniformis, Blautia obeum, Desulfovibrio desulfuricans, Neglecta timonensis, Bacteroides vulgatus, Blautia obeum, Dorea formicigenerans, Oxalobacter formigenes, Bacteroides vulgatus, Clostridium amygdalinum, Dorea longicatena and Oxalobacter formigenes.

[0124] In certain embodiments, the Consortium comprises a plurality of microbes (e.g., active microbes and support community microbes) designated as “Consortium V” In certain embodiments, the Consortium V comprises Acidaminococcus intestini, Bacteroides uniformis, Clostridium citoniae, Eubacterium ventriosum, Phascolarctobacterium faecium, Akkermansia muciniphila, Bacteroides vulgatus, Clostridium clostridioforme, Eubacterium siraeum, Phascolarctobacterium faecium, Alistipes finegoldii, Bacteroides vulgatus, Clostridium scindens, Eubacterium xylanophilum, Phocea massiliensis, Alistipes onderdonkii, Bacteroides xylanisolvens, Clostridium swellfunianum, Faecalibacterium prausnitzii, Phocea massiliensis, Alistipes onderdonkii, Bacteroides xylanisolvens, Clostridium symbiosum, Faecalibacterium prausnitzii, Porphyromonas asaccharolytica, Alistipes putredinis, Barnesiella human intestine, Clostridium symbiosum, Faecalicatena contorta, Porphyromonas asaccharolytica,Alistipes putredinis, Bifidobacterium adolescentis, Collinsella aerofaciens, Fusicatenibacter saccharivorans, Roseburia hominis, Alistipes senegalensis, Bifidobacterium adolescentis, Collinsella aerofaciens, Fusicatenibacter saccharivorans, Roseburia hominis, Alistipes senegalensis, Bifidobacterium bifidum, Coprococcus comes, Gordonibacter pamelaeae, Ruminococcus bromii, Alistipes shahii, Bifidobacterium bifidum, Coprococcus comes, Gordonibacter pamelaeae, Ruminococcus bromii, Alistipes timonensis, Bifidobacterium catenulatum, Coprococcus eutactus, Holdemanella, Petition 870250102358, dated 07 / 11 / 2025, p. 66 / 280 58 / 227 biformis, Ruminococcus faecis, Anaerofustis stercorihominis, Bifidobacterium dentium, Coprococcus eutactus, Holdemanella biformis, Ruminococcus faecis, Anaerostipes hadrus, Bifidobacterium faecale, Desulfovibrio desulfuricans, Hungatella effluvii, Ruthenibacterium lactatiformans, Anaerostipes hadrus, Bifidobacterium longum, Desulfovibrio desulfuricans, Hungatella hathawayi, Senegalmassilia anaerobia, Anaerotruncus colihominis, Bifidobacterium longum, Dialister invisus, Hungatella hathawayi, Sutterella massiliensis, Bacteroides caccae, Bifidobacterium pseudocatenulatum, Dialister succinatiphilus, Hydrogenoanaerobacterium saccharovorans, Sutterella wadsworthensis, Bacteroides caccae, Bifidobacterium pseudocatenulatum, Dielma fastidiosa, Lachnoclostridium pacaense, Sutterella wadsworthensis, Bacteroides coprocola, Bifidobacterium pseudocatenulatum, Dorea formicigenerans, Lachnoclostridium pacaense, Turicibacter sanguinis, Bacteroides faecis, Blautia faecis, Dorea formicigenerans,Lachnospira pectinoschiza, Bacteroides finegoldii, Blautia faecis, Dorea longicatena, Lachnospira pectinoschiza, Bacteroides fragilis, Blautia hydrogenotrophica, Dorea longicatena, Lactonifactor longoviformis, Bacteroides koreensis, Blautia luti, Eggerthella lenta, Longicatena caecimuris, Bacteroides koreensis, Blautia obeum, Eggerthella lenta, Megasphaera massiliensis, Bacteroides kribbi, Blautia obeum, Eggerthella lenta, Monoglobus pectinolyticus, Bacteroides kribbi, Blautia wexlerae, Eggerthella lenta, Monoglobus pectinolyticus, Bacteroides massiliensis, Blautia wexlerae, Eisenbergiella tayi, Neglecta timonensis, Bacteroides nordii, Butyricimonas faecihominis, Eisenbergiella tayi, Oxalobacter formigenes, Bacteroides oleiciplenus, Catabacter hongkongensis, Emergence timonensis, Oxalobacter formigenes, Bacteroides ovatus, Citrobacter freundii, Eubacterium eligens, Oxalobacter formigenes, Petition 870250102358, dated 07 / 11 / 2025, p. 67 / 280 59 / 227 Bacteroides salyersiae, Clostridium aldenense, Eubacterium eligens, Parabacteroides distasonis, Bacteroides stercoris, Clostridium aldenense, Eubacterium hallii, Parabacteroides merdae, Bacteroides stercoris, Clostridium amygdalinum, Eubacterium oxidoreducens, Parabacteroides merdae, Bacteroides thetaiotaomicron, Clostridium bolteae, Eubacterium rectale, Paraprevotella clara, Bacteroides thetaiotaomicron, Clostridium bolteae, Eubacterium rectale, Parasutterella excrementihominis, Bacteroides uniformis, Clostridium citroniae, Eubacterium ruminantium and Parasutterella excrementihominis.

[0125] In certain embodiments, the Consortium comprises a plurality of microbes (e.g., active microbes and supporting community microbes) designated as “Consortium VI”. In certain embodiments, Consortium VI comprises Acidaminococcus intestini, Bacteroides stercorirosoris, Butyricimonas sp. FBI00158, Enterococcus casseliflavus, Longicatena caecimuri, Acidaminococcus intestini, Bacteroides stercoris, Catabacter hongkongensis, Enterococcus casseliflavus, Megasphaera massiliensis, Acutalibacter timonensis, Bacteroides stercoris, Citrobacter portucalensis, Enterococcus durans, Methanobrevibacter smithii, Akkermansia muciniphila, Bacteroides thetaiotaomicron, Clostridiaceae sp.FBI00191, Enterococcus durans, Monoglobus pectinolyticus, Alistipes onderdonkii, Bacteroides thetaiotaomicron, Clostridium aldenense, Enterococcus durans, Monoglobus pectinolyticus, Alistipes onderdonkii, Bacteroides uniformis, Clostridium aldenense, Enterococcus faecalis, Oxalobacter formigenes, Alistipes putredinis, Bacteroides uniformis, Clostridium bolteae, Enterococcus faecium, Oxalobacter formigenes, Alistipes putredinis, Bacteroides vulgatus, Clostridium bolteae, Escherichia flexneri, Oxalobacter formigenes, Alistipes senegalensis, Bacteroides vulgatus, Clostridium citroniae, Eubacterium eligens, Parabacteroides. Petition 870250102358, dated 07 / 11 / 2025, p. 68 / 280 60 / 227 distasonis, Alistipes shahii, Bacteroides xylanisolvens, Clostridium citroniae, Eubacterium eligens, Parabacteroides distasonis, Alistipes shahii, Bacteroides xylanisolvens, Clostridium clostridioforme, Eubacterium hallii, Parabacteroides merdae, Alistipes sp. FBI00180, Bacteroides xylanisolvens, Clostridium fessum, Eubacterium rectale, Parabacteroides merdae, Alistipes sp. FBI00238, Barnesiella intestinihominis, Clostridium fessum, Eubacterium rectale, Paraprevotella clara, Alistipes timonensis, Bifidobacterium adolescentis, Clostridium scindens, Eubacterium siraeum, Parasutterella excrementihominis, Anaerofustis stercorihominis, Bifidobacterium adolescentis, Collinsella aerofaciens, Eubacterium ventriosum, Parasutterella excrementihominis, Anaerostipes hadrus, Bifidobacterium adolescentis, Collinsella aerofaciens, Eubacterium xylanophilum, Phascolarctobacterium faecium, Anaerostipes hadrus, Bifidobacterium adolescentis, Coprococcus comes, Faecalibacterium prausnitzii,Phascolarctobacterium faecium, Anaerotruncus massiliensis, Bifidobacterium bifidum, Coprococcus comes, Faecalibacterium prausnitzii, Porphyromonas asaccharolytica, Bacteroides caccae, Bifidobacterium bifidum, Coprococcus eutactus, Faecalitatena contorta, Porphyromonas asaccharolytica, Bacteroides caccae, Bifidobacterium catenulatum, Dialister invisus, Fusicatenibacter saccharivorans, Roseburia hominis, Bacteroides cellulosilyticus, Bifidobacterium dentium, Coprococcus eutactus, Fusicatenibacter saccharivorans, Roseburia hominis, Bacteroides cellulosilyticus, Bifidobacterium longum, Dialister succinatiphilus, Gordonibacter pamelaeae, Ruminococcaceae sp. FBI00097, Bacteroides coprocola, Bifidobacterium longum, Dialister succinatiphilus, Gordonibacter pamelaeae, Ruminococcaceae sp. FBI00097, Bacteroides dorei, Bifidobacterium pseudocatenulatum, Dielma fastidiosa, Holdemanella biformis, Ruminococcaceae sp. FBI00233, Bacteroides dorei, Bifidobacterium, Petition 870250102358, dated 07 / 11 / 2025, p. 69 / 280 61 / 227 pseudocatenulatum, Dorea formicigenerans, Holdemanella biformis, Ruminococcus bromii, Bacteroides faecis, Bilophila wadsworthia, Dorea formicigenerans, Hungatella effluvii, Ruminococcus bromii, Bacteroides finegoldii, Bilophila wadsworthia, Dorea longicatena, Hungatella effluvii, Ruminococcus faecis, Bacteroides fragilis, Blautia faecis, Dorea longicatena, Hungatella effluvii, Ruminococcus faecis, Bacteroides kribbi / Bacteroides koreensis species cluster, Blautia faecis, Eggerthella lenta, Lachnoclostridium pacaense, Ruthenibacterium lactatiformans, Bacteroides kribbi / Bacteroides koreensis species cluster, Blautia hydrogenotrophica, Eggerthella lenta, Lachnoclostridium pacaense, Senegalemassilia anaerobia, Bacteroides kribbi / Bacteroides koreensis species cluster, Blautia luti, Eisenbergiella tayi, Lachnospiraceae sp. FBI00033, Sutterella massiliensis, Bacteroides massiliensis, Blautia massiliensis, Emergencia timonensis, Lachnospiraceae sp.FBI00071, Sutterella wadsworthensis, Bacteroides massiliensis, Blautia obeum, Eisenbergiella tayi, Lachnospiraceae sp. FBI00150, Sutterella wadsworthensis, Bacteroides nordii, Blautia obeum, Enterobacter himalayensis, Lachnospiraceae sp. FBI00290, Turicibacter sanguinis, Bacteroides ovatus, Blautia wexlerae, Enterobacter hormaechei, Lactobacillus rogosae, Bacteroides salyersiae, Blautia wexlerae, Enterococcus casseliflavus, Lactobacillus rogosae, Bacteroides salyersiae, Butyricimonas faecihominis, Enterococcus casseliflavus and Lactonifactor longaviformis.

[0126] In certain embodiments, the Consortium comprises a plurality of microbes (e.g., active microbes and supporting community microbes) designated as “Consortium VII”. In certain embodiments, Consortium VII comprises Acidaminococcus intestini, Bacteroides thetaiotaomicron, Citrobacter portucalensis, Eubacterium eligens, Oxalobacter formigenes, Acutalibacter timonensis, Bacteroides uniformis, Petition 870250102358, dated 07 / 11 / 2025, p. 70 / 280 62 / 227 Clostridiaceae sp. FBI00191, Eubacterium hallii, Parabacteroides distasonis, Akkermansia muciniphila, Bacteroides uniformis, Clostridium aldenense, Eubacterium rectale, Parabacteroides merdae, Alistipes onderdonkii, Bacteroides vulgatus, Clostridium aldenense, Eubacterium rectale, Parabacteroides merdae, Alistipes onderdonkii, Bacteroides vulgatus, Clostridium bolteae, Eubacterium siraeum, Paraprevotella clara, Alistipes putredinis, Bacteroides xylanisolvens, Clostridium bolteae, Eubacterium ventriosum, Parasutterella excrementihominis, Alistipes putredinis, Bacteroides xylanisolvens, Clostridium citroniae, Faecalibacterium prausnitzii, Parasutterella excrementihominis, Alistipes senegalensis, Bacteroides xylanisolvens, Clostridium citroniae, Eubacterium xylanophilum, Phascolarctobacterium faecium, Alistipes shahii, Barnesiella intestinihominis, Clostridium clostridioforme, Faecalibacterium prausnitzii, Phascolarctobacterium faecium, Alistipes sp.FBI00180, Bifidobacterium adolescentis, Clostridium fessum, Faecalicatena contorta, Porphyromonas asaccharolytica, Alistipes sp. FBI00238, Bifidobacterium adolescentis, Clostridium fessum, Fusicatenibacter saccharivorans, Porphyromonas asaccharolytica, Alistipes timonensis, Bifidobacterium adolescentis, Clostridium scindens, Fusicatenibacter saccharivorans, Roseburia hominis, Anaerofustis stercorihominis, Bifidobacterium bifidum, Collinsella aerofaciens, Gordonibacter pamelaeae, Roseburia hominis, Anaerostipes hadrus, Bifidobacterium bifidum, Collinsella aerofaciens, Gordonibacter pamelaeae, Ruminococcaceae sp. FBI00097, Anaerostipes hadrus, Bifidobacterium catenulatum, Coprococcus comes, Holdemanella biformis, Ruminococcaceae sp. FBI00097, Anaerotruncus massiliensis, Bifidobacterium dentium, Coprococcus comes, Holdemanella biformis, Ruminococcaceae sp. FBI00233, Bacteroides caccae, Bifidobacterium longum, Coprococcus eutactus, Hungatella. Petition 870250102358, dated 07 / 11 / 2025, p. 71 / 280 63 / 227 effluvii, Ruminococcus bromii, Bacteroides caccae, Bifidobacterium longum, Coprococcus eutactus, Hungatella effluvii, Ruminococcus bromii, Bacteroides coprocola, Bifidobacterium pseudocatenulatum, Dialister invisus, Hungatella effluvii, Ruminococcus faecis, Bacteroides faecis, Bifidobacterium pseudocatenulatum, Dialister succinatiphilus, Lachnoclostridium pacaense, Ruminococcus faecis, Bacteroides finegoldii, Bifidobacterium pseudocatenulatum, Dielma fastidiosa, Lachnoclostridium pacaense, Ruthenibacterium lactatiformans, Bacteroides fragilis, Bilophila wadsworthia, Dorea formicigenerans, Lachnospiraceae sp . FBI00033, Senegalmassilia anaerobia, Bacteroides kribbi / Bacteroides koreensis species cluster, Bilophila wadsworthia, Dorea formicigenerans, Lachnospiraceae sp. FBI00071, Sutterella massiliensis, Bacteroides kribbi / Bacteroides koreensis species cluster, Blautia faecis, Dorea longicatena, Lachnospiraceae sp.FBI00290, Sutterella wadsworthensis, Bacteroides kribbi / Bacteroides koreensis species cluster, Blautia faecis, Dorea longicatena, Lactobacillus rogosae, Sutterella wadsworthensis, Bacteroides massiliensis, Blautia hydrogenotrophica, Eggerthella lenta, Lactobacillus rogosae, Turicibacter sanguinis, Bacteroides nordii, Blautia massiliensis, Eggerthella lenta, Lactonifactor longoviformis, Bacteroides ovatus, Blautia obeum, Eggerthella lenta, Longicatena caecimuris, Bacteroides salyersiae, Blautia obeum, Eggerthella lenta, Megasphaera massiliensis, Bacteroides stercorirosoris, Blautia wexlerae, Eisenbergiella tayi, Monoglobus pectinolyticus, Bacteroides stercoris, Blautia wexlerae, Eisenbergiella tayi, Monoglobus pectinolyticus, Bacteroides stercoris, Butyricimonas faecihominis, Emergence timonensis, Oxalobacter formigenes, Bacteroides thetaiotaomicron, Catabacter hongkongensis, Eubacterium eligens and Oxalobacter formigenes.

[0127] In certain modalities, the Consortium comprises Petition 870250102358, dated 07 / 11 / 2025, page 72 / 280 64 / 227 a plurality of microbes (e.g., active microbes and supporting community microbes) designated as “Consortium VIII”. In certain embodiments, Consortium VIII comprises Acidaminococcus intestini, Bacteroides thetaiotaomicron, Butyricimonas faecihominis, Eisenbergiella tayi, Monoglobus pectinilyticus, Acutalibacter timonensis, Bacteroides thetaiotaomicron, Catabacter hongkongensis, Emergencia timonensis, Monoglobus pectinilyticus, Akkermansia muciniphila, Bacteroides uniformis, Citrobacter portucalensis, Eubacterium eligens, Oxalobacter formigenes, Alistipes onderdonkii, Bacteroides uniformis, Clostridiaceae sp.FBI00191, Eubacterium eligens, Oxalobacter formigenes, Alistipes onderdonkii, Bacteroides vulgatus, Clostridium aldenense, Eubacterium hallii, Oxalobacter formigenes, Alistipes putredinis, Bacteroides vulgatus, Clostridium aldenense, Eubacterium rectale, Parabacteroides distasonis, Alistipes putredinis, Bacteroides xylanisolvens, Clostridium bolteae, Eubacterium rectale, Parabacteroides merdae, Alistipes senegalensis, Bacteroides xylanisolvens, Clostridium bolteae, Eubacterium siraeum, Parabacteroides merdae, Alistipes shahii, Bacteroides xylanisolvens, Clostridium citroniae, Eubacterium ventriosum, Paraprevotella clara, Alistipes sp. FBI00180, Barnesiella intestinihominis, Clostridium citroniae, Faecalibacterium prausnitzii, Parasutterella excrementihominis, Alistipes sp.FBI00238, Bifidobacterium adolescentis, Clostridium clostridioforme, Eubacterium xylanophilum, Parasutterella excrementihominis, Alistipes timonensis, Bifidobacterium adolescentis, Clostridium fessum, Faecalibacterium prausnitzii, Phascolarctobacterium faecium, Anaerofustis stercorihominis, Bifidobacterium adolescentis, Clostridium fessum, Faecalicatena contorta, Phascolarctobacterium faecium, Anaerostipes hadrus, Bifidobacterium bifidum, Clostridium scindens, Fusicatenibacter saccharivorans, Porphyromonas asaccharolytica, Anaerostipes. Petition 870250102358, dated 07 / 11 / 2025, p. 73 / 280 65 / 227 hadrus, Bifidobacterium bifidum, Collinsella aerofaciens, Fusicatenibacter saccharivorans, Porphyromonas asaccharolytica, Anaerotruncus massiliensis, Bifidobacterium catenulatum, Collinsella aerofaciens, Gordonibacter pamelaeae, Roseburia hominis, Bacteroides caccae, Bifidobacterium dentium, Coprococcus comes, Gordonibacter pamelaeae, Roseburia hominis, Bacteroides caccae, Bifidobacterium longum, Coprococcus comes, Holdemanella biformis, Ruminococcaceae sp. FBI00097, Bacteroides coprocola, Bifidobacterium longum, Coprococcus eutactus, Holdemanella biformis, Ruminococcaceae sp. FBI00097, Bacteroides faecis, Bifidobacterium pseudocatenulatum, Coprococcus eutactus, Hungatella effluvii, Ruminococcaceae sp.FBI00233, Bacteroides finegoldii, Bifidobacterium pseudocatenulatum, Dialister invisus, Hungatella effluvii, Ruminococcus bromii, Bacteroides fragilis, Bifidobacterium pseudocatenulatum, Dialister succinatiphilus, Hungatella effluvii, Ruminococcus bromii, Bacteroides kribbi / Bacteroides koreensis species cluster, Bilophila wadsworthia, Dielma fastidiosa, Lachnoclostridium pacaense, Ruminococcus faecis, Bacteroides kribbi / Bacteroides koreensis species cluster, Bilophila wadsworthia, Dorea formicigenerans, Lachnoclostridium pacaense, Ruminococcus faecis, Bacteroides kribbi / Bacteroides koreensis species cluster, Blautia faecis, Dorea formicigenerans, Lachnospiraceae sp. FBI00033, Ruthenibacterium lactatiformans, Bacteroides massiliensis, Blautia faecis, Dorea longicatena, Lachnospiraceae sp. FBI00071, Senegalimassilia anaerobia, Bacteroides nordii, Blautia hydrogenotrophica, Dorea longicatena, Lachnospiraceae sp.FBI00290, Sutterella massiliensis, Bacteroides ovatus, Blautia massiliensis, Eggerthella lenta, Lactobacillus rogosae, Sutterella wadsworthensis, Bacteroides salyersiae, Blautia obeum, Eggerthella lenta, Lactobacillus rogosae, Sutterella wadsworthensis, Bacteroides stercorirosoris, Blautia obeum,. Petition 870250102358, dated 07 / 11 / 2025, p. 74 / 280 66 / 227 Eggerthella lenta, Lactonifactor longoviformis, Turicibacter sanguinis, Bacteroides stercoris, Blautia wexlerae, Eggerthella lenta, Longicatena caecimuris, Bacteroides stercoris, Blautia wexlerae, Eisenbergiella tayi and Megasphaera massiliensis.

[0128] In certain embodiments, the Consortium comprises a plurality of microbes (e.g., active microbes and supporting community microbes) designated as “Consortium IX.” In certain embodiments, Consortium XI comprises Acidaminococcus intestini, Bacteroides thetaiotaomicron, Butyricimonas faecihominis, Eubacterium eligens, Neglecta timonensis, Akkermansia muciniphila, Bacteroides thetaiotaomicron, Catabacter hongkongensis, Eubacterium eligens, Oxalobacter formigenes, Alistipes onderdonkii, Bacteroides uniformis, Clostridiaceae sp. FBI00191, Eubacterium hallii, Oxalobacter formigenes, Alistipes onderdonkii, Bacteroides uniformis, Clostridiales sp.FBI00377, Eubacterium rectale, Oxalobacter formigenes, Alistipes putredinis, Bacteroides vulgatus, Clostridium aldenense, Eubacterium rectale, Parabacteroides distasonis, Alistipes putredinis, Bacteroides vulgatus, Clostridium aldenense, Eubacterium siraeum, Parabacteroides distasonis, Alistipes senegalensis, Bacteroides xylanisolvens, Clostridium bolteae, Eubacterium ventriosum, Parabacteroides merdae, Alistipes shahii, Bacteroides xylanisolvens, Clostridium bolteae, Eubacterium xylanophilum, Parabacteroides merdae, Alistipes shahii, Bacteroides xylanisolvens, Clostridium citroniae, Faecalibacterium prausnitzii, Paraprevotella clara, Alistipes sp. FBI00180, Barnesiella intestinihominis, Clostridium citroniae, Fusicatenibacter saccharivorans, Parasutterella excrementihominis, Alistipes sp.FBI00238, Bifidobacterium adolescentis, Clostridium clostridioforme, Fusicatenibacter saccharivorans, Parasutterella excrementihominis, Alistipes timonensis, Bifidobacterium adolescentis, Clostridium fessum,. Petition 870250102358, dated 07 / 11 / 2025, p. 75 / 280 67 / 227 Gordonibacter pamelaeae, Phascolarctobacterium faecium, Anaerofustis stercorihominis, Bifidobacterium adolescentis, Clostridium scindens, Gordonibacter pamelaeae, Porphyromonas asaccharolytica, Anaerostipes hadrus, Bifidobacterium bifidum, Collinsella aerofaciens, Holdemanella biformis, Porphyromonas asaccharolytica, Anaerostipes hadrus, Bifidobacterium catenulatum, Collinsella aerofaciens, Hungatella effluvii, Roseburia hominis, Anaerotruncus massiliensis, Bifidobacterium dentium, Coprococcus comes, Hungatella effluvii, Roseburia hominis, Bacteroides caccae, Bifidobacterium longum, Coprococcus comes, Hungatella effluvii, Ruminococcaceae sp. FBI00082, FBI00097, Bacteroides caccae, Bifidobacterium longum, Coprococcus eutactus, Lachnoclostridium pacaense, Ruminococcaceae sp.FBI00233, Bacteroides coprocola, Bifidobacterium pseudocatenulatum, Dialister invisus, Lachnoclostridium pacaense, Ruminococcus bromii, Bacteroides faecis, Bifidobacterium pseudocatenulatum, Dialister succinatiphilus, Lachnospiraceae sp. FBI00033, Ruminococcus bromii, Bacteroides finegoldii, Bifidobacterium pseudocatenulatum, Dielma fastidiosa, Lachnospiraceae sp. FBI00071, Ruminococcus faecis, Bacteroides fragilis, Bilophila wadsworthia, Dorea formicigenerans, Lachnospiraceae sp.FBI00290, Ruminococcus faecis, Bacteroides kribbi / Bacteroides koreensis species cluster, Bilophila wadsworthia, Dorea formicigenerans, Lactobacillus rogosae, Ruthenibacterium lactatiformans, Bacteroides kribbi / Bacteroides koreensis species cluster, Blautia faecis, Dorea longicatena, Lactobacillus rogosae, Senegalmassilia anaerobia, Bacteroides massiliensis, Blautia faecis, Dorea longicatena, Longicatena caecimuris, Sutterella massiliensis, Bacteroides nordii, Blautia hydrogenotrophica, Eggerthella lenta, Megasphaera massiliensis, Sutterella wadsworthensis, Bacteroides ovatus, Blautia massiliensis, Eggerthella lenta, Methanobrevibacter smithii,. Petition 870250102358, dated 07 / 11 / 2025, p. 76 / 280 68 / 227 Sutterella wadsworthensis, Bacteroides salyersiae, Blautia obeum, Eggerthella lenta, Methanobrevibacter smithii, Turicibacter sanguinis, Bacteroides stercorirosoris, Blautia obeum, Eggerthella lenta, Monoglobus pectinolyticus, Bacteroides stercoris, Blautia wexlerae, Eisenbergiella tayi, Monoglobus pectinolyticus, Bacteroides stercoris, Blautia wexlerae, Eisenbergiella tayi and Neglecta timonensis.

[0129] In certain embodiments, the Consortium comprises a plurality of microbes (e.g., active microbes and supporting community microbes) designated as “Consortium X.” In certain embodiments, Consortium X comprises Acidaminococcus intestini, Bacteroides thetaiotaomicron, Butyricimonas faecihominis, Eubacterium eligens, Monoglobus pectinilyticus, Akkermansia muciniphila, Bacteroides thetaiotaomicron, Catabacter hongkongensis, Eubacterium eligens, Neglecta timonensis, Alistipes onderdonkii, Bacteroides uniformis, Clostridiaceae sp. FBI00191, Eubacterium hallii, Neglecta timonensis, Alistipes onderdonkii, Bacteroides uniformis, Clostridiales sp.FBI00377, Eubacterium rectale, Oxalobacter formigenes, Alistipes putredinis, Bacteroides vulgatus, Clostridium aldenense, Eubacterium rectale, Oxalobacter formigenes, Alistipes putredinis, Bacteroides vulgatus, Clostridium aldenense, Eubacterium siraeum, Oxalobacter formigenes, Alistipes senegalensis, Bacteroides xylanisolvens, Clostridium bolteae, Eubacterium ventriosum, Parabacteroides distasonis, Alistipes shahii, Bacteroides xylanisolvens, Clostridium bolteae, Eubacterium xylanophilum, Parabacteroides distasonis, Alistipes shahii, Bacteroides xylanisolvens, Clostridium citroniae, Faecalibacterium prausnitzii, Parabacteroides merdae, Alistipes sp. FBI00180, Barnesiella intestinihominis, Clostridium citroniae, Faecalibacterium prausnitzii, Parabacteroides merdae, Alistipes sp. FBI00238, Bifidobacterium adolescentis, Clostridium. Petition 870250102358, dated 07 / 11 / 2025, p. 77 / 280 69 / 227 clostridioforme, Fusicatenibacter saccharivorans, Paraprevotella clara, Alistipes timonensis, Bifidobacterium adolescentis, Clostridium fessum, Fusicatenibacter saccharivorans, Parasutterella excrementihominis, Anaerofustis stercorihominis, Bifidobacterium adolescentis, Clostridium scindens, Gordonibacter pamelaeae, Parasutterella excrementihominis, Anaerostipes hadrus, Bifidobacterium bifidum, Collinsella aerofaciens, Gordonibacter pamelaeae, Phascolarctobacterium faecium, Anaerostipes hadrus, Bifidobacterium catenulatum, Collinsella aerofaciens, Holdemanella biformis, Porphyromonas asaccharolytica, Anaerotruncus massiliensis, Bifidobacterium dentium, Coprococcus comes, Holdemanella biformis, Porphyromonas asaccharolytica, Bacteroides caccae, Bifidobacterium longum, Coprococcus comes, Hungatella effluvii, Roseburia hominis, Bacteroides caccae, Bifidobacterium longum, Coprococcus eutactus, Hungatella effluvii, Roseburia hominis, Bacteroides coprocola,Bifidobacterium pseudocatenulatum, Dialister invisus, Hungatella effluvii, Ruminococcaceae sp . FBI00082 FBI00097, Bacteroides faecis, Bifidobacterium pseudocatenulatum, Dialister succinatiphilus, Lachnoclostridium pacaense, Ruminococcaceae sp. FBI00233, Bacteroides finegoldii, Bifidobacterium pseudocatenulatum, Dielma fastidiosa, Lachnoclostridium pacaense, Ruminococcus bromii, Bacteroides fragilis, Bilophila wadsworthia, Dorea formicigenerans, Lachnospiraceae sp. FBI00033, Ruminococcus bromii, Bacteroides kribbi / Bacteroides koreensis species cluster, Bilophila wadsworthia, Dorea formicigenerans, Lachnospiraceae sp. FBI00071, Ruminococcus faecis, Bacteroides kribbi / Bacteroides koreensis species cluster, Blautia faecis, Dorea longicatena, Lachnospiraceae sp. FBI00290, Ruminococcus faecis, Bacteroides massiliensis, Blautia faecis, Dorea longicatena, Lactobacillus rogosae, Ruthenibacterium lactatiformans, Bacteroides nordii, Petition 870250102358, dated 07 / 11 / 2025, p. 78 / 280 70 / 227 Blautia hydrogenotrophica, Eggerthella lenta, Lactobacillus rogosae, Senegalmassilia anaerobia, Bacteroides ovatus, Blautia massiliensis, Eggerthella lenta, Longicatena caecimuris, Sutterella massiliensis, Bacteroides salyersiae, Blautia obeum, Eggerthella lenta, Megasphaera massiliensis, Sutterella wadsworthensis, Bacteroides stercorirosoris, Blautia obeum, Eggerthella lenta, Methanobrevibacter smithii, Sutterella wadsworthensis, Bacteroides stercoris, Blautia wexlerae, Eisenbergiella tayi, Methanobrevibacter smithii, Turicibacter sanguinis, Bacteroides stercoris, Blautia wexlerae, Eisenbergiella tayi and Monoglobus pectinolyticus.

[0130] In certain embodiments, the Consorcio comprises a plurality of microbes (for example, active microbes and microbes from the community of support) designated as "Consórcio XI" In certain embodiments, the Consorcio XI comprises Acidaminococcus intestini, Bifidobacterium longum, Fusicatenibacter saccharivorans, Bacteroides xylanisolvens, Clostridium bolteae, Akkermansia muciniphila, Bilophila wadsworthia, Gordonibacter pamelaeae, Turicibacter sanguinis, Collinsella aerofaciens, Alistipes onderdonkii, Blautia hydrogenotrophica, Hungatella effluvii, Bifidobacterium adolescentis, Coprococcus comes, Alistipes putredinis, Blautia massiliensis, Lachnoclostridium pacaense, Bifidobacterium pseudocatenulatum, Dorea formicigenerans, Alistipes senegalensis, Blautia obeum, Lachnospiraceae sp. FBI00033, Blautia faecis, Dorea longicatena, Alistipes shahii, Blautia wexlerae, Lachnospiraceae sp. FBI00071, Clostridium citroniae, Eggerthella lenta, Alistipes sp.FBI00180, Butyricimonas faecihominis, Lachnospiraceae sp. FBI00290, Faecalibacterium prausnitzii, Eggerthella lenta, Alistipes sp. FBI00238, Catabacter hongkongensis, Lactobacillus rogosae, Holdemanella biformis, Eggerthella lenta, Alistipes timonensis, Clostridiaceae sp. FBI00191, Longicatena caecimuris, Bacteroides. Petition 870250102358, dated 07 / 11 / 2025, p. 79 / 280 71 / 227 xylanisolvens, Eisenbergiella tayi, Anaerofustis stercorihominis, Clostridiales sp. FBI00377, Megasphaera massiliensis, Bifidobacterium adolescentis , Eubacterium eligens, Anaerostipes hadrus, Clostridium aldenense, Methanobrevibacter smithii, Bifidobacterium pseudocatenulatum, Eubacterium rectale, Anaerotruncus massiliensis, Clostridium bolteae, Monoglobus pectinolyticus, Blautia faecis, Fusicatenibacter saccharivorans, Bacteroides caccae, Clostridium clostridioforme, Neglecta timonensis, Alistipes onderdonkii, Gordonibacter pamelaeae, Bacteroides coprocola, Clostridium fessum, Oxalobacter formigenes, Clostridium citroniae, Hungatella effluvia, Bacteroides faecis, Clostridium scindens, Oxalobacter formigenes, Alistipes putredinis, Hungatella effluvia, Bacteroides finegoldii, Collinsella aerofaciens, Oxalobacter formigenes, Alistipes shahii, Lachnoclostridium pacaense, Bacteroides fragilis, Coprococcus comes, Parabacteroides distasonis, Anaerostipes hadrus, Lactobacillus rogosae, Bacteroides kribbi / Bacteroides koreensis species cluster, Coprococcus eutactus, Parabacteroides merdae, Bacteroides caccae, Methanobrevibacter smithii, Bacteroides massiliensis, Dialister invisus, Paraprevotella clara, Bacteroides kribbi / Bacteroides koreensis species cluster, Monoglobus pectinolyticus, Bacteroides nordii, Dialister succinatiphilus, Parasutterella excrementihominis, Bacteroides stercoris, Neglecta timonensis, Bacteroides ovatus, Dielma fastidiosa, Phascolarctobacterium faecium, Bacteroides thetaiotaomicron, Parabacteroides distasonis, Bacteroides salyersiae, Dorea formicigenerans, Porphyromonas asaccharolytica, Bacteroides uniformis, Parabacteroides merdae, Bacteroides stercorirosoris, Dorea longicatena,Roseburia hominis, Bacteroides vulgatus, Parasutterella excrementihominis, Bacteroides stercoris, Eggerthella lenta, Ruminococcaceae sp. FBI00082 FBI00097, Bacteroides, Petition 870250102358, dated 07 / 11 / 2025, p. 80 / 280 72 / 227 xylanisolvens, Porphyromonas asaccharolytica, Bacteroides thetaiotaomicron, Eisenbergiella tayi, Ruminococcaceae sp. FBI00233, Bifidobacterium adolescentis, Roseburia hominis, Bacteroides uniformis, Eubacterium eligens, Ruminococcus bromii, Bifidobacterium longum, Ruminococcus bromii, Bacteroides vulgatus, Eubacterium hallii, Ruminococcus faecis, Bifidobacterium pseudocatenulatum, Ruminococcus faecis, Barnesiella intestinihominis, Eubacterium rectale, Ruthenibacterium lactatiformans, Bilophila wadsworthia, Sutterella wadsworthensis, Bifidobacterium bifidum, Eubacterium siraeum, Senegalmassilia anaerobia, Blautia obeum, Bifidobacterium catenulatum, Eubacterium ventriosum, Sutterella massiliensis, Blautia wexlerae, Bifidobacterium dentium, Eubacterium xylanophilum, Sutterella wadsworthensis and Clostridium aldenense.

[0131] In particular, the Consorcio comprises a plurality of microbes (for example, active microbes and microbios from the community of support) designated as "Consórcio XII" In particular, the Consorcio XII comprises Acidaminococcus intestini, Bacteroides uniformis, Clostridium bolteae, Faecalibacterium prausnitzii, Parasutterella excrementihominis, Akkermansia muciniphila, Bacteroides vulgatus, Clostridium bolteae, Faecalibacterium prausnitzii, Phascolarctobacterium faecium, Alistipes onderdonkii, Bacteroides vulgatus, Clostridium citroniae, Fusicatenibacter saccharivorans, Phascolarctobacterium faecium, Alistipes onderdonkii, Bacteroides xylanisolvens, Clostridium citroniae, Fusicatenibacter saccharivorans, Porphyromonas asaccharolytica, Alistipes putredinis, Bacteroides xylanisolvens, Clostridium clostridioforme, Gordonibacter pamelaeae, Porphyromonas asaccharolytica, Alistipes putredinis, Bacteroides xylanisolvens, Clostridium fessum,Gordonibacter pamelaeae, Roseburia hominis, Alistipes senegalensis, Barnesiella, Petition 870250102358, dated 07 / 11 / 2025, p. 81 / 280 73 / 227 intestinihominis, Clostridium fessum, Holdemanella biformis, Roseburia hominis, Alistipes shahii, Bifidobacterium adolescentis, Clostridium scindens, Holdemanella biformis, Ruminococcaceae sp. FBI00082 FBI00097, Alistipes shahii, Bifidobacterium adolescentis, Collinsella aerofaciens, Hungatella effluvii, Ruminococcaceae sp. FBI00082 FBI00097, Alistipes sp. FBI00180, Bifidobacterium adolescentis, Collinsella aerofaciens, Hungatella effluvii, Ruminococcaceae sp. FBI00233, Alistipes sp. FBI00238, Bifidobacterium bifidum, Coprococcus comes, Hungatella effluvii, Ruminococcus bromii, Alistipes timonensis, Bifidobacterium bifidum, Coprococcus comes, Lachnoclostridium pacaense, Ruminococcus bromii, Anaerofustis stercorihominis, Bifidobacterium catenulatum, Coprococcus eutactus, Lachnoclostridium pacaense, Ruminococcus faecis, Anaerostipes hadrus, Bifidobacterium dentium, Coprococcus eutactus, Lachnospiraceae sp.FBI00033, Ruminococcus faecis, Anaerostipes hadrus, Bifidobacterium longum, Dialister invisus, Lachnospiraceae sp. FBI00071, Ruthenibacterium lactatiformans, Anaerotruncus massiliensis, Bifidobacterium longum, Dialister succinatiphilus, Lachnospiraceae sp.FBI00290, Senegalmassilia anaerobia, Bacteroides caccae, Bifidobacterium pseudocatenulatum, Dielma fastidiosa, Lactobacillus rogosae, Sutterella massiliensis, Bacteroides caccae, Bifidobacterium pseudocatenulatum, Dorea formicigenerans, Lactobacillus rogosae, Sutterella wadsworthensis, Bacteroides coprocola, Bifidobacterium pseudocatenulatum, Dorea formicigenerans, Longicatena caecimuris, Sutterella wadsworthensis, Bacteroides faecis, Bilophila wadsworthia, Dorea longicatena, Megasphaera massiliensis, Turicibacter sanguinis, Bacteroides finegoldii, Bilophila wadsworthia, Dorea longicatena, Methanobrevibacter smithii, Bacteroides thetaiotaomicron, Bacteroides fragilis, Blautia faecis, Eggerthella lenta, Methanobrevibacter smithii, Bacteroides uniformis, Bacteroides kribbi / Bacteroides. Petition 870250102358, dated 07 / 11 / 2025, p. 82 / 280 74 / 227 koreensis species cluster, Blautia faecis, Eggerthella lenta, Monoglobus pectinolyticus, Clostridium aldenense, Bacteroides kribbi / Bacteroides koreensis species cluster, Blautia hydrogenotrophica, Eggerthella lenta, Monoglobus pectinolyticus, Clostridium aldenense, Bacteroides kribbi / Bacteroides koreensis species cluster, Blautia massiliensis, Eggerthella lenta, Neglecta timonensis, Eubacterium ventriosum, Bacteroides massiliensis, Blautia obeum, Eisenbergiella tayi, Neglecta timonensis, Eubacterium xylanophilum, Bacteroides nordii, Blautia obeum, Eisenbergiella tayi, Oxalobacter formigenes, Paraprevotella clara, Bacteroides ovatus, Blautia wexlerae, Eubacterium eligens, Oxalobacter formigenes, Parasutterella excrementihominis, Bacteroides salyersiae, Blautia wexlerae, Eubacterium eligens, Oxalobacter formigenes, Bacteroides thetaiotaomicron, Bacteroides stercorirosoris, Butyricimonas faecihominis, Eubacterium hallii, Parabacteroides distasonis, Clostridiales sp.FBI00377, Bacteroides stercoris, Catabacter hongkongensis, Eubacterium rectale, Parabacteroides distasonis, Eubacterium siraeum, Bacteroides stercoris, Clostridiaceae sp. FBI00191, Eubacterium rectale, Parabacteroides merdae, and Parabacteroides merdae.

[0132] In certain embodiments, the Consorcio comprises a plurality of microbes (for example, active microbes and microbiomes from comunidade de apoio) designated as "Consórcio XIII" In certain embodiments, the Consorcio XIII comprises Acidaminococcus intestini, Bacteroides thetaiotaomicron, Butyricimonas faecihominis, Eubacterium eligens, Monoglobus pectinilyticus, Akkermansia muciniphila, Bacteroides thetaiotaomicron, Catabacter hongkongensis, Eubacterium eligens, Neglecta timonensis, Alistipes onderdonkii, Bacteroides uniformis, Clostridiaceae sp. FBI00191, Eubacterium hallii, Neglecta timonensis, Alistipes onderdonkii, Bacteroides uniformis, Clostridiales sp. FBI00377, Eubacterium rectal, Petition 870250102358, dated 07 / 11 / 2025, p. 83 / 280 75 / 227 Oxalobacter formigenes , Alistipes putredinis , Bacteroides vulgatus, Clostridium aldenense , Eubacterium rectale, Oxalobacter formigenes , Alistipes putredinis, Bacteroides vulgatus, Clostridium aldenense, Eubacterium siraeum, Oxalobacter formigenes, Alistipes senegalensis, Bacteroides xylanisolvens, Clostridium bolteae, Eubacterium ventriosum, Parabacteroides distasonis, Alistipes shahii, Bacteroides xylanisolvens, Clostridium bolteae, Eubacterium xylanophilum, Parabacteroides distasonis, Alistipes shahii, Bacteroides xylanisolvens, Clostridium citroniae, Faecalibacterium prausnitzii, Parabacteroides merdae, Alistipes sp . FBI00180, Barnesiella intestinihominis, Clostridium citroniae, Faecalibacterium prausnitzii, Parabacteroides merdae, Alistipes sp . FBI00238, Bifidobacterium adolescentis, Clostridium clostridioforme, Fusicatenibacter saccharivorans, Paraprevotella clara, Alistipes timonensis, Bifidobacterium adolescentis, Clostridium fessum, Fusicatenibacter saccharivorans,Parasutterella excrementihominis, Anaerofustis stercorihominis, Bifidobacterium adolescentis, Clostridium scindens, Gordonibacter pamelaeae, Parasutterella excrementihominis, Anaerostipes hadrus, Bifidobacterium bifidum, Collinsella aerofaciens, Gordonibacter pamelaeae, Phascolarctobacterium faecium, Anaerostipes hadrus, Bifidobacterium catenulatum, Collinsella aerofaciens, Holdemanella biformis, Porphyromonas asaccharolytica, Anaerotruncus massiliensis, Bifidobacterium dentium, Coprococcus comes, Holdemanella biformis, Porphyromonas asaccharolytica, Bacteroides caccae, Bifidobacterium longum, Coprococcus comes, Hungatella effluvii, Roseburia hominis, Bacteroides caccae, Bifidobacterium longum, Coprococcus eutactus, Hungatella effluvii, Roseburia hominis, Bacteroides coprocola, Bifidobacterium pseudocatenulatum, Dialister invisus, Hungatella effluvii, Ruminococcaceae sp. FBI00082 Petition 870250102358, dated 07 / 11 / 2025, p. 84 / 280 76 / 227 FBI00097, Bacteroides faecis, Bifidobacterium pseudocatenulatum, Dialister succinatiphilus, Lachnoclostridium pacaense, Ruminococcaceae sp. FBI00233, Bacteroides finegoldii, Bifidobacterium pseudocatenulatum, Dielma fastidiosa, Lachnoclostridium pacaense, Ruminococcus bromii, Bacteroides fragilis, Bilophila wadsworthia, Dorea formicigenerans, Lachnospiraceae sp. FBI00033, Ruminococcus bromii, Bacteroides kribbi / Bacteroides koreensis species cluster, Bilophila wadsworthia, Dorea formicigenerans, Lachnospiraceae sp. FBI00071, Ruminococcus faecis, Bacteroides kribbi / Bacteroides koreensis species cluster, Blautia faecis, Dorea longicatena, Lachnospiraceae sp.FBI00290, Ruminococcus faecis, Bacteroides massiliensis, Blautia faecis, Dorea longicatena, Lactobacillus rogosae, Ruthenibacterium lactatiformans, Bacteroides nordii, Blautia hydrogenotrophica, Eggerthella lenta, Lactobacillus rogosae, Senegalmassilia anaerobia, Bacteroides ovatus, Blautia massiliensis, Eggerthella lenta, Longicatena caecimuris, Sutterella massiliensis, Bacteroides salyersiae, Blautia obeum, Eggerthella lenta, Megasphaera massiliensis, Sutterella wadsworthensis, Bacteroides stercorirosoris, Blautia obeum, Eggerthella lenta, Methanobrevibacter smithii, Sutterella wadsworthensis, Bacteroides stercoris, Blautia wexlerae, Eisenbergiella tayi, Methanobrevibacter smithii, Turicibacter sanguinis, Bacteroides stercoris, Blautia wexlerae, Eisenbergiella tayi and Monoglobus pectinolyticus.

[0133] In certain embodiments, the Consortium comprises a plurality of microbes (e.g., active microbes and supporting community microbes) designated as “Consortium XIV.” In certain embodiments, Consortium XIV comprises Acidaminococcus intestini, Bacteroides uniformis, Clostridium citroniae, Eubacterium siraeum, Parasutterella excrementihominis, Akkermansia muciniphila, Bacteroides uniformis, Clostridium citroniae, Eubacterium ruminantium, Petition 870250102358, dated 07 / 11 / 2025, p. 85 / 280 77 / 227 Parasutterella excrementihominis, Alistipes finegoldii, Bacteroides vulgatus, Clostridium clostridioforme, Eubacterium ventriosum, Phascolarctobacterium faecium, Alistipes onderdonkii, Bacteroides vulgatus, Clostridium scindens, Eubacterium xylanophilum, Phascolarctobacterium faecium, Alistipes onderdonkii, Bacteroides xylanisolvens, Clostridium swellfunianum, Faecalibacterium prausnitzii, Phocea massiliensis, Alistipes putredinis, Bacteroides xylanisolvens, Clostridium symbiosum, Faecalibacterium prausnitzii, Phocea massiliensis, Alistipes putredinis, Barnesiella intestinihominis, Clostridium symbiosum, Fusicatenibacter saccharivorans, Porphyromonas asaccharolytica, Alistipes senegalensis, Bifidobacterium adolescentis, Collinsella aerofaciens, Fusicatenibacter saccharivorans, Porphyromonas asaccharolytica, Alistipes senegalensis, Bifidobacterium adolescentis, Collinsella aerofaciens, Gordonibacter pamelaeae, Roseburia hominis, Alistipes shahii, Bifidobacterium bifidum,Coprococcus comes, Gordonibacter pamelaeae, Roseburia hominis, Alistipes shahii, Bifidobacterium bifidum, Coprococcus comes, Holdemanella biformis, Ruminococcus bromii, Alistipes timonensis, Bifidobacterium catenulatum, Coprococcus eutactus, Holdemanella biformis, Ruminococcus bromii, Anaerofustis stercorihominis, Bifidobacterium dentium, Coprococcus eutactus, Hungatella effluvii, Ruminococcus faecis, Anaerostipes hadrus, Bifidobacterium faecale, Desulfovibrio desulfuricans, Hungatella hathawayi, Ruminococcus faecis, Anaerostipes hadrus, Bifidobacterium longum, Desulfovibrio desulfuricans, Hungatella hathawayi, Ruthenibacterium lactatiformans, Anaerotruncus colihominis, Bifidobacterium longum, Dialister invisus, Hydrogenoanaerobacterium saccharovorans, Senegalemassilia anaerobia, Bacteroides caccae, Bifidobacterium pseudocatenulatum, Dialister succinatiphilus, Lachnoclostridium pacaense, Sutterella massiliensis, Bacteroides caccae, Petition 870250102358, dated 07 / 11 / 2025, p. 86 / 280 78 / 227 Bifidobacterium pseudocatenulatum, Dielma fastidiosa, Lachnoclostridium pacaense, Sutterella wadsworthensis, Bacteroides coprocola, Bifidobacterium pseudocatenulatum, Dorea formicigenerans, Lachnospira pectinoschiza, Sutterella wadsworthensis, Bacteroides faecis, Blautia faecis, Dorea formicigenerans, Lachnospira pectinoschiza, Turicibacter sanguinis, Bacteroides finegoldii, Blautia faecis, Dorea longicatena, Longicatena caecimuris, Bacteroides stercoris, Bacteroides fragilis, Blautia hydrogenotrophica, Dorea longicatena, Megasphaera massiliensis, Bacteroides stercoris, Bacteroides koreensis, Blautia luti, Eggerthella lenta, Methanobrevibacter smithii, Bacteroides thetaiotaomicron, Bacteroides koreensis, Blautia obeum, Eggerthella lenta, Methanobrevibacter smithii, Bacteroides thetaiotaomicron, Bacteroides kribbi, Blautia obeum, Eggerthella lenta, Monoglobus pectinilyticus, Clostridium aldenense, Bacteroides kribbi, Blautia wexlerae, Eggerthella lenta, Monoglobus pectinilyticus,Clostridium aldenense, Bacteroides massiliensis, Blautia wexlerae, Eisenbergiella tayi, Neglecta timonensis, Clostridium bolteae, Bacteroides nordii, Butyricimonas faecihominis, Eisenbergiella tayi, Oxalobacter formigenes, Clostridium bolteae, Bacteroides oleiciplenus, Catabacter hongkongensis, Emergence timonensis, Oxalobacter formigenes, Parabacteroides medoe, Bacteroides ovatus, Citrobacter freundii, Eubacterium eligens, Oxalobacter formigenes, Parabacteroides medoe, Bacteroides salyersiae, Clostridiaceae sp., Eubacterium eligens, Parabacteroides distasonis, Paraprevotella clara, Eubacterium rectale, Eubacterium rectale, Eubacterium hallii, Parabacteroides distasonis, and Eubacterium oxidoreducens.,

[0134] In certain embodiments, the Consortium comprises a plurality of microbes (e.g., active microbes and supporting community microbes) designated as “Consortium XV”. In certain embodiments, Consortium XV comprises Petition 870250102358, dated 07 / 11 / 2025, p. 87 / 280 79 / 227 Acidaminococcus intestini, Bacteroides thetaiotaomicron, Butyricimonas faecihominis, Eubacterium eligens, Monoglobus pectinolyticus, Akkermansia muciniphila, Bacteroides thetaiotaomicron, Catabacter hongkongensis, Eubacterium eligens, Neglecta timonensis, Alistipes onderdonkii, Bacteroides uniformis, Clostridiaceae sp. FBI00191, Eubacterium hallii, Neglecta timonensis, Alistipes onderdonkii, Bacteroides uniformis, Clostridiales sp.FBI00377, Eubacterium rectale, Oxalobacter formigenes, Alistipes putredinis, Bacteroides vulgatus, Clostridium aldenense, Eubacterium rectale, Oxalobacter formigenes, Alistipes putredinis, Bacteroides vulgatus, Clostridium aldenense, Eubacterium siraeum, Oxalobacter formigenes, Alistipes senegalensis, Bacteroides xylanisolvens, Clostridium bolteae, Eubacterium ventriosum, Parabacteroides distasonis, Alistipes shahii, Bacteroides xylanisolvens, Clostridium bolteae, Eubacterium xylanophilum, Parabacteroides distasonis, Alistipes shahii, Bacteroides xylanisolvens, Clostridium citroniae, Faecalibacterium prausnitzii, Parabacteroides merdae, Alistipes sp. FBI00180, Barnesiella intestinihominis, Clostridium citroniae, Faecalibacterium prausnitzii, Parabacteroides merdae, Alistipes sp.FBI00238, Bifidobacterium adolescentis, Clostridium clostridioforme, Fusicatenibacter saccharivorans, Paraprevotella clara, Alistipes timonensis, Bifidobacterium adolescentis, Clostridium fessum, Fusicatenibacter saccharivorans, Parasutterella excrementihominis, Anaerofustis stercorihominis, Bifidobacterium adolescentis, Clostridium scindens, Gordonibacter pamelaeae, Parasutterella excrementihominis, Anaerostipes hadrus, Bifidobacterium bifidum, Collinsella aerofaciens, Gordonibacter pamelaeae, Phascolarctobacterium faecium, Anaerostipes hadrus, Bifidobacterium catenulatum, Collinsella aerofaciens, Holdemanella biformis, Porphyromonas asaccharolytica,. Petition 870250102358, dated 07 / 11 / 2025, p. 88 / 280 80 / 227 Anaerotruncus massiliensis, Bifidobacterium dentium, Coprococcus comes, Holdemanella biformis, Porphyromonas asaccharolytica, Bacteroides caccae, Bifidobacterium longum, Coprococcus comes, Hungatella effluvii, Roseburia hominis, Bacteroides caccae, Bifidobacterium longum, Coprococcus eutactus, Hungatella effluvii, Roseburia hominis, Bacteroides coprocola, Bifidobacterium pseudocatenulatum, Dialister invisus, Hungatella effluvii, Ruminococcaceae sp. FBI00082 FBI00097, Bacteroides faecis, Bifidobacterium pseudocatenulatum, Dialister succinatiphilus, Lachnoclostridium pacaense, Ruminococcaceae sp. FBI00233, Bacteroides finegoldii, Bifidobacterium pseudocatenulatum, Dielma fastidiosa, Lachnoclostridium pacaense, Ruminococcus bromii, Bacteroides fragilis, Bilophila wadsworthia, Dorea formicigenerans, Lachnospiraceae sp. FBI00033, Ruminococcus bromii, Bacteroides kribbi / Bacteroides koreensis species cluster, Bilophila wadsworthia, Dorea formicigenerans, Lachnospiraceae sp.FBI00071, Ruminococcus faecis, Bacteroides kribbi / Bacteroides koreensis species cluster, Blautia faecis, Dorea longicatena, Lachnospiraceae sp. FBI00290, Ruminococcus faecis, Bacteroides massiliensis, Blautia faecis, Dorea longicatena, Lactobacillus rogosae, Ruthenibacterium lactatiformans, Bacteroides nordii, Blautia hydrogenotrophica, Eggerthella lenta, Lactobacillus rogosae, Senegalmassilia anaerobia, Bacteroides ovatus, Blautia massiliensis, Eggerthella lenta, Longicatena caecimuris, Sutterella massiliensis, Bacteroides salyersiae, Blautia obeum, Eggerthella lenta, Megasphaera massiliensis, Sutterella wadsworthensis, Bacteroides stercorirosoris, Blautia obeum, Eggerthella lenta, Methanobrevibacter smithii, Sutterella wadsworthensis, Bacteroides stercoris, Blautia wexlerae, Eisenbergiella tayi, Methanobrevibacter smithii, Turicibacter sanguinis, Bacteroides stercoris, Blautia wexlerae, Eisenbergiella tayi and Monoglobus pectinolyticus. Petition 870250102358, dated 07 / 11 / 2025, p. 89 / 280 81 / 227

[0135] In certain embodiments, the Consortium comprises a plurality of microbes (e.g., active microbes and community support microbes) designated as “Consortium XVI” In certain embodiments, the Consortium XVI comprises Acidaminococcus intestini, Bacteroides uniformis, Clostridium citoniae, Eubacterium ventriosum, Parasutterella excrementihominis, Akkermansia muciniphila, Bacteroides uniformis, Clostridium clostridioforme, Eubacterium siraeum, Phascolarctobacterium faecium, Alistipes finegoldii, Bacteroides vulgatus, Clostridium scindens, Eubacterium xylanophilum, Phascolarctobacterium faecium, Alistipes onderdonkii, Bacteroides vulgatus, Clostridium swellfunianum, Faecalibacterium prausnitzii, Phocea massiliensis, Alistipes onderdonkii, Bacteroides xylanisolvens, Clostridium symbiosum, Faecalibacterium prausnitzii, Phocea massiliensis, Alistipes putredinis, Bacteroides xylanisolvens, Clostridium symbiosum, Fusicatenibacter saccharivorans,Porphyromonas asaccharolytica, Alistipes putredinis, Barnesiella intestinihominis, Collinsella aerofaciens, Fusicatenibacter saccharivorans, Porphyromonas asaccharolytica, Alistipes senegalensis, Bifidobacterium adolescentis, Collinsella aerofaciens, Gordonibacter pamelaeae, Roseburia hominis, Alistipes senegalensis, Bifidobacterium adolescentis, Coprococcus comes, Gordonibacter pamelaeae, Roseburia hominis, Alistipes shahii, Bifidobacterium bifidum, Coprococcus comes, Holdemanella biformis, Ruminococcus bromii, Alistipes shahii, Bifidobacterium bifidum, Coprococcus eutactus, Holdemanella biformis, Ruminococcus bromii, Alistipes timonensis, Bifidobacterium catenulatum, Coprococcus eutactus, Hungatella effluvii, Ruminococcus faecis, Anaerofustis stercorihominis, Bifidobacterium dentium, Desulfovibrio desulfuricans, Hungatella hathawayi, Ruminococcus faeces, Anaerostipes hadrus, Bifidobacterium faecale, Desulfovibrio desulfuricans, Hungatella hathawayi, Ruthenibacterium, Petition 870250102358, dated 07 / 11 / 2025, pp. 90 / 280 82 / 227 lactatiformans, Anaerostipes hadrus, Bifidobacterium longum, Dialister invisus, Hydrogenoanaerobacterium saccharovorans, Senegalmassilia anaerobia, Anaerotruncus colihominis, Bifidobacterium longum, Dialister succinatiphilus, Lachnoclostridium pacaense, Sutterella massiliensis, Bacteroides caccae, Bifidobacterium pseudocatenulatum, Dielma fastidiosa, Lachnoclostridium pacaense, Sutterella wadsworthensis, Bacteroides caccae, Bifidobacterium pseudocatenulatum, Dorea formicigenerans, Lachnospira pectinoschiza, Sutterella wadsworthensis, Bacteroides coprocola, Bifidobacterium pseudocatenulatum, Dorea formicigenerans, Lachnospira pectinoschiza, Turicibacter sanguinis, Bacteroides faecis, Blautia faecis, Dorea longicatena, Longicatena caecimuris, Bacteroides stercoris, Bacteroides finegoldii, Blautia faecis, Dorea longicatena, Megasphaera massiliensis, Bacteroides stercoris, Bacteroides fragilis, Blautia hydrogenotrophica, Eggerthella lenta, Methanobrevibacter smithii,Bacteroides thetaiotaomicron, Bacteroides koreensis, Blautia luti, Eggerthella lenta, Methanobrevibacter smithii, Bacteroides thetaiotaomicron, Bacteroides koreensis, Blautia obeum, Eggerthella lenta, Monoglobus pectinolyticus, Clostridium aldenense, Bacteroides kribbi, Blautia obeum, Eggerthella lenta, Monoglobus pectinolyticus, Clostridium bolteae, Bacteroides kribbi, Blautia wexlerae, Eisenbergiella tayi, Neglecta timonensis, Clostridium bolteae, Bacteroides massiliensis, Blautia wexlerae, Eisenbergiella tayi, Oxalobacter formigenes, Clostridium citroniae, Bacteroides nordii, Butyricimonas faecihominis, Emergence timonensis, Oxalobacter formigenes, Eubacterium oxidoreducens, Bacteroides oleiciplenus, Catabacter hongkongensis, Eubacterium eligens, Oxalobacter formigenes, Eubacterium rectale, Bacteroides ovatus, Clostridiaceae sp., Eubacterium eligens, Parabacteroides distasonis, Eubacterium, Petition 870250102358, dated 07 / 11 / 2025, p. 91 / 280 83 / 227 rectale, Bacteroides salyersiae, Clostridium aldenense, Eubacterium hallii, Parabacteroides distasonis, Eubacterium ruminantium, Parasutterella excrementihominis, Paraprevotella clara, Parabacteroides merdae and Parabacteroides merdae.

[0136] In certain embodiments, the Consortium comprises a plurality of microbes (e.g., active microbes and supporting community microbes) designated as “Consortium XVII”. In certain embodiments, Consortium XVII comprises Acidaminococcus intestini, Bacteroides uniformis, Clostridium bolteae, Faecalicatena contorta, Roseburia hominis, Acutalibacter timonensis, Bacteroides vulgatus, Clostridium citroniae, Fusicatenibacter saccharivorans, Roseburia hominis, Akkermansia muciniphila, Bacteroides vulgatus, Clostridium citroniae, Fusicatenibacter saccharivorans, Ruminococcaceae sp. FBI00097, Alistipes onderdonkii, Bacteroides xylanisolvens, Clostridium clostridioforme, Gordonibacter pamelaeae, Ruminococcaceae sp. FBI0009, Alistipes onderdonkii, Bacteroides xylanisolvens, Clostridium fessum, Gordonibacter pamelaeae, Ruminococcaceae sp.FBI00233, Alistipes putredinis, Bacteroides xylanisolvens, Clostridium fessum, Holdemanella biformis, Ruminococcus bromii, Alistipes putredinis, Barnesiella intestinihominis, Clostridium scindens, Holdemanella biformis, Ruminococcus bromii, Alistipes senegalensis, Bifidobacterium adolescentis, Collinsella aerofaciens, Hungatella effluvii, Ruminococcus faecis, Alistipes shahii, Bifidobacterium adolescentis, Collinsella aerofaciens, Hungatella effluvii, Ruminococcus faecis, Alistipes sp. FBI00180, Bifidobacterium adolescentis, Coprococcus comes, Hungatella effluvii, Ruthenibacterium lactatiformans, Alistipes sp. FBI00238, Bifidobacterium bifidum, Coprococcus comes, Lachnoclostridium pacaense, Senegalmassilia anaerobia, Alistipes timonensis, Bifidobacterium bifidum, Coprococcus eutactus, Lachnoclostridium pacaense, Sutterella massiliensis,. Petition 870250102358, dated 07 / 11 / 2025, p. 92 / 280 84 / 227 Anaerofustis stercorihominis, Bifidobacterium catenulatum, Coprococcus eutactus, Lachnospiraceae sp. FBI00033, Sutterella wadsworthensis, Anaerostipes hadrus, Bifidobacterium dentium, Dialister invisus, Lachnospiraceae sp. FBI00071, Sutterella wadsworthensis, Anaerostipes hadrus, Bifidobacterium longum, Dialister succinatiphilus, Lachnospiraceae sp.FBI00290, Turicibacter sanguinis, Anaerotruncus massiliensis, Bifidobacterium longum, Dielma fastidiosa, Lactobacillus rogosae, Bacteroides stercoris, Bacteroides caccae, Bifidobacterium pseudocatenulatum, Dorea formicigenerans, Lactobacillus rogosae, Bacteroides stercoris, Bacteroides caccae, Bifidobacterium pseudocatenulatum, Dorea formicigenerans, Lactonifactor longoviformis, Bacteroides thetaiotaomicron, Bacteroides coprocola, Bilophila wadsworthia, Dorea longicatena, Longicatena caecimuris, Bacteroides thetaiotaomicron, Bacteroides faecis, Bilophila wadsworthia, Dorea longicatena, Megasphaera massiliensis, Bacteroides uniformis, Bacteroides finegoldii, Blautia faecis, Eggerthella lenta, Monoglobus pectinolyticus, Citrobacter portucalensis, Bacteroides fragilis, Blautia faecis, Eggerthella lenta, Monoglobus pectinolyticus, Clostridiaceae sp.FBI00191, Bacteroides kribbi / Bacteroides koreensis species cluster, Blautia hydrogenotrophica, Eisenbergiella tayi, Oxalobacter formigenes, Clostridium aldenense, Bacteroides kribbi / Bacteroides koreensis species cluster, Blautia massiliensis, Eisenbergiella tayi, Oxalobacter formigenes, Clostridium aldenense, Bacteroides kribbi / Bacteroides koreensis species cluster, Blautia obeum, Emergencia timonensis, Oxalobacter formigenes, Clostridium bolteae, Bacteroides massiliensis, Blautia obeum, Eubacterium eligens, Parabacteroides distasonis, Eubacterium siraeum, Bacteroides nordii, Blautia wexlerae, Eubacterium eligens, Parabacteroides merdae, Eubacterium ventriosum, Bacteroides ovatus, Blautia wexlerae, Eubacterium. Petition 870250102358, dated 07 / 11 / 2025, p. 93 / 280 85 / 227 hallii, Parabacteroides merdae, Eubacterium xylanophilum, Bacteroides salyersiae, Butyricimonas faecihominis, Eubacterium rectale, Paraprevotella clara, Faecalibacterium prausnitzii, Bacteroides stercorirosoris, Catabacter hongkongensis, Eubacterium rectale, Parasutterella excrementihominis, Faecalibacterium prausnitzii, Phascolarctobacterium faecium, Phascolarctobacterium faecium, Porphyromonas asaccharolytica, Parasutterella excrementihominis and Porphyromonas asaccharolytica.

[0137] In certain embodiments, the Consortium comprises a plurality of microbes (e.g., active microbes and community support microbes) designated as “Consortium XVIII” In certain embodiments, the Consortium XVIII comprises Bacteroides caccae, Bifidobacterium longum, Clostridium scindens, Eggerthella lenta, Parabacteroides merdae, Bacteroides salyersiae, Bifidobacterium pseudocatenulatum, Clostridium symbiosum, Eggerthella lenta, Ruminococcus bromii, Bacteroides thetaiotaomicron, Bifidobacterium pseudocatenulatum, Collinsella aerofaciens, Faecalibacterium prausnitzii, Ruminococcus bromii, Bacteroides thetaiotaomicron, Bifidobacterium pseudocatenulatum, Desulfovibrio desulfuricans, Neglecta timonensis, Bacteroides vulgatus, Clostridium amygdalinum, Dorea longicatena, Oxalobacter formigenes, Bifidobacterium dentium, Clostridium citoniae, Eggerthella lenta, Oxalobacter formigenes, Bifidobacterium longum, Clostridium citroniae,Eggerthella longa and Oxalobacter formigenes.

[0138] In certain embodiments, the Consortium comprises a plurality of microbes (e.g., active microbes and supporting community microbes) designated as “Consortium XIX”. In certain embodiments, Consortium XIX comprises Acidaminococcus intestini, Bacteroides stercoris, Blautia wexlerae, Eisenbergiella tayi, Monoglobus pectinilyticus, Petition 870250102358, dated 07 / 11 / 2025, page 94 / 280 86 / 227 Acutalibacter timonensis, Bacteroides stercoris, Blautia wexlerae, Eisenbergiella tayi, Monoglobus pectinolyticus, Akkermansia muciniphila, Bacteroides thetaiotaomicron, Butyricimonas faecihominis, Emergencia timonensis, Parabacteroides distasonis, Alistipes onderdonkii, Bacteroides thetaiotaomicron, Catabacter hongkongensis, Eubacterium eligens, Oxalobacter formigenes, Alistipes onderdonkii, Bacteroidesuniformis, Clostridiaceae sp.FBI00191, Eubacterium eligens, Oxalobacter formigenes, Alistipes putredinis, Bacteroides uniformis, Clostridium aldenense, Eubacterium hallii, Oxalobacter formigenes, Alistipes putredinis, Bacteroides vulgatus, Clostridium aldenense, Eubacterium rectale, Parabacteroides distasonis, Alistipes senegalensis, Bacteroides vulgatus, Clostridium bolteae, Eubacterium rectale, Parabacteroides merdae, Alistipes shahii, Bacteroides xylanisolvens, Clostridium bolteae, Eubacterium siraeum, Parabacteroides merdae, Alistipes shahii, Bacteroides xylanisolvens, Clostridium citroniae, Eubacterium ventriosum, Paraprevotella clara, Alistipes sp. FBI00180, Bacteroides xylanisolvens, Clostridium citroniae, Eubacterium xylanophilum, Parasutterella excrementihominis, Alistipes sp.FBI00238, Barnesiella intestinihominis, Clostridium clostridioforme, Faecalibacterium prausnitzii, Parasutterella excrementihominis, Alistipes timonensis, Bifidobacterium adolescentis, Clostridium fessum, Fusicatenibacter saccharivorans, Phascolarctobacterium faecium, Anaerofustis stercorihominis, Bifidobacterium adolescentis, Clostridium scindens, Fusicatenibacter saccharivorans, Porphyromonas asaccharolytica, Anaerostipes hadrus, Bifidobacterium bifidum, Collinsella aerofaciens, Gordonibacter pamelaeae, Roseburia hominis, Anaerostipes hadrus, Bifidobacterium catenulatum, Collinsella aerofaciens, Gordonibacter pamelaeae, Roseburia hominis, Anaerotruncus massiliensis, Bifidobacterium dentium, Coprococcus comes,. Petition 870250102358, dated 07 / 11 / 2025, p. 95 / 280 87 / 227 Holdemanella biformis, Ruminococcaceae sp. FBI00097, Bacteroides caccae, Bifidobacterium longum, Coprococcus comes, Hungatella effluvii, Ruminococcaceae sp. FBI00233, Bacteroides caccae, Bifidobacterium longum, Coprococcus eutactus, Hungatella effluvii, Ruminococcus bromii, Bacteroides coprocola, Bifidobacterium pseudocatenulatum, Dialister invisus, Hungatella hathawayi, Ruminococcus bromii, Bacteroides faecis, Bifidobacterium pseudocatenulatum, Dialister succinatiphilus, Lachnoclostridium pacaense, Ruminococcus faecis, Bacteroides finegoldii, Bifidobacterium pseudocatenulatum, Dielma fastidiosa, Lachnoclostridium pacaense, Ruminococcus faecis, Bacteroides fragilis, Bifidobacterium adolescentis, Dorea formicigenerans, Lachnospiraceae sp. FBI00033, Ruthenibacterium lactatiformans, Bacteroides kribbi, Bilophila wadsworthia, Dorea formicigenerans, Lachnospiraceae sp. FBI00071, Senegalimassilia anaerobia, Bacteroides kribbi, Bilophila wadsworthia, Dorea longicatena, Lachnospiraceae sp.FBI00290, Sutterella massiliensis, Bacteroides massiliensis, Blautia faecis, Dorea longicatena, Lactobacillus rogosae, Sutterella wadsworthensis, Bacteroides nordii, Blautia hydrogenotrophica, Eggerthella longa, Lactobacillus rogosae, Sutterella wadsworthensis, Bacteroides ovatus, Blautia massiliensis, Eggerthella longa, Longicatena caecimuris, Turicibacter sanguinis, Bacteroides salyersiae, Blautia obeum, Eggerthella longa, Megasphaera massiliensis, Bacteroides stercorirosoris, Blautia obeum, Eggerthella longa, and Methanobrevibacter smithii.

[0139] In certain modalities, the Consortium comprises the microbiota included in Consortium I. In certain modalities, the Consortium comprises the microbiota included in Consortium II. In certain modalities, the Consortium comprises the microbiota included in Consortium III. In certain modalities, the Consortium comprises the microbiota included in Consortium IV. In certain modalities, the Petition 870250102358, dated 07 / 11 / 2025, p. 96 / 280 88 / 227 The Consortium includes the microbiota included in Consortium V. In certain modalities, the Consortium includes the microbiota included in Consortium VI. In certain modalities, the Consortium includes the microbiota included in Consortium VII. In certain modalities, the Consortium includes the microbiota included in Consortium VIII. In certain modalities, the Consortium includes the microbiota included in Consortium IX. In certain modalities, the Consortium includes the microbiota included in Consortium X. In certain modalities, the Consortium includes the microbiota included in Consortium XI. In certain modalities, the Consortium includes the microbiota included in Consortium XII. In certain modalities, the Consortium includes the microbiota included in Consortium XIII. In certain modalities, the Consortium includes the microbiota included in Consortium XIV.In certain modalities, the Consortium includes the microbiota included in Consortium XV. In certain modalities, the Consortium includes the microbiota included in Consortium XVI. In certain modalities, the Consortium includes the microbiota included in Consortium XVII. In certain modalities, the Consortium includes the microbiota included in Consortium XVIII. In certain modalities, the Consortium includes the microbiota included in Consortium XIX.

[0140] In certain embodiments, the Consortium comprises microbiota that is at least 97% or at least 98% identical to those listed in Consortium I. In certain embodiments, the Consortium comprises microbiota that is at least 97% or at least 98% identical to those listed in Consortium II. In certain embodiments, the Consortium comprises microbiota that is at least 97% or at least 98% identical to those listed in Consortium III. In certain embodiments, the Consortium comprises microbiota that is at least 97% or at least 98% identical to those listed in Consortium IV. In certain embodiments Petition 870250102358, dated 07 / 11 / 2025, page 97 / 280 In certain modalities, the Consortium comprises microbiota that is at least 97% or at least 98% identical to those listed in Consortium V. In certain modalities, the Consortium comprises microbiota that is at least 97% or at least 98% identical to those listed in Consortium VI. In certain modalities, the Consortium comprises microbiota that is at least 97% or at least 98% identical to those listed in Consortium VII. In certain modalities, the Consortium comprises microbiota that is at least 97% or at least 98% identical to those listed in Consortium VIII. In certain modalities, the Consortium comprises microbiota that is at least 97% or at least 98% identical to those listed in Consortium IX. In certain modalities, the Consortium comprises microbiota that is at least 97% or at least 98% identical to those listed in Consortium X.In certain modalities, the Consortium comprises microbiota that is at least 97% or at least 98% identical to those listed in Consortium XI. In certain modalities, the Consortium comprises microbiota that is at least 97% or at least 98% identical to those listed in Consortium XII. In certain modalities, the Consortium comprises microbiota that is at least 97% or at least 98% identical to those listed in Consortium XIII. In certain modalities, the Consortium comprises microbiota that is at least 97% or at least 98% identical to those listed in Consortium XIV. In certain modalities, the Consortium comprises microbiota that is at least 97% or at least 98% identical to those listed in Consortium XV. In certain modalities, the Consortium comprises microbiota that is at least 97% or at least 98% identical to those listed in Consortium XVI.In certain modalities, the Consortium comprises microbiota that is at least 97% or at least 98% identical to those listed in Consortium XVII. In certain modalities, the Consortium comprises microbiota that is at least 97% or at least 98% identical to those listed in the Consortium. Petition 870250102358, dated 07 / 11 / 2025, page 98 / 280 90 / 227 XVIII. In certain modalities, the Consortium comprises microbiota that is at least 97% or at least 98% identical to those listed in Consortium XIX.

[0141] In certain embodiments, the Consortium comprises at least 146 microbes, at least 147 microbes, or at least 148 microbes from Consortium I. In certain embodiments, the Consortium comprises at least 72 microbes, at least 73 microbes, or at least 74 microbes from Consortium II. In certain embodiments, the Consortium comprises at least 85 microbes, at least 86 microbes, or at least 87 microbes from Consortium III. In certain embodiments, the Consortium comprises at least 84 microbes, at least 85 microbes, or at least 86 microbes from Consortium IV. In certain embodiments, the Consortium comprises at least 153 microbes, at least 154 microbes, or at least 155 microbes from Consortium V. In certain embodiments, the Consortium comprises at least 176 microbes, at least 177 microbes, or at least 178 microbes from Consortium VI.In certain embodiments, the Consortium comprises at least 153 microbes, at least 154 microbes, or at least 155 microbes from Consortium VII. In certain embodiments, the Consortium comprises at least 153 microbes, at least 154 microbes, or at least 155 microbes from Consortium VIII. In certain embodiments, the Consortium comprises at least 148 microbes, at least 149 microbes, or at least 150 microbes from Consortium IX. In certain embodiments, the Consortium comprises at least 149 microbes, at least 150 microbes, or at least 151 microbes from Consortium X. In certain embodiments, the Consortium comprises at least 147 microbes, at least 148 microbes, or at least 149 microbes from Consortium XI. In certain embodiments, the Consortium comprises at least 155 microbes, at least 156 microbes, or at least 157 microbes from Consortium XII. In certain embodiments, the Consortium comprises at least 149. Petition 870250102358, dated 07 / 11 / 2025, p. 99 / 280 91 / 227 microbes, at least 150 microbes or at least 151 microbes from Consortium XIII. In certain embodiments, the Consortium comprises at least 155 microbes, at least 156 microbes or at least 157 microbes from Consortium XIV. In certain embodiments, the Consortium comprises at least 149 microbes, at least 150 microbes or at least 151 microbes from Consortium XV. In certain embodiments, the Consortium comprises at least 153 microbes, at least 154 microbes or at least 155 microbes from Consortium XVI. In certain embodiments, the Consortium comprises at least 150 microbes, at least 151 microbes, or at least 152 microbes from Consortium XVII. In certain embodiments, the Consortium comprises at least 29 microbes, or at least 30 microbes from Consortium XVIII. In certain embodiments, the Consortium comprises at least 143 microbes, at least 144 microbes, or at least 145 microbes from Consortium XIX.

[0142] In certain embodiments, a microbial consortium described herein comprises a microbial strain with a relative abundance of approximately 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5%, 1%, 0.1%, 0.01%, 0.001%, 0.0001%, 0.00001%, or 0.000001% of the total microbial consortium. In certain embodiments, the relative abundance of a microbial strain is determined by metagenomic sequencing and calculated as the percentage of reads classified as an identified microbial strain, divided by the genome size. In certain embodiments, the relative abundance of a microbial strain of the present disclosure is determined by shotgun metagenomic sequencing.

[0143] In certain modalities, the Consortium comprises the microbiota established in Table 1. In certain modalities, the Consortium comprises microbiota that is at least 97% or at least 98% identical to those listed in Table 1. In certain modalities, the Consortium comprises a plurality Petition 870250102358, dated 07 / 11 / 2025, pages 100 / 280 92 / 227 microbes (e.g., active microbes and supporting community microbes) designated as “FB-001”. In certain embodiments, the Consortium comprises a plurality of microbes listed in Table 1. In certain embodiments, the Consortium comprises at least 143 microbes, at least 144 microbes, or at least 145 microbes from FB-001. Table 1 is provided below: Table 1. Medicinal substances of FB-001 Substância medicamentosa (DS) (also known as CoCultura, CoC) ID da Cepa Espécie de Cepa DS1 FBI00001 Clostridium citroniae FBI00002 Bacteroides salyersiae FBI00010 Blautia obeum FBI00013 Parabacteroides merdae FBI00029 Parabacteroides distasonis FBI00032 Anaerostipes hadrus FBI00033 Lachnospiraceae sp. FBI00033 FBI00034 Eubacterium eligens FBI00043 Bifidobacterium dentium FBI00044 Blautia wexlerae FBI00048 Fusicatenibacter saccharivorans FBI00050 Bacteroides nordii FBI00051 Dorea formicigenerans FBI00057 Dorea longicatena FBI00059 Bacteroides stercorirosoris FBI00060 Bifidobacterium longum FBI00070 Bacteroides kribbi FBI00071 Lachnospiraceae sp. FBI00071 FBI00076 Bacteroides thetaiotaomicron FBI00079 Clostridium clostridioforme FBI00087 Clostridium scindens FBI00093 Roseburia hominis FBI000102 Clostridium fessum Petition 870250102358, dated 07 / 11 / 2025, p. 101 / 280 93 / 227 Drug substance (DS) (also known as CoCulture, CoC) Strain ID Strain Species FBI00109 Coprococcus comes FBI00117 Blautia faecis FBI00120 Hungatella hathewayi FBI00125 Bacteroides stercoris FBI00127 Collinsella aerofaciens FBI00128 Hungatella effluvia FBI00145 Bifidobacterium adolescentis FBI00162 Bifidobacterium catenulatum FBI00174 Lactobacillus rogosae FBI00184 Bacteroides faecis FBI00190 Bacteroides finegoldii FBI00191 Clostridiaceae sp.FBI00191 FBI00194 Ruminococcus faecis FBI00198 Lachnoclostridium pacaense FBI00199 Clostridium bolteae FBI00200 Longicatena caecimuris FBI00201 Eggerthella lenta FBI00205 Blautia massiliensis FBI00206 Bacteroides xylanisolvens FBI00211 Bacteroides vulgatus FBI00220 Megasphaera massiliensis FBI00221 Butyricimonas faecihominis FBI00236 Eisenbergiella tayi FBI00245 Acidaminococcus intestini FBI00248 Emergencia timonensis FBI00251 Bifidobacterium pseudocatenulatum FBI00254 Eubacterium hallii FBI00267 Anaerofustis stercorihominis FBI00278 Eubacterium ventriosum FBI00288 Blautia hydrogenotrophica. Petition 870250102358, dated 07 / 11 / 2025, p. 102 / 280 94 / 227 Medicinal substance (DS) (also known as CoCultura, CoC) ID da Cepa Species de Cepa FBI00290 Lachnospiraceae sp. FBI00290 DS2 FBI00004 Acutalibacter timonensis FBI00012 Alistipes onderdonkii FBI00015 Bacteroides uniformis FBI00018 Eubacterium rectale FBI00019 Alistipes timonensis FBI00021 Bacteroides kribbi FBI00038 Coprococcus eutactus FBI00040 Bilophila wadsworthia FBI00046 Bacteroides caccae FBI00061 Alistipes shahii FBI00066 Parasutterella excrementihominis FBI00075 Paraprevotella clara FBI00077 Sutterella wadsworthensis FBI00080 Sutterella massiliensis FBI00081 Porphyromonas asaccharolytica FBI00085 Ruminococcus bromii FBI00092 Monoglobus pectinolyticus FBI00097 Ruminococcaceae sp.FBI00097 FBI00099 Gordonibacter pamelaeae FBI00112 Bacteroides uniformis FBI00132 Gordonibacter pamelaeae FBI00137 Bacteroides fragilis FBI00140 Phascolarctobacterium faecium FBI00149 Monoglobus pectinolyticus FBI00151 Clostridium aldenense FBI00176 Ruthenibacterium lactatiformans FBI00189 Bacteroides ovatus FBI00197 Bifidobacterium bifidum FBI00208 Anaerotruncus massiliensis. Petition 870250102358, dated 07 / 11 / 2025, p. 103 / 280 95 / 227 Medicinal substance (DS) (also known as CoCulture, CoC) Strain ID Strain species FBI00212 Clostridium aldenense FBI00224 Sutterella wadsworthensis FBI00226 Catabacter hongkongensis FBI00229 Alistipes senegalensis FBI00233 Ruminococcaceae sp.FBI00233 FBI00235 Alistipes shahii FBI00237 Dielma fastidiosa FBI00243 Eubacterium siraeum FBI00244 Faecalibacterium prausnitzii FBI00258 Turicibacter sanguinis FBI00260 Eubacterium rectale FBI00263 Bacteroides caccae FBI00270 Methanobrevibacter smithii FBI00273 Barnesiella intestinihominis FBI00277 Alistipes onderdonkii FBI00292 Methanobrevibacter smithii DS3 FBI00009 Bifidobacterium adolescentis FBI00011 Bifidobacterium longum FBI00016 Bifidobacterium pseudocatenulatum FBI00020 Bacteroides thetaiotaomicron FBI00025 Coprococcus comes FBI00027 Fusicatenibacter saccharivorans FBI00030 Eggerthella lenta FBI00047 Eubacterium eligens FBI00052 Bacteroides xylanisolvens FBI00053 Lactobacillus rogosae FBI00056 Clostridium citroniae FBI00062 Collinsella aerofaciens FBI00078 Blautia obeum FBI00096 Eggerthella lenta. Petition 870250102358, dated 07 / 11 / 2025, p. 104 / 280 96 / 227 Drug substance (DS) (also known as CoCulture, CoC) Strain ID Strain Species FBI00104 Blautia wexlerae FBI00110 Lachnoclostridium pacaense FBI00111 Bacteroides vulgatus FBI00113 Parabacteroides merdae FBI00115 Dorea formicigenerans FBI00116 Ruminococcus faecis FBI00123 Roseburia hominis FBI00124 Anaerostipes hadrus FBI00126 Bifidobacterium adolescentis FBI00135 Bifidobacterium pseudocatenulatum FBI00147 Clostridium bolteae FBI00159 Eisenbergiella tayi FBI00167 Dorea longicatena FBI00170 Eggerthella lenta FBI00232 Bacteroides stercoris FBI00255 Hungatella hathewayi FBI00271 Bacteroides xylanisolvens DS4 FBI00022 Alistipes putredinis FBI00049 Dialister succinatiphilus FBI00068 Akkermansia muciniphila FBI00069 Ruminococcus bromii FBI00152 Dialister invisus FBI00165 Bacteroides massiliensis FBI00171 Bilophila wadsworthia FBI00175 Holdemanella biformis FBI00177 Parasutterella excrementihominis FBI00180 Alistipes sp.FBI00180 FBI00182 Bacteroides coprocola FBI00238 Alistipes sp. FBI00238 FBI00269 Alistipes putredinis. Petition 870250102358, dated 07 / 11 / 2025, p. 105 / 280 97 / 227 Medicinal substance (DS) (also known as CoCulture, CoC) Strain ID Strain species FBI00274 Eubacterium xylanophilum FBI00281 Senegalimassilia anaerobia DS5 (DS-OF1) FBI00067 Oxalobacter formigenes DS6 (DS-OF2) FBI00133 Oxalobacter formigenes DS7 (DS-OF3) FBI00289 Oxalobacter formigenes

[0144] In certain embodiments, the Consortium is FB-003, as set out in Table 2. In certain embodiments, the Consortium comprises microbiota that is at least 97% or at least 98% identical to those listed in Table 2. In certain embodiments, the Consortium comprises a plurality of microbes (e.g., active microbes and supporting community microbes) designated as FB-003. In certain embodiments, the Consortium comprises a plurality of microbes listed in Table 2. In certain embodiments, the Consortium comprises at least 140 microbes, at least 141 microbes, or at least 142 microbes of FB-001. Table 2 is provided below: Table 2. Medicinal substances of FB-003 Drug Substance (DS) (also known as CoCulture, CoC) Strain ID Strain Species DS1 Same as Table 1 Same as Table 1 DS2 Same as Table 1 Same as Table 1 DS3 Same as Table 1 Same as Table 1 DS4 Same as Table 1 Same as Table 1

[0145] In certain forms, the Consortium comprises microbiota that is at least 97% or at least 98% identical to those listed in either Consortia I-XIX or Tables 1 or 2.

[0146] In certain embodiments, the Consortium comprises a plurality of microbes (e.g., active microbes and supporting community microbes) designated as Consortium A Petition 870250102358, dated 07 / 11 / 2025, p. 106 / 280 98 / 227 In certain embodiments, Consortium A comprises one or more strains of each of the species Anaerofustis stercorihominis, Anaerostipes hadrus, Bacteroides kribbi, Bacteroides stercoris, Bacteroides thetaiotaomicron, Bacteroides vulgatus, Bacteroides xylanisolvens, Bifidobacterium adolescentis, Bifidobacterium catenulatum, Bifidobacterium dentinum, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Blautia obeum, Blautia wexlerae, Butyricimonas faecihominis, Clostridium bolteae, Clostridium citoniae, Clostridium scindens, Collinsella aerofaciens, Coprococcus comes, Dorea formicigenerans, Dorea longicatena, Eggerthella lenta, Emergence timonensis, Eubacterium eligens, Eubacterium hallii, Eubacterium ventriosum, Hungatella hathewayi, Parabacteroides distasonis, Parabacteroides merdae, Roseburia hominis, Ruminococcus faecis, Alistipes onderdonkii, Alistipes senegalensis, Alistipes shahii, Alistipes timonensis, Anaerotruncus massiliensis, Bacteroides caccae,Bacteroides fragilis, Bacteroides ovatus, Bacteroides uniformis, Bifidobacterium bifidum, Bilophila wadsworthia, Catabacter hongkongensis, Clostridium aldenense, Coprococcus eutactus, Dielma fastidiosa, Eubacterium rectale, Eubacterium siraeum, Faecalibacterium prausnitzii, Gordonibacter pamelaeae, Methanobrevibacter smithii, Monoglobus pectinolyticus, Paraprevotella clara, Ruminococcus bromii, Ruthenibacterium lactatiformans, Sutterella wadsworthensis, Akkermansia muciniphila, Bacteroides massiliensis, Dialister succinatiphilus, Eubacterium xylanophilum, Acidaminococcus intestine, Bacteroides faecis, Blautia faecis, Blautia hydrogenotrophica, Blautia massiliensis, Eisenbergiella tayi, Fusicatenibacter saccharivorans, Megasphaera massiliensis, Parasutterella excrementihominis, Phascolarctobacterium faecium, Ruminococcaceae sp. FBI00097, Ruminococcaceae sp. FBI00233, Sutterella massiliensis, Alistipes putredinis, Petition 870250102358, dated 07 / 11 / 2025, p. 107 / 280 99 / 227 Holdemanella biformis, Bifidobacterium dentium, Bacteroides finegoldii, Bacteroides nordii, Bacteroides salyersiae, Bacteroides stercorirosoris, Clostridiaceae sp. FBI00191, Clostridium clostridioforme, Clostridium fessum, Hungatella effluvia, Lachnoclostridium pacaense, Lachnospiraceae sp. FBI00033, Lachnospiraceae sp. FBI00071, Lachnospiraceae sp. FBI00290, Lactobacillus rogosae, Longicatena caecimuris, Barnesiella intestinihominis, Porphyromonas asaccharolytica, Acutalibacter timonensis, Turicibacter sanguinis, Alistipes sp. FBI00238, Bacteroides coprocola, Dialister invisus.

[0147] In certain circumstances, the Consorcio comprises a plurality of microbes (for example, active microbes and microbes from the community of support) designated as "Consórcio B" In certain circumstances, the Consorcio B comprises one or more strains of each of the species Anaerofustis stercorihominis, Anaerostipes hadrus, Bacteroides kribbi, Bacteroides stercoris, Bacteroides thetaiotaomicron, Bacteroides vulgatus, Bacteroides xylanisolvens, Bifidobacterium adolescentis, Bifidobacterium catenulatum, Bifidobacterium dentinum, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Blautia obeum, Blautia wexlerae, Butyricimonas faecihominis, Clostridium bolteae, Clostridium citroniae, Clostridium scindens, Collinsella aerofaciens, Coprococcus comes, Dorea formicigenerans, Dorea longicatena, Eggerthella lenta, Emergencia timonensis, Eubacterium choosing, Eubacterium hallii, Eubacterium ventriosum, Hungatella hathawayi, Parabacteroides distasonis, Parabacteroides merdae,Roseburia hominis, Ruminococcus faecis, Alistipes onderdonkii, Alistipes senegalensis, Alistipes shahii, Alistipes timonensis, Anaerotruncus massiliensis, Bacteroides caccae, Bacteroides fragilis, Bacteroides ovatus, Bacteroides uniformis, Bifidobacterium bifidum, Bilophila wadsworthia, Catabacter hongkongensis, Clostridium aldenense, Coprococcus, Petition 870250102358, dated 07 / 11 / 2025, p. 108 / 280 100 / 227 eutactus, Dielma fastidiosa, Eubacterium rectale, Eubacterium siraeum, Faecalibacterium prausnitzii, Gordonibacter pamelaeae, Methanobrevibacter smithii, Monoglobus pectinolyticus, Paraprevotella clara, Ruminococcus bromii, Ruthenibacterium lactatiformans, Sutterella wadsworthensis, Akkermansia muciniphila, Bacteroides massiliensis, Dialister succinatiphilus, Eubacterium xylanophilum, Acidaminococcus intestine, Bacteroides faecis, Blautia faecis, Blautia hydrogenotrophica, Blautia massiliensis, Eisenbergiella tayi, Fusicatenibacter saccharivorans, Megasphaera massiliensis, Parasutterella excrementihominis, Phascolarctobacterium faecium, Ruminococcaceae, Sutterella massiliensis, Alistipes putredinis, Holdemanella biformis, Bifidobacterium dentium, Bacteroides finegoldii, Bacteroides nordii, Bacteroides salyersiae, Bacteroides stercorirosoris, Clostridiaceae, Clostridium clostridioforme, Clostridium fessum, Hungatella effluvia, Lachnoclostridium pacaense, Lachnospiraceae,Lactobacillus rogosae, Longicatena caecimuris, Barnesiella intestinihominis, Porphyromonas asaccharolytica, Acutalibacter timonensis, Turicibacter sanguinis, Alistipes sp., Bacteroides coprocola, Dialister invisus.,

[0148] In certain modalities, Consortium A and Consortium B comprise strains with the function of each species, as described in Figure 26.

[0149] In certain embodiments, Consortium A and Consortium B additionally comprise one or more strains of O. formigenes. In certain embodiments, Consortium A and Consortium B include strains with the function of each species, as described in Figure 26, and one or more strains of O. formigenes.

[0150] In certain embodiments, a consortium comprises a microbial strain with a relative abundance of approximately 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5%, 1%, 0.1%, 0.01%, 0.001%, 0.0001%, 0.00001% or 0.000001% of Petition 870250102358, dated 07 / 11 / 2025, page 109 / 280 101 / 227 total microbial consortium. In certain embodiments, the relative abundance of a microbial strain is determined by metagenomic sequencing and calculated as the percentage of reads classified as an identified microbial strain, divided by the genome size. In certain embodiments, the relative abundance of a microbial strain from the present disclosure is determined by shotgun metagenomic sequencing. An active and supportive community of microbes.

[0151] The consortia described in this document comprise a plurality of active microbes.

[0152] In addition, the consortia of this disclosure further comprise a supporting community of microbes that enhances one or more characteristics of the active microbial plurality. For example, in certain non-limiting embodiments, the supporting community of microbes increases the gastrointestinal graft of the active microbial plurality. In other embodiments, the supporting community of microbes increases the biomass of the active microbial plurality. In other embodiments, the supporting community of microbes increases the first metabolic substrate metabolism of the active microbial plurality. In other embodiments, the supporting community of microbes increases the longitudinal stability of the active microbial plurality.

[0153] The supporting community of microbes disclosed herein metabolizes one or more metabolites produced by the plurality of active microbes, and one or more of these metabolites inhibit the metabolism of the plurality of active microbes. For example, in certain non-limiting embodiments, the supporting community of microbes metabolizes formate produced by the plurality of active microbes, and the presence of formate inhibits oxalate metabolism by the plurality of active microbes. In certain embodiments, the supporting community of microbes of Petition 870250102358, dated 07 / 11 / 2025, page 110 / 280 102 / 227 present disclosure catalyzes the fermentation of polysaccharides into one or more of the group consisting of acetate, acetoin, 2-oxoglutarate, propionate, 1,3-propanediol, succinate, ethanol, lactate, butyrate, 2,3-butanediol, acetone, butanol, formate, H2 and CO2. In certain embodiments, the supporting community of microbes catalyzes the fermentation of amino acids into one or more of the group consisting of acetate, propionate, butanoate, butyrate, isobutyrate, 2-methylbutyrate, isovalerate, isocaproate, 3-phenylpropanoate, phlorethate, 3-(1H-indol-3-yl)propanoate, 5-aminopentanoate, H2, H2S and CO2.In certain embodiments, the supporting community catalyzes the synthesis of one or more elements of the group consisting of methane from H2 and CO2, methane from formate and H2, acetate from H2 and CO2, acetate from formate and H2, acetate and sulfide from H2, CO2 and sulfate, propionate and CO2 from succinate, succinate from H2 and fumarate; synthesis of succinate from formate and fumarate, and butyrate, acetate, H2 and CO2 from lactate. In certain embodiments, the supporting community of microbes of the present disclosure catalyzes the deconjugation of conjugated bile acids to produce primary bile acids, the conversion of cholic acid (CA) to 7-oxocholic acid, the conversion of 7-oxocholic acid to 7-beta-cholic acid (7betaCA), the conversion of chenodeoxycholic acid (CDCA) to 7oxocenedeoxycholic acid, and / or the conversion of 7oxocenedeoxycholic acid to ursodeoxycholic acid (UDCA). Consortium project

[0154] In certain embodiments, the microbial consortia disclosed in this document are designed to meet one or more of the following criteria: (i) an ability to eliminate or reduce the levels of a primary metabolic substrate that causes or contributes to a disease in an animal; (ii) an ability to metabolize or convert one or more Petition 870250102358, dated 07 / 11 / 2025, p. 111 / 280 103 / 227 metabolites produced by the metabolism of the first metabolic substrate; (iii) an ability to metabolize one or more nutrients normally found in the human diet; (iv) ability to perform unique and potentially beneficial biological functions in the gastrointestinal (GI) tract (e.g., bile salt hydrolase activity or butyrate production); (v) ability to graft into various biological niches and physical and metabolic compartments of an animal's gastrointestinal tract; (vi) an ability to increase biomass after grafting in the gastrointestinal tract; (vii) a capacity for longitudinal stability in the gastrointestinal tract of an animal; (viii) an ability to increase the flux of a precursor of the first metabolic substrate in a biochemical pathway that converts that precursor into a metabolite that is not the first metabolic substrate; (ix) diversity of component microbial species in one or more taxonomic phyla; and (x) natural prevalence of component microbial species in the gastrointestinal tract of healthy adults.

[0155] In certain embodiments, the microbial consortia of the present disclosure are designed to include a plurality of active microbes capable of metabolizing a primary metabolic substrate that causes or contributes to disease in an animal. In certain embodiments, the primary metabolic substrate may be selected from, but not limited to, oxalate and a bile acid (e.g., lithocholic acid (LCA), deoxycholic acid (DCA)). In certain embodiments, the microbial consortium is designed to be capable of metabolizing the primary metabolic substrate in Petition 870250102358, dated 07 / 11 / 2025, page 112 / 280 104 / 227 a variety of pH ranges found in the gastrointestinal tract (e.g., pH 4 to 8). In certain embodiments, the microbial consortium is designed to be able to metabolize the first metabolic substrate in the presence of varying concentrations of the first metabolic substrate, as existing in different regions of the gastrointestinal tract.

[0156] In certain modalities, the Consortium is FB-001 (for example, disclosed in Table 1) or a functional equivalent thereof. In certain modalities, FB-001 is defined by its function. In certain modes, FB-001 is defined by its function, as established in Tables 3 and / or 4. In certain modes, FB-001 is defined by its function, as established in Tables 3 and 4. In certain modes, FB-001 is defined by its function, as established in Table 3 or 4. In certain modes, FB001 is defined by its function, as established in Tables 14, 15, and 16. In certain modes, FB-001 is defined by its function, as established in one or more of Tables 14, 15, and 16. In certain modes, FB-001 is defined by its function, as established in Tables 3, 4, 14, 15, and 16. In certain modes, FB-001 is defined by its function as established in one or more of Tables 3, 4, 14, 15, and 16.In certain embodiments, the methods for determining the function of FB-001 are provided in Examples 5 and 6.

[0157] In certain modalities, the Consortium is FB-003 (for example, disclosed in Table 2) or a functional equivalent thereof. In certain modalities, FB-003 is defined by its function. In certain modalities, FB-003 is defined by its function, as set out in Tables 3 and / or 4. In certain modalities, FB-003 is defined by its function, as set out in Tables 3 and 4. In certain modalities, FB-003 is defined by its function as set out in Table 3 or 4. In certain modalities, FB Petition 870250102358, dated 07 / 11 / 2025, page 113 / 280 105 / 227 003 is defined by its function, as set forth in Tables 14, 15, and 16. In certain embodiments, FB-003 is defined by its function as set forth in one or more of Tables 14, 15, and 16. In certain embodiments, FB-003 is defined by its function, as set forth in Tables 3, 4, 14, 15, and 16. In certain embodiments, FB-003 is defined by its function as set forth in one or more of Tables 3, 4, 14, 15, and 16.

[0158] In certain modalities, the Consortium is Consortium A or B or a functional equivalent thereof. In certain modalities, Consortia A and B are defined by their function. In certain modalities, FB-003 is the consortium of Consortium A or Consortium B. In certain modalities, Consortia A and B are defined by their function, as set forth in Tables 3 and / or 4. In certain modalities, Consortia A and B are defined by their function, as set forth in Tables 3 and 4. In certain modalities, Consortia A and B are defined by their function, as set forth in Table 3 or 4. In certain modalities, Consortia A and B are defined by their function, as set forth in Tables 14, 15 and 16. In certain modalities, Consortia A and B are defined by their function, as set forth in one or more of Tables 14, 15 and 16.In certain modalities, Consortia A and B are defined by their function, as established in Tables 3, 4, 14, 15, and 16. In certain modalities, Consortia A and B are defined by their function, as established in one or more of Tables 3, 4, 14, 15, and 16. Preparation methods

[0159] This disclosure also provides methods for preparing and / or manufacturing the microbial consortia described in this document. Figures 10 to 12 illustrate specific methods for preparing and manufacturing the described microbial consortia. Petition 870250102358, dated 07 / 11 / 2025, page 114 / 280 106 / 227 in this document.

[0160] In certain embodiments, the methods comprise obtaining stool from a donor and preparing a stool dilution. In certain embodiments, the stool dilution is placed on an agar plate. In certain embodiments, the agar plate includes an anaerobic medium. In certain embodiments, the agar plate includes colonies. Characterization and quality analysis of these colonies can be performed. For example, but without limitation, 16s RNA and / or MALDI mass spectrometry can be performed. In certain embodiments, the characterized colonies can be expanded in a broth culture. After growth and expansion, the microbes can be stored in flasks for later use.

[0161] In certain embodiments, microbes can be expanded in a bioreactor that includes a cell culture medium. In certain embodiments, the cell culture medium may include: a) soy, D-cellobiose, yeast extract, dextrose (glucose), maltose monohydrate, magnesium sulfate heptahydrate, calcium chloride dihydrate, monobasic potassium phosphate, dibasic potassium phosphate, sodium chloride, sodium bicarbonate, volatile fatty acid solution, L-cysteine ​​HCl monohydrate, hemin solution, vitamin solution, or a combination thereof; or b) soy, D-cellobiose, yeast extract, dextrose (glucose), maltose monohydrate, magnesium sulfate heptahydrate, calcium chloride dihydrate, monobasic potassium phosphate, dibasic potassium phosphate, sodium chloride, ammonium sulfate, sodium bicarbonate, volatile fatty acid solution, L-cysteine ​​HCl monohydrate, hemin solution, vitamin solution, or a combination thereof.

[0162] In certain modalities, the means of culture Petition 870250102358, dated 07 / 11 / 2025, page 115 / 280 107 / 227 cellular is YCFAC. In certain embodiments, the cell culture medium additionally comprises threonine.

[0163] In certain embodiments, microbes can be expanded in a bioreactor under anaerobic conditions. In certain embodiments, microbes can be expanded in a bioreactor in the presence of gas overrun. In certain embodiments, microbes can be expanded in a bioreactor in the absence of gas overrun.

[0164] In certain forms, the methods include the expansion of microbes in mixed cultures.

[0165] In certain embodiments, the methods include the expansion of microbes in a first mixed culture or composition comprising: a) Clostridium citoniae, Bacteroides salyersiae, Blautia obeum, Parabacteroides merdae, Parabacteroides distasonis, Anaerostipes hadrus, Lachnospiraceae sp. FBI00033, Eubacterium eligens, Bifidobacterium dentium, Blautia wexlerae, Fusicatenibacter saccharivorans, Bacteroides nordii, Dorea formicigenerans, Dorea longicatena, Bacteroides stercorirosoris, Bifidobacterium longum, Bacteroides kribbi, Lachnospiraceae sp. FBI00071, Bacteroides thetaiotaomicron, Clostridium clostridioforme, Clostridium scindens, Roseburia hominis, Clostridium fessum, Coprococcus comes, Blautia faecis, Hungatella hathewayi, Bacteroides stercoris, Collinsella aerofaciens, Hungatella effluvii, Bifidobacterium adolescentis, Bifidobacterium catenulatum, Lactobacillus rogosae, Bacteroides faecis, Bacteroides finegoldii, Clostridiaceae sp.FBI00191, Ruminococcus faecis, Lachnoclostridium pacaense, Clostridium bolteae, Longicatena caecimuris, Eggerthella lenta, Blautia massiliensis, Bacteroides xylanisolvens, Bacteroides vulgatus, Megasphaera massiliensis, Butyricimonas faecihominis, Eisenbergiella tayi, Acidaminococcus intestini, Emergencia timonensis, Bifidobacterium pseudocatenulatum, Eubacterium. Petition 870250102358, dated 07 / 11 / 2025, p. 116 / 280 108 / 227 hallii, Anaerofustis stercorihominis, Eubacterium ventriosum, Blautia hydrogenotrophica from Lachnospiraceae sp. FBI00290, ou um equivalent funcional dos mesmos; ou b) FBI00001, FBI00002, FBI00010, FBI00013, FBI00029, FBI00032, FBI00033, FBI00034, FBI00043, FBI00044, FBI00048, FBI00050, FBI00051, FBI00057, FBI00059, FBI00060, FBI00070, FBI00071, FBI00076, FBI00079, FBI00087, FBI00093, FBI00102, FBI00109, FBI00117, FBI00120, FBI00125, FBI00127, FBI00128, FBI00145, FBI00162, FBI00174, FBI00184, FBI00190, FBI00191, FBI00194, FBI00198, FBI00199, FBI00200, FBI00201, FBI00205, FBI00206, FBI00211, FBI00220, FBI00221, FBI00236, FBI00245, FBI00248, FBI00251, FBI00254, FBI00267, FBI00278, FBI00288 and FBI00290, or a functional equivalent thereof.

[0166] In certain embodiments, the methods comprise the expansion of microbes in a second mixed culture or composition comprising: a) Acutalibacter timonensis, Alistipes onderdonkii, Bacteroides uniformis, Eubacterium rectale, Alistipes timonensis, Bacteroides kribbi, Coprococcus eutactus, Bilophila wadsworthia, Bacteroides caccae, Alistipes shahii, Parasutterella excrementihominis, Paraprevotella clara, Sutterella wadsworthensis, Sutterella massiliensis, Porphyromonas asaccharolytica, Ruminococcus bromii, Monoglobus pectinolyticus, Ruminococcaceae sp. FBI00097, Gordonibacter pamelaeae, Bacteroides uniformis, Gordonibacter pamelaeae, Bacteroides fragilis, Phascolarctobacterium faecium, Monoglobus pectinolyticus, Clostridium aldenense, Ruthenibacterium lactatiformans, Bacteroides ovatus, Bifidobacterium bifidum, Anaerotruncus massiliensis, Clostridium aldenense, Sutterella wadsworthensis, Catabacter hongkongensis, Alistipes senegalensis, Ruminococcaceae sp. FBI00233, Alistipes shahii, Dielma fastidiosa, Eubacterium siraeum, Faecalibacterium prausnitzii, Turicibacter sanguinis, Eubacterium rectale, Petition 870250102358, dated 07 / 11 / 2025, page 117 / 280 109 / 227 Bacteroides caccae, Methanobrevibacter smithii, Barnesiella intestinihominis, Alistipes onderdonkii and Methanobrevibacter smithii, or a functional equivalent thereof; or b) FBI00004, FBI00012, FBI00015, FBI00018, FBI00019, FBI00021, FBI00038, FBI00040, FBI00046, FBI00061, FBI00066, FBI00075, FBI00077, FBI00080, FBI00081, FBI00085, FBI00092, FBI00097, FBI00099, FBI00112, FBI00132, FBI00137, FBI00140, FBI00149, FBI00151, FBI00176, FBI00189, FBI00197, FBI00208, FBI00212, FBI00224, FBI00226, FBI00229, FBI00233, FBI00235, FBI00237, FBI00243, FBI00244, FBI00258, FBI00260, FBI00263, FBI00270, FBI00273, FBI00277 and FBI00292, or a functional equivalent thereof.

[0167] In certain embodiments, the methods include the expansion of microbes in a third mixed culture or composition comprising: a) Bifidobacterium adolescentis, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Bacteroides thetaiotaomicron, Coprococcus comes, Fusicatenibacter saccharivorans, Eggerthella lenta, Eubacterium eligens, Bacteroides xylanisolvens, Lactobacillus rogosae, Clostridium citoniae, Collinsella aerofaciens, Blautia obeum, Eggerthella lenta, Blautia wexlerae, Lachnoclostridium pacaense, Bacteroides vulgatus, Parabacteroides merdae, Dorea formicigenerans, Ruminococcus faecis, Roseburia hominis, Anaerostipes hadrus, Bifidobacterium adolescentis, Bifidobacterium pseudocatenulatum, Clostridium bolteae, Eisenbergiella tayi, Dorea longicatena, Eggerthella lenta, Bacteroides stercoris, Hungatella hathawayi and Bacteroides xylanisolvens, or a functional equivalent thereof; or b) FBI00009, FBI00011, FBI00016, FBI00020, FBI00025, FBI00027, FBI00030, FBI00047, FBI00052, FBI00053, FBI00056, FBI00062, FBI00078, FBI00096, FBI00104, FBI00110, FBI00111, FBI00113, FBI00115, FBI00116, FBI00123, FBI00124, FBI00126, Petition 870250102358, dated 07 / 11 / 2025, page 118 / 280 110 / 227 FBI00135, FBI00147, FBI00159, FBI00167, FBI00170, FBI00232, FBI00255 and FBI00271, or a functional equivalent thereof.

[0168] In certain embodiments, the methods comprise the expansion of microbes in a fourth mixed culture or composition comprising: a) Alistipes putredinis, Dialister succinatiphilus, Akkermansia muciniphila, Ruminococcus bromii, Dialister invisus, Bacteroides massiliensis, Bilophila wadsworthia, Holdemanella biformis, Parasutterella excrementihominis, Alistipes sp. FBI00180, Bacteroides coprocola, Alistipes sp. FBI00238, Alistipes putredinis, Eubacterium xylanophilum and Senegalmassilia anaerobia, or a functional equivalent thereof; or b) FBI00022, FBI00049, FBI00068, FBI00069, FBI00152, FBI00165, FBI00171, FBI00175, FBI00177, FBI00180, FBI00182, FBI00238, FBI00269, FBI00274 and FBI00281, or an equivalent functional dos mesmos.

[0169] In certain embodiments, the methods include the expansion of each of the three O. formigenes microbes from FB-001 in single cultures. In certain embodiments, the methods comprise the expansion of microbes in a first single culture (or fifth composition) that includes: a) a first strain of O. formigenes; or b) FBI00067 or a functional equivalent. In certain embodiments, the methods comprise the expansion of microbes in a second single culture (or sixth composition) that includes a) a second strain of O. formigenes; or b) FBI00133 or a functional equivalent thereof. In certain embodiments, the methods comprise the expansion of microbes in a third single culture (or seventh composition) that includes a) a third strain of O. formigenes; or b) FBI00289 or a functional equivalent.

[0170] In certain embodiments, the methods comprise the lyophilization of cultures and compositions described herein. Petition 870250102358, dated 07 / 11 / 2025, page 119 / 280 111 / 227 document. In certain embodiments, the cultures and compositions comprise a lipoprotective agent. In certain embodiments, the lipoprotective agent comprises maltodextrin. In certain embodiments, the lipoprotective agent comprises inulin. In certain embodiments, the lipoprotective agent comprises maltodextrin and inulin. In certain embodiments, maltodextrin is present at a concentration of approximately 8%. In certain embodiments, inulin is present at a concentration of approximately 0.5%.

[0171] In certain embodiments, the methods comprise the mixing and / or combination of lyophilized cultures and compositions described above. Additional information on the strains of each composition can be found in Table 1 or Table 2.

[0172] In certain embodiments, DS1, as described in Table 1, is prepared using the method described in Figure 17. In certain embodiments, DS2, as described in Table 1, is prepared using the method described in Figure 18. In certain embodiments, DS3, as described in Table 1, is prepared using the method described in Figure 19. In certain embodiments, DS4, as described in Table 1, is prepared using the method described in Figure 20. In certain embodiments, for FB-001, DS5-DS7 (i.e., the manufacture of O. formigenes), as described in Table 21, are prepared using the method described in Figure 16. In certain embodiments, the manufacture of FB-001 and FB-003 comprises the separate manufacture of each of the DS1-DS4 (and DS5-DS7 for FB-001), as described in Figures 16 to 20, followed by mixing to obtain a distribution uniform of each of the DSs.In certain embodiments, the mixture of DS1-DS4 (for FB-003) and DS1-DS7 (for FB-003) is followed by encapsulation for oral administration. Pharmaceutical compositions

[0173] This publication also offers compositions Petition 870250102358, dated 07 / 11 / 2025, pages 120 / 280 112 / 227 pharmaceuticals containing an effective amount of a microbial consortium described in this document. The composition can be formulated for use in a variety of delivery systems. One or more physiologically acceptable buffers or carriers may also be included in the composition for proper formulation. Suitable formulations for use in the present disclosure are found in Remington's Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, Pennsylvania, 17th ed., 1985. For a brief review of drug administration methods, see, for example, Langer (Science 249:1527-1533, 1990).

[0174] In certain embodiments, the currently disclosed pharmaceutical composition comprises Consortium I. In certain embodiments, the currently disclosed pharmaceutical composition comprises Consortium II. In certain embodiments, the currently disclosed pharmaceutical composition comprises Consortium I. In certain embodiments, the currently disclosed pharmaceutical composition comprises Consortium III. In certain embodiments, the currently disclosed pharmaceutical composition comprises Consortium IV. In certain embodiments, the currently disclosed pharmaceutical composition comprises Consortium V. In certain embodiments, the currently disclosed pharmaceutical composition comprises Consortium VI. In certain embodiments, the currently disclosed pharmaceutical composition comprises Consortium VII. In certain embodiments, the currently disclosed pharmaceutical composition comprises Consortium VIII.In certain embodiments, the currently disclosed pharmaceutical composition comprises Consortium IX. In certain embodiments, the currently disclosed pharmaceutical composition comprises Consortium X. In certain embodiments, the currently disclosed pharmaceutical composition comprises Consortium XI. In certain embodiments, the currently disclosed pharmaceutical composition comprises Consortium XII. In certain embodiments... Petition 870250102358, dated 07 / 11 / 2025, pp. 121 / 280 113 / 227 modalities, the currently disclosed pharmaceutical composition comprises Consortium XIII. In certain modalities, the currently disclosed pharmaceutical composition comprises Consortium XIV. In certain modalities, the currently disclosed pharmaceutical composition comprises Consortium XV. In certain modalities, the currently disclosed pharmaceutical composition comprises Consortium XVI. In certain modalities, the currently disclosed pharmaceutical composition comprises Consortium XVII. In certain modalities, the currently disclosed pharmaceutical composition comprises Consortium XVIII. In certain modalities, the currently disclosed pharmaceutical composition comprises Consortium XIX. In certain modalities, the currently disclosed pharmaceutical composition comprises Consortium A. In certain modalities, the currently disclosed pharmaceutical composition comprises Consortium B.

[0175] In certain embodiments, the currently disclosed pharmaceutical composition comprises FB-001. In certain embodiments, the currently disclosed pharmaceutical composition comprises FB-003.

[0176] In certain embodiments, the currently disclosed pharmaceutical composition comprises a quantity of at least about 10, at least about 102, at least about 103, at least about 104, at least about 105, at least about 106, at least about 107, at least about 108, at least about 109, at least about 1010, at least about 1011, at least about 1012 or at least about 1013 microbes of each strain (for example, each strain of FB-001 or FB-003). In certain embodiments, the currently disclosed pharmaceutical composition comprises between approximately 10 and approximately 1013, between approximately 102 and approximately 1013, between approximately 103 and approximately 1013, between approximately 104 and approximately 1013, between approximately 105 and approximately 1013, between approximately 106 and approximately 1013, between Petition 870250102358, dated 07 / 11 / 2025, pp. 122 / 280 114 / 227 approximately 107 and approximately 1013, between approximately 108 and approximately 1013, between approximately 109 and approximately 1013, between approximately 1010 and approximately 1013, between approximately 1011 and approximately 1013, between approximately 1012 and approximately 1013, between approximately 102 and approximately 1012, between approximately 102 and approximately 1011, between approximately 102 and approximately 1010, between approximately 102 and approximately 109, between approximately 102 and approximately 108, between approximately 102 and approximately 107, between approximately 102 and approximately 106, between approximately 102 and approximately 105, between approximately 102 and approximately 104, between approximately between approximately 102 and approximately 103, between approximately 102 and approximately 109, between approximately 103 and approximately 109, between approximately 104 and approximately 109, between approximately 105 and approximately 109, between approximately 106 and approximately 109, between approximately 107 and approximately 109, between approximately 108 and approximately 109, between approximately 102 and approximately 106, between approximately 103 and approximately 106, between approximately 104 and approximately 106, or between approximately 105 and approximately 106 microbes for each strain (for example,each strain of FB-001 or FB-003). In certain embodiments, each strain may be present in different quantities. For example, but without limitation, a pharmaceutical composition comprising a first strain, a second strain and a third strain may include 10 microbes of the first strain, 107 microbes of the second strain and 103 microbes of the third strain.

[0177] In certain embodiments, the currently disclosed pharmaceutical composition comprises an amount of at least about 10, at least about 10², at least about 10³, at least about 10⁴, at least about 10⁵, at least about 10⁶, at least about 10⁷, at least about 10⁸, at least about 10⁹, at least about 10¹⁰, at least about 10¹¹, at least about 10¹², or at least about 10¹³ CFUs of each strain (for example, each strain of FB-001 or FB003). In certain embodiments, the currently disclosed pharmaceutical composition comprises between about 10 and about 10¹³, between about 10² and about 10¹³, between about 10³ and Petition 870250102358, dated 07 / 11 / 2025, pp. 123 / 280 115 / 227 approximately 1013, between approximately 104 and approximately 1013, between approximately 105 and approximately 1013, between approximately 106 and approximately 1013, between approximately 107 and approximately 1013, between approximately 108 and approximately 1013, between approximately 109 and approximately 1013, between approximately 1010 and approximately 1013, between approximately 1011 and approximately 1013, between approximately 1012 and approximately 1013, between approximately 102 and approximately 1012, between approximately 102 and approximately 1011, between approximately 102 and approximately 1010, between approximately 102 and approximately 109, between approximately 102 and approximately 108, between approximately 102 and about 107, between about 102 and about 106, between about 102 and about 105, between about 102 and about 104, between about 102 and about 103, between about 102 and about 109, between about 103 and about 109, between about 104 and about 109, between about 105 and about 109, between about 106 and about 109, between about 107 and about 109, between about 108 and about 109, between about 102 and about 106, between about 103 and about 106,between approximately 10⁴ and approximately 10⁶, or between approximately 10⁵ and approximately 10⁶ CFUs for each strain (for example, each strain of FB-001 or FB-003). In certain embodiments, each strain may be present in different quantities. For example, but without limitation, a pharmaceutical composition comprising a first strain, a second strain, and a third strain may include 10 CFUs of the first strain, 10⁷ CFUs of the second strain, and 10³ CFUs of the third strain.

[0178] In certain embodiments, the currently disclosed pharmaceutical composition comprises an amount of at least about 10⁻¹, at least about 10⁻², at least about 10⁻³, at least about 10⁻⁴, at least about 10⁵, at least about 10⁻⁶, at least about 10⁻⁷, at least about 10⁻⁸, at least about 10⁻⁹, at least about 10¹⁰, at least about 10⁻¹¹, or at least about 10⁻¹², or at least about 10¹³ grams of each strain (for example, each strain of FB-001 or FB-003). In certain embodiments, each strain may be present in different amounts. For example, Petition 870250102358, dated 07 / 11 / 2025, pp. 124 / 280 116 / 227 but without any limitation, a pharmaceutical composition comprising a first strain, a second strain and a third strain may comprise 10-4 grams of the first strain, 10-3 grams of the second strain and 10-6 grams of the third strain.

[0179] In certain embodiments, the currently disclosed pharmaceutical composition comprises a total quantity of at least about 10, at least about 102, at least about 103, at least about 104, at least about 105, at least about 106, at least about 107, at least about 108, at least about 109, at least about 1010, at least about 1011, at least about 1012 or at least about 1013 microbes (for example, total quantity of microbes of FB-001 or total quantity of microbes of FB-003). In certain embodiments, the currently disclosed pharmaceutical composition comprises a total quantity of between 10 and 1013, between 102 and 1013, between 103 and 1013, between 104 and 1013, between 105 and 1013, between 106 and 1013, between approximately 107 and approximately 1013, between approximately 108 and approximately 1013, between approximately 109 and approximately 1013, between approximately 1010 and approximately 1013, between approximately 1011 and approximately 1013, between approximately 1012 and approximately 1013,between about 102 and about 1012, between about 102 and about 1011, between about 102 and about 1010, between about 102 and about 109, between about 102 and about 108, between about 102 and about 107, between about 102 and about 106, between about 102 and about of 105, between about 102 and about 104, between about 102 and about 103, between about 102 and about 109, between about 103 and about 109, between about 104 and about 109, between about 105 and about 109, between about 106 and about 109, between about 107 and about 109, between about 108 and approximately 109, between approximately 102 and approximately 106, between approximately 103 and approximately 106, between approximately 104 and approximately 106, or between approximately 105 and approximately 106 microbes.

[0180] In certain modalities, the composition Petition 870250102358, dated 07 / 11 / 2025, pages 125 / 280 The pharmaceutical product currently disclosed as 117 / 227 comprises a total quantity of at least about 10, at least about 102, at least about 103, at least about 104, at least about 105, at least about 106, at least about 107, at least about 108, at least about 109, at least about 1010, at least about 1011, at least about 1012 or at least about 1013 CFUs (e.g., total CFUs of FB-001 or total CFUs of FB-003). In certain embodiments, the currently disclosed pharmaceutical composition comprises a total quantity between about 10 and about 1013, between about 102 about 1013, between about 103 about 1013, between about 104 about 1013, between about 105 about 1013, between about 106 about 1013, between about 107 about 1013, between about 108 about 1013, between about 109 about 1013, between about 1010 about 1013, between about 1011 about 1013, between about 1012 about 1013,between about 102 and about 1012, between about 102 and about 1011, between about 102 and about 1010, between about 102 and about 109, between about 102 and about 108, between about 102 and about 107, between about 102 and about 106, between about 102 and about of 105, between about 102 and about 104, between about 102 and about 103, between about 102 and about 109, between about 103 and about 109, between about 104 and about 109, between about 105 and about 109, between about 106 and about 109, between about 107 and about 109, between about Between approximately 108 and approximately 109, between approximately 102 and approximately 106, between approximately 103 and approximately 106, between approximately 104 and approximately 106, or between approximately 105 and approximately 106 CFUs. In certain embodiments, the currently disclosed pharmaceutical composition comprises between approximately 105 and approximately 1013, between approximately 106 and approximately 1013, between approximately 107 and approximately 1013, between approximately 108 and approximately 1013, between approximately 109 and approximately 1013,between about 1010 and about 1013, between about 1011 and about 1013, between about 1012 and about 1013, between about 105 and about, Petition 870250102358, dated 07 / 11 / 2025, pp. 126 / 280 118 / 227 of 1012, between about 106 e about 1012, between about 107e about 1012, between about 108e about 1012, between about 109e about 1012, between about 1010e about 1012, between about 1011e about 1012, between about 105e close to 1011, between close to 106 e close to 1011, between close to 107e close to 1011, between close to 108e close to 1011, between close to 109e close to 1011, between close to 1010e close to 1011, between close to 105e close to 1010, between close to 106 e about 1010, between about 107e near 1010, between near 108e near 1010, between near 109e near 1010, between near 105e near 109, between near 106e near 109, between near 107e near 109, between near 108e near 109, between near 5χ 109e near 5χ 1010, between near 5χ 109e near 5χ 1011, between near 5χ 109e near 5χ 1012, between near 5χ 1010e near 5χ 1012, between near 5χ 1011e near 5χ 1012,or between approximately 5χ¹⁰ and approximately 5χ¹⁰ viable cells. In certain embodiments, the currently disclosed pharmaceutical composition comprises between approximately 5χ¹⁰ and approximately 5χ¹⁰¹² viable cells. In certain embodiments, the currently disclosed pharmaceutical composition comprises between approximately 5χ¹⁰ and approximately 5χ¹⁰ viable cells. In certain embodiments, the currently disclosed pharmaceutical composition comprises between approximately 5χ¹⁰ and approximately 5χ¹⁰ viable cells. In certain embodiments, the currently disclosed pharmaceutical composition comprises between approximately 5χ¹⁰ and approximately 5χ¹⁰ viable cells.

[0181] In certain embodiments, the currently disclosed pharmaceutical composition comprises up to about 10⁵, up to about 10⁶, up to about 10⁷, up to about 10⁸, up to about 10⁹, up to about 10¹⁰, up to about 10¹¹, up to about 10¹² or up to about 10¹³ viable cells. In certain embodiments, the currently disclosed pharmaceutical composition comprises up to about 10¹¹ viable cells. In certain embodiments, the Petition 870250102358, dated 07 / 11 / 2025, pages 127 / 280 The currently disclosed pharmaceutical composition of 119 / 227 comprises up to approximately 1012 viable cells.

[0182] In certain embodiments, the pharmaceutical composition currently disclosed may be present in the form of a food product comprising a consortium disclosed in this document (e.g., FB-001 or FB-003). As used in this document, the term “food product” refers to a composition intended for ingestion by an individual (e.g., a human being). Non-limiting examples of food products covered by this disclosure include juices, soft drinks, tea-based drinks, beverage preparations, gelatin-based drinks, functional drinks, milk, dairy drinks, ice cream, cheeses, yogurts, biscuits, cookies, candies, chewing gum, gums, gelatins, creamy caramels, frozen desserts, and instant foods. In addition, examples also include health foods and beverages prepared in the forms of powders, granules, tablets, capsules, liquids, pastes, and gelatins.In certain embodiments, the food product comprising a currently disclosed consortium additionally comprises a prebiotic. As used in this document, the term “prebiotic” refers to a substance that can promote the growth of the microbes in the consortia. Non-limiting examples of prebiotics include fructose, galactose, mannose, soy, inulin, dietary fiber, or a combination thereof.

[0183] In certain embodiments, the microbial cells of the present disclosure are collected by microfiltration and centrifugation. In certain embodiments, microfiltration is performed with a membrane composed of a non-reactive polymer. For example, in certain non-limiting embodiments, said membrane comprises polyvinylidene fluoride, polysulfones, or nitrocellulose. In certain embodiments, a microfiltration membrane has a pore size of about 0.2 µm to about Petition 870250102358, dated 07 / 11 / 2025, pages 128 / 280 120 / 227 at 0:45 pm. In certain methods, the cells are centrifuged at a speed of approximately 1000 g to 30000 g, approximately 5000 g to 30000 g, approximately 10000 g to 30000 g, approximately 15000 g to 30000 g, approximately 20000 g to 30000 g, approximately 25000 g to 30000 g, approximately 1000 g to 25000 g, approximately 5000 g to 25000 g, approximately 10000 g to 25000 g, approximately 15000 g to 25000 g, approximately 20000 g to 25000 g, of about 1000 ga about 20000 g, of about 5000 ga about 20000 g, of about 10000 ga about 20000 g, of about 15000 ga about 20000 g, of about 1000 ga about 15000 g, of about 5000 ga about 15000 g, of about 10000 ga about 15000 g, of about 1000 ga about 10000 g, of about 5000 ga about 10000 g or of about 1000 ga about 5000 g of strength.

[0184] In certain modalities, the cells are concentrated at approximately 1 x 10⁶ CFUs per milliliter to approximately 1 x 10¹² CFUs per milliliter, at approximately 1 x 10⁷ CFUs per milliliter to approximately 1 x 10¹² CFUs per milliliter, at approximately 1 x 10⁸ CFUs per milliliter to approximately 1 x 10¹² CFUs per milliliter, at approximately 1 x 10⁹ CFUs per milliliter to approximately 1 x 10¹² CFUs per milliliter, at approximately 1 x 10¹⁰ CFUs per milliliter to approximately 1 x 10¹² CFUs per milliliter, at approximately 1 x 10¹¹ CFUs per milliliter to approximately 1 10¹² CFUs per milliliter, from about 1 10⁶ CFUs per milliliter to about 1 10¹¹ CFUs per milliliter, from about 1 10⁷ CFUs per milliliter to about 1 10¹¹ CFUs per milliliter, from about 1 10⁸ CFUs per milliliter to about 1 10¹¹ CFUs per milliliter, from about 1 10⁹ CFUs per milliliter to about 1 10¹¹ CFUs per milliliter, from about 1 10¹⁰ CFUs per milliliter to about 1 10¹¹ CFUs per milliliter, from about 1 10⁶ CFUs per milliliter to about 1 10 1010 CFUs per milliliter,from about 1 x 10⁷ CFUs per milliliter to about 1 x 10¹⁰ CFUs per milliliter, from about 1 x 10⁸ CFUs per milliliter, Petition 870250102358, dated 07 / 11 / 2025, page. 129 / 280 121 / 227 to about 1 x 10¹⁰ CFUs per milliliter, from about 1 x 10⁹ CFUs per milliliter to about 1 x 10¹⁰ CFUs per milliliter, from about 1 x 10⁶ CFUs per milliliter to about 1 x 10⁹ CFUs per milliliter, from about 1 x 10⁷ CFUs per milliliter to about 1 x 10⁹ CFUs per milliliter, from about 1 x 10⁸ CFUs per milliliter to about 1 x 10⁹ CFUs per milliliter, from about 1 x 10⁶ CFUs per milliliter to about 1 x 10⁸ CFUs per milliliter, from about 1 x 10⁷ CFUs per milliliter to about of 1 x 108 CFUs per milliliter, or from about 1 x 106 CFUs per milliliter to about 1 x 107 CFUs per milliliter.

[0185] In certain embodiments, the microbial cells of the present disclosure are frozen. In certain embodiments, the microbial cells of the present disclosure are mixed with one or more cryoprotective agents (CPAs) before freezing. In certain embodiments, the ratio of cells to CPA is approximately 25:1, 10:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:10, or 1:25. In certain embodiments, a CPA comprises one or more of the following components: glycerol, maltodextrin, sucrose, inulin, trehalose, and alginate. In certain embodiments, a CPA further comprises one or more antioxidants. In certain embodiments, an antioxidant is selected from the list of cysteine, ascorbic acid, and riboflavin.

[0186] In certain embodiments, the microbial cells of the present disclosure are lyophilized. In certain embodiments, the lyophilized cells are used to produce an orally administered dose of the disclosure. In certain embodiments, primary drying is conducted below approximately -20 °C. In certain embodiments, primary drying is followed by secondary drying at a higher temperature, for example, greater than 0 °C, greater than 5 °C, or greater than 10 °C. Functionally equivalent and identical medicinal products Petition 870250102358, dated 07 / 11 / 2025, pp. 130 / 280 122 / 227 to FB-001

[0187] The strains included in FB-001 are described in this document by 16S RNA sequences and functional characteristics. Based on this, consortia equivalent to FB-001 can be generated by screening several identical strains to find equivalent strains with function equivalent to those comprising FB-001. Thus, identical strains can theoretically have different functions; strains can be searched using 16S RNA and Biolog, as described in this document, to identify functionally identical and equivalent strains from any fecal collection using the collection methods described in this document.

[0188] It is important to note that FB-001 was designed in an articulated manner to have multiple strains of the same strain in the consortia. The reason for this is to have redundancy to ensure function; however, this redundancy is not necessary for equivalent function, provided that one of the redundant strains is included in the final drug product in a sufficient viable cell count to achieve function in vivo in an individual. Thus, a consortium equivalent or identical to FB-001 may contain all redundancies (see Table 1) or, alternatively, may contain no or fewer redundancies per strain, provided that the included strains achieve function in vivo in an individual.

[0189] In an alternative approach to creating a consortium functionally equivalent to FB-001, a person skilled in the art could recreate a consortium of supporting microbes from healthy fecal donors and supplement the supporting microbes with one or more strains of O. formigenes. In certain embodiments, the supporting microbes will be supplemented with two or more strains of O. formigenes or, specifically, three strains of O. formigenes. The supporting microbes may include between 10 and 200 microbes, provided that this Petition 870250102358, dated 07 / 11 / 2025, pp. 131 / 280 123 / 227 support community to support and encourage the growth, health, and grafting of the O. formigenes strain(s) in an individual. FB001 was designed to have 148 microbes to mimic a complete and healthy microbiome. In this way, equivalent consortia can comprise approximately 148 microbes, including the O. formigenes strain(s). However, it is interesting to note that older individuals generally have smaller microbiomes; Therefore, a consortium functionally equivalent to FB-001 may also have far fewer microbes (e.g., 30-40, 40-50, 50-60, 60-70, 70-80, 8-90, 90-100, 100-110, 110-120, 120-130, 130-140, or 140-150 microbes, including the O. formigenes strain(s)). Medicinal products that are functionally equivalent and identical to FB-003.

[0190] The strains included in FB-003 are described in this document by 16S RNA sequences and functional characteristics. Based on this, FB-003 equivalent consortia can be generated through multiple screening of the same strain to find equivalent strains with equivalent function to those comprising FB-003. Thus, identical strains can theoretically have different functions; strains can be screened using 16S RNA and Biolog, as described in this document, to identify functionally identical and equivalent strains from any fecal collection using the collection methods described in this document.

[0191] It is important to note that FB-003 was designed in an articulated manner to have several of the same strain in the consortia. The reason for this is to have redundancy to ensure function; however, this redundancy is not necessary for equivalent function, provided that one of the redundant strains is included in the final drug product in a sufficient quantity of viable cell count to achieve function in vivo in an individual. In this way, a Consortium that is equivalent or Petition 870250102358, dated 07 / 11 / 2025, page 132 / 280 124 / 227 identical to FB-003 may contain all redundancies (see Table 2) or, alternatively, may contain no or fewer redundancies per strain, provided that the included strains achieve in vivo function in an individual. Therapeutic applications

[0192] This disclosure provides consortia capable of grafting into one or more niches of a gastrointestinal tract, where it is possible to treat dysbiosis that causes or contributes to disease in an animal. In certain modalities, the animal is a human being.

[0193] In certain embodiments of the disclosure, when administered to an animal, the animal is pre-treated with one or more antibiotics prior to administration of the Consortium. In certain embodiments, one or more antibiotics are selected from ampicillin, enrofloxacin, clarithromycin, and metronidazole. In certain embodiments, the animal is pre-treated with a polyethylene glycol bowel preparation procedure.

[0194] In certain modalities, a consortium is used to treat an individual who has or is at risk of developing dysbiosis of the gastrointestinal tract. In certain modalities, dysbiosis is caused by or causes irritable bowel disease (IBD), colitis, ulcerative colitis, or Crohn's disease. In certain modalities, dysbiosis is caused by or causes IBD. In certain modalities, dysbiosis is caused by or causes colitis. In certain modalities, dysbiosis is caused by or causes ulcerative colitis. In certain modalities, dysbiosis is caused by or causes Crohn's disease.

[0195] In certain embodiments, a consortium significantly alters the profile and / or concentration of bile acids present in an animal. For example, in certain non-limiting embodiments, a consortium significantly alters the profile and / or concentration of Tβ-MCA, Ta Petition 870250102358, dated 07 / 11 / 2025, page 133 / 280 125 / 227 MCA, TUDCA, THDCA, TCA, 7β-0Α, 7-oxo-CA, TCDCA, Τω-MCA, TDCA, αMCA, β-MCA, ω-MCA, Muro-CA, d4-CA, CA, TLCA, UDCA, HDCA, CDCA, DCA, and LCA in an animal. In certain embodiments, FB-003 alters the profile and / or concentration of one or more Τβ-MCA, TUDCA, THDCA, TCA, 7β-CA, 7-oxo-CA, TCDCA, Τω-MCA, TDCA, αMCA, β-MCA, ω-MCA, Muro-CA, d4-CA, CA, TLCA, UDCA, HDCA, CDCA, DCA, and LCA in an animal.

[0196] In certain embodiments, a defined intestinal microbial community of high complexity of the present disclosure may be used to treat an animal with a cholestatic disease, such as, for example, primary sclerosing cholangitis, primary biliary cholangitis, progressive familial intrahepatic cholestasis, or non-alcoholic steatohepatitis. For example, in certain non-limiting embodiments, the animal may be a mammal and, more specifically, a human being.

[0197] In certain embodiments, a Consortium may be administered enterally. For example, in certain non-limiting embodiments, a microbial consortium is administered orally, rectally (e.g., by enema, suppository or colonoscope) or by oral or nasal tube.

[0198] In certain forms, the Consortium is administered orally. In certain forms, oral administration is done by means of a powder. In certain forms, oral administration is done by means of a paste. In certain forms, oral administration is done by means of tablets or capsules.

[0199] In certain embodiments, a Consortium may be administered at a specific site along the gastrointestinal tract. For example, in certain non-limiting embodiments, a microbial consortium may be administered at one or more gastrointestinal sites, including the mouth, esophagus, stomach, small intestine (duodenum, jejunum, ileum), large intestine (cecum, ascending colon, transverse colon, Petition 870250102358, dated 07 / 11 / 2025, page 134 / 280 126 / 227 descending colon) or the rectum. In certain modalities, a microbial consortium can be administered to all regions of the gastrointestinal tract.

[0200] In certain embodiments, FB-001 and FB-003 may be administered orally by means of a tablet or capsule. Treatment methods for dysbiosis and IBD

[0201] This disclosure provides methods for preventing and / or treating dysbiosis in an individual. In certain embodiments, the methods may include administering an effective amount of a Consortium or a pharmaceutical composition thereof, as disclosed in this document. In certain embodiments, the Consortium is FB-001 or a functional equivalent thereof. In certain embodiments, the Consortium is FB-003 or a functional equivalent thereof. In certain embodiments, administration of the Consortia or their pharmaceutical composition results in the grafting of microbes from the Consortia. In certain embodiments, administration of the Consortium or its pharmaceutical composition results in an increase in microbial diversity in the gastrointestinal tract. In certain embodiments, administration of the Consortium or its pharmaceutical composition results in an increase in short-chain fatty acids (SCFAs) (e.g., in the individual's gastrointestinal tract).In certain modalities, administration of the Consortium or its pharmaceutical composition results in an increase in secondary bile acids (e.g., in the individual's gastrointestinal tract). In certain modalities, administration of the Consortium or its pharmaceutical composition results in a decrease in bacterial pathogens (e.g., in the individual's gastrointestinal tract).

[0202] This disclosure also offers methods for reducing dysbiosis (e.g., dysbiosis of the gastrointestinal tract) in an individual. In certain modalities, Petition 870250102358, dated 07 / 11 / 2025, pp. 135 / 280 127 / 227 The methods may include administering an effective amount of a consortium or pharmaceutical composition disclosed in this document. In certain embodiments, the Consortium is FB-001 or a functional equivalent thereof. In certain embodiments, the Consortium is FB-003 or a functional equivalent thereof. In certain embodiments, administration of the Consortia or their pharmaceutical composition results in the grafting of microbes from the Consortia. In certain embodiments, administration of the Consortium or its pharmaceutical composition results in an increase in microbial diversity in the gastrointestinal tract. In certain embodiments, administration of the Consortium or its pharmaceutical composition results in an increase in short-chain fatty acids (SCFAs) (e.g., in the individual's gastrointestinal tract).In certain modalities, administration of the Consortium or its pharmaceutical composition results in an increase in secondary bile acids (e.g., in the individual's gastrointestinal tract). In certain modalities, administration of the Consortium or its pharmaceutical composition results in a decrease in bacterial pathogens (e.g., in the individual's gastrointestinal tract).

[0203] In addition, this disclosure provides methods for restoring the microbiome in an individual. In certain embodiments, the methods may include administering an effective amount of a consortium or pharmaceutical composition disclosed in this document. In certain embodiments, the Consortium is FB-001 or a functional equivalent thereof. In certain embodiments, the Consortium is FB-003 or a functional equivalent thereof. In certain embodiments, administration of the Consortia or their pharmaceutical composition results in the grafting of microbes from the Consortia. In certain embodiments, administration of the Consortium or its pharmaceutical composition results in an increase in the microbial diversity of the gastrointestinal tract. In certain embodiments, the Petition 870250102358, dated 07 / 11 / 2025, page 136 / 280 128 / 227 Administration of the Consortium or its pharmaceutical composition results in an increase in short-chain fatty acids (SCFAs) (e.g., in the individual's gastrointestinal tract). In certain embodiments, administration of the Consortium or its pharmaceutical composition results in an increase in secondary bile acids (e.g., in the individual's gastrointestinal tract). In certain embodiments, administration of the Consortium or its pharmaceutical composition results in a decrease in bacterial pathogens (e.g., in the individual's gastrointestinal tract).

[0204] In addition, this disclosure provides methods for restoring a healthy microbiome in an individual undergoing a dysbiosis-inducing event. In certain non-limiting embodiments, for example and without limitation, the dysbiosis-inducing event may be antibiotic treatment, an infectious disease, or an underlying disease. In certain non-limiting embodiments, the underlying disease may be IBD, colitis, ulcerative colitis, or Crohn's disease. In certain embodiments, the methods may include administering an effective amount of a consortium or pharmaceutical composition disclosed in this document. In certain embodiments, the Consortium is FB-001 or a functional equivalent thereof. In certain embodiments, the Consortium is FB-003 or a functional equivalent thereof. In certain embodiments, administration of the Consortia or their pharmaceutical composition results in the grafting of microbes from the Consortia.In certain embodiments, administration of the Consortium or its pharmaceutical composition results in an increase in microbial diversity in the gastrointestinal tract. In certain embodiments, administration of the Consortium or its pharmaceutical composition results in an increase in short-chain fatty acids (SCFAs) (e.g., in the individual's gastrointestinal tract). In certain embodiments, administration of the Consortium or its pharmaceutical composition results in an increase in short-chain fatty acids (SCFAs) (e.g., in the individual's gastrointestinal tract). Petition 870250102358, dated 07 / 11 / 2025, page 137 / 280 129 / 227 its pharmaceutical composition results in an increase in secondary bile acids (e.g., in the individual's gastrointestinal tract). In certain modalities, administration of the Consortium or its pharmaceutical composition results in a decrease in bacterial pathogens (e.g., in the individual's gastrointestinal tract).

[0205] This disclosure also offers methods for reducing the severity of at least one symptom of a gastrointestinal disease (e.g., associated with dysbiosis of the gastrointestinal tract) in an individual. Non-limiting examples of gastrointestinal diseases include irritable bowel syndrome, diarrhea, constipation, celiac disease, and leaky gut syndrome. In certain embodiments, the methods may include administering an effective amount of a consortium or pharmaceutical composition disclosed in this document. In certain embodiments, the Consortium is FB-001 or a functional equivalent thereof. In certain embodiments, the Consortium is FB-003 or a functional equivalent thereof. In certain embodiments, administration of the Consortia or their pharmaceutical composition results in the grafting of microbes from the Consortia.In certain embodiments, administration of the Consortium or its pharmaceutical composition results in an increase in microbial diversity in the gastrointestinal tract. In certain embodiments, administration of the Consortium or its pharmaceutical composition results in an increase in short-chain fatty acids (SCFAs) (e.g., in the individual's gastrointestinal tract). In certain embodiments, administration of the Consortium or its pharmaceutical composition results in an increase in secondary bile acids (e.g., in the individual's gastrointestinal tract). In certain embodiments, administration of the Consortium or its pharmaceutical composition results in a decrease in bacterial pathogens (e.g., in the individual's gastrointestinal tract). Petition 870250102358, dated 07 / 11 / 2025, pp. 138 / 280 130 / 227

[0206] This disclosure also offers methods for treating a disease in an individual. In certain embodiments, the disease is irritable bowel syndrome, diarrhea, constipation, celiac disease and leaky gut syndrome, colitis, ulcerative colitis, or Crohn's disease. In certain embodiments, the methods may include administering an effective amount of a consortium or pharmaceutical composition disclosed in this document. In certain embodiments, the Consortium is FB-001 or a functional equivalent thereof. In certain embodiments, the Consortium is FB-003 or a functional equivalent thereof. In certain embodiments, administration of the Consortia or their pharmaceutical composition results in the grafting of microbes from the Consortia. In certain embodiments, administration of the Consortium or its pharmaceutical composition results in an increase in the microbial diversity of the gastrointestinal tract.In certain embodiments, administration of the Consortium or its pharmaceutical composition results in an increase in short-chain fatty acids (SCFAs) (e.g., in the individual's gastrointestinal tract). In certain embodiments, administration of the Consortium or its pharmaceutical composition results in an increase in secondary bile acids (e.g., in the individual's gastrointestinal tract). In certain embodiments, administration of the Consortium or its pharmaceutical composition results in a decrease in bacterial pathogens (e.g., in the individual's gastrointestinal tract).

[0207] This disclosure also offers methods for treating inflammatory bowel disease (IBD) in an individual. In certain embodiments, the methods may include administering an effective amount of a consortium or pharmaceutical composition disclosed in this document. In certain embodiments, the Consortium is FB-001 or a functional equivalent thereof. In certain embodiments, the Consortium is Petition 870250102358, dated 07 / 11 / 2025, pp. 139 / 280 131 / 227 FB-003 or a functional equivalent thereof. In certain embodiments, administration of the Consortium or its pharmaceutical composition results in the grafting of microbes from the Consortium. In certain embodiments, administration of the Consortium or its pharmaceutical composition results in an increase in microbial diversity in the gastrointestinal tract. In certain embodiments, administration of the Consortium or its pharmaceutical composition results in an increase in short-chain fatty acids (SCFAs) (e.g., in the individual's gastrointestinal tract). In certain embodiments, administration of the Consortium or its pharmaceutical composition results in an increase in secondary bile acids (e.g., in the individual's gastrointestinal tract). In certain embodiments, administration of the Consortium or its pharmaceutical composition results in a decrease in bacterial pathogens (e.g., in the individual's gastrointestinal tract).

[0208] IBD (including colitis, ulcerative colitis, and Crohn's disease) is a debilitating disease whose treatment remains a major unmet need, despite approved commercial products. It is a disorder characterized by chronic inflammation and hyperpermeability of the intestine. There are no known pharmacological cures for IBD; instead, the current standard of care is based on symptom control, maintenance of remission, relapse prevention, and palliative care. By 2022, there will be over 1.7 million patients with IBD in the US alone, and a disease-modifying therapy with a good tolerability profile would be a game-changer. There are also no therapies to treat the underlying dysbiosis of IBD.

[0209] In certain modalities, FB-001 is a disease-modifying therapy for the treatment of IBD. In certain modalities, FB-001 treats the underlying dysbiosis of IBD. In certain modalities, a functional equivalent of FB-001 is Petition 870250102358, dated 07 / 11 / 2025, pages 140 / 280 132 / 227 is a disease-modifying therapy for the treatment of IBD. In certain modalities, a functional equivalent of FB-001 treats the underlying dysbiosis of IBD.

[0210] In certain modalities, FB-003 is a disease-modifying therapy for the treatment of IBD. In certain modalities, FB-003 treats the underlying dysbiosis of IBD. In certain modalities, a functional equivalent of FB-003 is a disease-modifying therapy for the treatment of IBD. In certain modalities, a functional equivalent of FB-003 treats the underlying dysbiosis of IBD.

[0211] As a result of dysbiosis in IBD patients, microbial diversity, short-chain fatty acids (SCFAs), and secondary bile acids are reduced, while there is an increase in the presence of bacterial pathogens. In certain modalities, FB-001 or a functional equivalent thereof can increase (or restore to normal and / or healthy levels) microbial diversity in an IBD patient, increase SCFAs in an IBD patient, increase secondary bile acids in IBD patients, and decrease the presence of bacterial pathogens, thus restoring the intestinal ecosystem and promoting healthy barrier responses.In certain modalities, FB-003 or a functional equivalent thereof can increase (or restore to normal and / or healthy levels) microbial diversity in a patient with IBD, increase SCFAs in a patient with IBD, increase secondary bile acids in patients with IBD, and decrease the presence of bacterial pathogens, thereby restoring the intestinal ecosystem and promoting healthy barrier responses.

[0212] Limitations in the field of IBD microbiome treatments include low microbial diversity. For example, certain microbiome treatments for IBD include spore preparations that limit diversity based on how the spores are isolated and manufactured (i.e., the preparation of Petition 870250102358, dated 07 / 11 / 2025, pp. 141 / 280 133 / 227 spores results in a loss of microbial diversity and a complete taxonomic recapitulation of a healthy microbiome is not possible (see, for example, Figure 13) and small defined consortia of fewer than 20 strains (i.e., limited microbial diversity, if any, and no complete or near-complete taxonomic recapitulation of a healthy microbiome). In certain embodiments, the consortia described in this document address the unmet need for a microbiome therapy with taxonomic and functional diversity for the treatment of IBD. In certain embodiments, the Consortium is FB-001 or a functional equivalent thereof. In certain embodiments, the Consortium is FB-003 or a functional equivalent thereof.

[0213] In certain embodiments, FB-001 or a functional equivalent thereof and FB-003 or a functional equivalent thereof are grafted into the gastrointestinal tract of patients. In certain embodiments, FB-001 or a functional equivalent thereof and FB-003 or a functional equivalent thereof are robustly grafted into the gastrointestinal tract of patients. In certain embodiments, FB-001, or a functional equivalent thereof, and FB-003, or a functional equivalent thereof, are grafted into the gastrointestinal tract of patients and restore microbial diversity. In certain embodiments, FB-001 or a functional equivalent thereof and FB-003 or a functional equivalent thereof are grafted into the gastrointestinal tract of patients and restore the key functions of a healthy gut microbiome.In certain modalities, the main functions are: 1) to increase microbial diversity, 2) to increase SCFAs, 3) to increase secondary bile acids, 4) to decrease the presence of bacterial pathogens and / or 5) to promote healthy barrier responses.

[0214] In certain modalities, a Consortium is used to treat IBD, colitis, ulcerative colitis and / or Crohn's disease. Petition 870250102358, dated 07 / 11 / 2025, pp. 142 / 280 134 / 227 In certain embodiments, FB-001 is used to treat IBD, colitis, ulcerative colitis, and / or Crohn's disease. In certain embodiments, FB-003 is used to treat IBD, colitis, ulcerative colitis, and / or Crohn's disease.

[0215] In certain modalities, a Consortium is administered in a single dose or in multiple doses. In certain modalities, a Consortium is administered once a day for 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, or 1 year. In certain modalities, a Consortium is administered several times a day. In certain modalities, a Consortium is administered twice a day, three times a day, four times a day, or five times a day. In certain modalities, a Consortium is administered intermittently. In certain modalities, a Consortium is administered once a week, once a month, or when an individual needs it. In certain modalities, the consortia are FB-001 or FB-003. In certain modalities, the Consortium is FB-003.

[0216] In certain modalities, a Consortium is administered at an effective dose to enable engraftment and substrate metabolism. In certain modalities, a consortium is administered at an effective dose to enable engraftment and significant SCFA production. In certain modalities, a Consortium is administered at an effective dose to enable engraftment and reduction of gastrointestinal tract inflammation.

[0217] In certain modalities, a Consortium is administered in an initial loading dose followed by maintenance doses. In certain modalities, the initial loading dose is administered for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, or 10 days. In certain modalities, the loading dose is administered for 1 to 3 days. In certain modalities, the loading dose is administered for 2 Petition 870250102358, dated 07 / 11 / 2025, pp. 143 / 280 135 / 227 for 4 days. In certain modalities, the loading dose is administered for 2 to 3 days. In certain modalities, the loading dose is administered for 3 to 5 days. In certain modalities, the loading dose is administered for 4 to 6 days. In certain modalities, the loading dose is administered for 5 to 7 days. In certain modalities, the loading dose is administered for 1 day. In certain modalities, the loading dose is administered for 3 days. In certain modalities, the loading dose is administered for 2 days. In certain modalities, maintenance doses are administered for 5 to 10 days after the last loading dose. In certain modalities, maintenance doses are administered for 7 to 12 days after the last loading dose. In certain modalities, maintenance doses are administered for 10 to 14 days after the last loading dose.In certain modalities, maintenance doses are administered for 14 to 21 days after the last loading dose. In certain modalities, maintenance doses are administered for 21 to 28 days after the last loading dose. In certain modalities, maintenance doses are administered for 14 days after the last loading dose. In certain modalities, maintenance doses are administered for 21 days after the last loading dose. In certain modalities, maintenance doses are administered for 28 days after the last loading dose. In certain modalities, maintenance doses are administered for approximately 8 days after the last loading dose. In certain modalities, maintenance doses are administered for approximately 7 days after the last loading dose. In certain modalities, maintenance doses are administered for approximately 6 days after the last loading dose.In certain modalities, maintenance doses are administered for approximately 9 days after the last loading dose. In certain modalities, maintenance doses are... Petition 870250102358, dated 07 / 11 / 2025, pp. 144 / 280 136 / 227 administered for approximately 10 days after the last loading dose. In certain modalities, the loading dose is administered for 2 days and the maintenance dose is administered for 6 days (for a total of 8 days of treatment). In certain modalities, the loading dose is administered for 2 days and the maintenance dose is administered for 7 days (for a total of 9 days of treatment). In certain modalities, the loading dose is administered for 2 days and the maintenance dose is administered for 8 days (for a total of 10 days of treatment). In certain modalities, the loading dose is administered for 9 days and the maintenance dose is administered for 9 days (for a total of 11 days of treatment). In certain modalities, the loading dose is administered for 2 days and the maintenance dose is administered for 10 days (for a total of 12 days of treatment). In certain modalities, the Consortium is FB-001.In certain modalities, the loading dose follows pretreatment with antibiotics, as described in the Combination Therapy section below. In certain modalities, the loading dose follows pretreatment with bowel preparation, as described in the Combination Therapy section below. In certain modalities, the loading dose follows pretreatment with antibiotics and bowel preparation, as described in the Combination Therapy section below.

[0218] In certain embodiments, FB-001 is formulated by mixing the seven lyophilized DSs containing the 148 microbial species and filling them into enteric-coated capsules. In certain embodiments, FB-003 is formulated by mixing the four lyophilized DSs containing the 145 microbial species and filling them into enteric-coated capsules. In certain embodiments, the FB-001 or FB-003 capsules are supplied in blister packaging or alternative packaging to allow for no or low oxygen exposure (e.g., packaging to maintain the viability of anaerobic microbes). In certain embodiments, each capsule contains a range of 5 χ 1010a 5 χ Petition 870250102358, dated 07 / 11 / 2025, pages 145 / 280 137 / 227 1011 viable cells / capsule. In certain embodiments, each capsule contains a range of 5 χ 109 to 5 χ 1010 viable cells / capsule. In certain embodiments, each capsule contains a range of 5 χ 1011 to 5 χ 1012 viable cells / capsule. In certain embodiments, FB-001 or FB-003 is orally dosed to up to 1012 viable cells on Days 1 and 2, and to up to 1011 viable cells on Days 3 to 10. In certain embodiments, maltodextrin is included as an excipient in the capsules.

[0219] In certain embodiments, each FB-001 or FB-003 capsule contains a range of 5 χ 1010 to 5 χ 1011 viable cells / capsule and a baseline viable cell count and relative abundance values ​​of strains 145 (excluding O. formigenes, which is present only in FB-001) ranging from 18% to 0.015%.

[0220] In certain embodiments, the methods presented here comprise the diagnosis of dysbiosis in the individual and then the treatment of the individual with the Consortium or pharmaceutical composition thereof. For example, but not as a limitation, a method of treating an individual with dysbiosis may include (a) the diagnosis of dysbiosis in the individual and (b) the administration of an effective amount of a Consortium (e.g., FB-001 or FB-003) or pharmaceutical composition thereof to the individual. In certain embodiments, the method for diagnosing dysbiosis includes organic acid testing, comprehensive digestive stool analysis (CDSA), hydrogen breath testing, or a combination thereof.

[0221] In certain embodiments, the methods described herein comprise the diagnosis of IBD in the individual and then the treatment of the individual with the Consortium or pharmaceutical composition thereof. For example, but not exclusively, a method of treating an individual with IBD may include (a) diagnosing the individual with IBD and (b) administering an effective amount of a Consortium (e.g., FB-001 or FB-003) or pharmaceutical composition thereof to the individual. In certain embodiments Petition 870250102358, dated 07 / 11 / 2025, pp. 146 / 280 138 / 227 modalities, the method for diagnosing IBD includes endoscopy, colonoscopy, flexible sigmoidoscopy, upper endoscopy, capsule endoscopy, analysis of C-reactive protein (CRP) in a blood sample, analysis of erythrocyte sedimentation rate in a blood sample, detection of calprotectin in stool, detection of lactoferrin in stool, or a combination thereof.

[0222] In certain embodiments, the consortia described in this document are used to treat dysbiosis caused by chemical insult. In certain embodiments, the consortia described in this document are used to treat a disease associated with dysbiosis caused by chemical insult. In certain embodiments, FB-003, FB-001, Consortium A, or Consortium B described in this document are used to treat dysbiosis caused by chemical insult. In certain embodiments, FB-003, FB-001, Consortium A, or Consortium B described in this document are used to treat a disease associated with dysbiosis caused by chemical insult.

[0223] In certain embodiments, the consortia described in this document are used to treat dysbiosis caused by inflammation. In certain embodiments, the consortia described in this document are used to treat a disease associated with dysbiosis caused by inflammation. In certain embodiments, FB-003, FB-001, Consortium A, or Consortium B described in this document are used to treat dysbiosis caused by inflammation. In certain embodiments, FB-003, FB-001, Consortium A, or Consortium B described in this document are used to treat a disease associated with dysbiosis caused by inflammation.

[0224] In certain embodiments, the consortia described in this document are used to treat dysbiosis caused by infectious diseases. In certain embodiments, the consortia described in this document are used to treat a disease associated with dysbiosis caused by an infectious disease. In Petition 870250102358, dated 07 / 11 / 2025, pp. 147 / 280 139 / 227 certain embodiments, FB-003, FB-001, Consortium A or Consortium B described in this document are used to treat dysbiosis caused by infectious diseases. In certain embodiments, FB-003, FB-001, Consortium A or Consortium B described in this document are used to treat a disease associated with dysbiosis caused by an infectious disease.

[0225] In certain modalities, the consortia described in this document are used to treat dysbiosis by improving the epithelial barrier of the intestines and / or colon. In certain modalities, the consortia described in this document are used to treat dysbiosis by strengthening the epithelial barrier of the intestines and / or colon. In certain modalities, the consortia described in this document are used to treat dysbiosis by transforming the epithelial barrier of the intestines and / or colon into the barrier of a healthy individual. In certain modalities, the consortium is FB-003, FB-001, consortium A, or consortium B. Combination therapy

[0226] In certain embodiments, a Consortium may be administered in combination with other agents. In certain embodiments, a consortium may be administered with an antimicrobial agent, an antifungal agent, an antiviral agent, an antiparasitic agent, or a prebiotic. In certain embodiments, a Consortium may be administered after the administration of an antimicrobial, antifungal, antiviral, antiparasitic, or prebiotic agent. In certain embodiments, administration may be sequential over a period of hours or days, or simultaneous.

[0227] For example, in certain non-limiting embodiments, a microbial consortium may be administered with, or pre-administered with, one or more antibacterial agents selected from among fluoroquinolone antibiotics (ciprofloxacin, Levaquin, floxin, tequin, avelox and norflox); Petition 870250102358, dated 07 / 11 / 2025, pages 148 / 280 140 / 227 cephalosporin antibiotics (cephalexin, cefuroxime, cefadroxil, cefazolin, cephalothin, cefaclor, cefamandole, cefoxitin, cefprozil and ceftobiprole); penicillin antibiotics (amoxicillin, ampicillin, penicillin V, dicloxacillin, carbenicillin, vancomycin and methicillin); tetracycline antibiotics (tetracycline, minocycline, oxytetracycline and doxycycline); and carbapenem antibiotics (ertapenem, doripenem, imipenem / cilastatin and meropenem).

[0228] For example, in certain non-limiting embodiments, a microbial consortium may be administered with one or more antiviral agents selected from Abacavir, Acyclovir, Adefovir, Amprenavir, Atazanavir, Cidofovir, Darunavir, Delavirdine, Didanosine, Docosanol, Efavirenz, Elvitegravir, Emtricitabine, Enfuvirtide, Etravirine, Famciclovir, Foscamet, Fomivirsen, Ganciclovir, Indinavir, Idoxuridine, Lamivudine, Lopinavir, Maraviroc, MK-2048, Nelfinavir, Nevirapine, Penciclovir, Raltegravir, Rilpivirine, Ritonavir, Saquinavir, Stavudine, Tenofovir, Trifluridine, Valacyclovir, Valganciclovir, Vidarabine, Ibacitabine, Amantadine, Oseltamivir, Rimantidine, Tipranavir, Zalcitabine, Zanamivir, and Zidovudine.

[0229] In certain embodiments, a microbial consortium may be administered with one or more antifungal agents selected from miconazole, ketoconazole, clotrimazole, econazole, omoconazole, bifonazole, butoconazole, fenticonazole, isoconazole, oxiconazole, sertaconazole, sulconazole and tioconazole; triazole antifungals, such as fluconazole, itraconazole, isavuconazole, ravuconazole, posaconazole, voriconazole, terconazole and albaconazole; thiazole antifungals, such as abafungin; allylamine antifungals, such as terbinafine, naftifine and butenafine; and echinocandin antifungals, such as anidulafungin, caspofungin and micafungin; poligodial; benzoic acid; ciclopirox; tolnaftate; undecylenic acid; Petition 870250102358, dated 07 / 11 / 2025, pp. 149 / 280 141 / 227 flucytosine or 5-fluorocytosine; griseofulvin and haloprogin.

[0230] In certain modalities, a microbial consortium may be administered with one or more anti-inflammatory and / or immunosuppressive agents selected from cyclophosphamide, mycophenolate mofetil, corticosteroids, mesalazine, mesalamine, sulfasalazine, sulfasalazine derivatives, cyclosporine A, mercaptopurine, azathiopurine, prednisone, methotrexate, antihistamines, glucocorticoids, epinephrine, theophylline, sodium cromoglycate, antileukotrienes, anticholinergics, anti-monoclonal IgE, immunomodulatory peptides, small immunomodulatory molecules, immunomodulatory cytokines, immunomodulatory antibodies, and vaccines.

[0231] In certain embodiments, a consortium may be administered with one or more prebiotics selected from, among others, amino acids, biotin, fructo-oligosaccharides, galacto-oligosaccharides, inulin, lactulose, mannan-oligosaccharides, inulin enriched with oligofructose, oligofructose, oligodextrose, tagatose, transgalactooligosaccharide and xylo-oligosaccharides.

[0232] In certain embodiments, a consortium described in this document is administered in combination with an anti-inflammatory drug.

[0233] In certain embodiments, a consortium described in this document is administered in combination with an antidiarrheal drug.

[0234] In certain embodiments, a Consortium described in this document is administered in combination with an analgesic. In certain embodiments, a Consortium described in this document is administered in combination with a non-steroidal anti-inflammatory drug (NSAID).

[0235] In certain modalities, a consortium described in this document is administered in combination with vitamins and Petition 870250102358, dated 07 / 11 / 2025, pages 150 / 280 142 / 227 supplements.

[0236] In certain embodiments, a Consortium described in this document is administered in combination with aminosalicylates.

[0237] In certain embodiments, a consortium described in this document is administered in combination with antibiotics.

[0238] In certain embodiments, a consortium described in this document is administered in combination with biological products. In certain embodiments, the biological products interrupt the immune system signals that cause inflammation.

[0239] In certain embodiments, a Consortium described in this document is administered in combination with corticosteroids or steroids.

[0240] In certain modalities, a consortium described in this document is administered in combination with immunomodulators.

[0241] In certain modalities, the combined treatment of a consortium includes pretreatment with antibiotics. In certain modalities, antibiotic pretreatment.

[0242] In certain modalities, a bowel preparation (e.g., MiraLax) is administered in the late afternoon or early evening after the final dose of antibiotics. Kits

[0243] The currently disclosed subject provides kits for treating or preventing dysbiosis of the gastrointestinal tract. In certain embodiments, dysbiosis is caused by or causes IBD, colitis, ulcerative colitis, and / or Crohn's disease. In certain embodiments, the kit comprises an effective amount of the currently disclosed Consortia or a pharmaceutical composition comprising them.

[0244] In certain embodiments, the kit includes an effective quantity of FB-001 or a pharmaceutical composition that Petition 870250102358, dated 07 / 11 / 2025, pages 151 / 280 143 / 227 comprises the same. In certain embodiments, the kit comprises an effective quantity of a consortium functionally equivalent to FB-001 or a pharmaceutical composition comprising the same. In certain embodiments, the kit comprises an effective quantity of a consortium functionally identical to FB-001 or a pharmaceutical composition comprising the same.

[0245] In certain embodiments, the kit includes an effective quantity of FB-003 or a pharmaceutical composition comprising the same. In certain embodiments, the kit comprises an effective quantity of a consortium functionally equivalent to FB-003 or a pharmaceutical composition comprising the same. In certain embodiments, the kit comprises an effective quantity of a consortium functionally identical to FB-003 or a pharmaceutical composition comprising the same.

[0246] In certain embodiments, the kit includes a sterile container; such containers may be boxes, ampoules, bottles, vials, tubes, bags, pouches, blisters, or other suitable forms of containers known in the art. Such containers may be made of plastic, glass, foil, metal foil, or other materials suitable for containing medicinal products. In certain non-limiting embodiments, the kit includes anaerobic containers for storing the consortia described in this document. In certain non-limiting embodiments, the kit includes blister packs for maintaining the consortia described in this document in the presence of limited or no oxygen. In certain non-limiting embodiments, the kit includes blister packs with desiccant for maintaining the consortia described in this document in the presence of limited or no oxygen.In certain non-limiting configurations, the kit includes bottles with desiccant to maintain the... Petition 870250102358, dated 07 / 11 / 2025, pp. 152 / 280 144 / 227 consortia described in this document in the presence of limited or non-existent quantities of oxygen.

[0247] In certain embodiments, the kits include instructions for administering the Consortia as described in this document. In certain embodiments, the instructions include instructions for administering the loading dose and the maintenance dose.

[0248] In certain models, the kits include storage instructions. In certain models, the storage instructions are for storage at approximately -20 °C. In certain models, the storage instructions are for storage at less than 5 °C. In certain models, the storage instructions are for storage at less than approximately -15 to -20 °C, -10 to -20 °C, -10 to -15 °C, -5 to -10 °C, 0 to -5 °C, below 0 °C, or 0 to -20 °C. In certain models, the storage instructions are for storage at less than approximately 4 °C. In certain models, the storage instructions are for storage at room temperature.

[0249] In certain models, the kits include instructions for maintaining the consortia in low or no oxygen conditions.

[0250] In certain modalities, the kits include instructions for the individual not to take any antibiotics during treatment with the Consortia.

[0251] In certain modalities, the kit includes FB-001 and instructions for administering FB-001.

[0252] In certain modalities, the kit includes FB-003 and instructions for administering FB-003. Examples Example 1: Consortium Project

[0253] Although microbial consortia of two or more microbial strains have been created previously, there are Petition 870250102358, dated 07 / 11 / 2025, pp. 153 / 280 145 / 227 limitations that hinder manufacturing and clinical efficacy. Specifically, manufacturing limitations have prevented the design and generation of large consortia capable of developing in the gastrointestinal tract and creating a functional microbiota system.

[0254] Isolation of microbial strains derived from donors. The microbial strains were isolated and identified using the methods described in document PCT / US2021 / 021790.

[0255] Generation of Consortia. Through the use of microbial strains identified by the isolation and identification methods described in document PCT / US2021 / 021790, more than 30 large consortia were created and examined for their functional ability to metabolize oxalate, absence of phages, acceptable endotoxin levels, and their ability to be manufactured into multi-strain drug substances. The reason for the large number of large experimental consortia was the fact that it was not known which combination of microbial strains would be necessary, considering the above considerations. In addition, the combination of microbial strains could not be predicted with algorithms and required work in a wet laboratory to determine efficacy and manufacturability.

[0256] Nineteen exemplary consortia are provided in Consortia I-XIX.

[0257] Although Consortium V was more effective in metabolizing and degrading oxalate (i.e., Consortium V showed the lowest urinary oxalate concentration), further investigations and modifications to the Consortium were needed to develop a product for the treatment of a disease, specifically a disease that causes or is caused by a decreased ability or inability to effectively metabolize and degrade oxalate in the gastrointestinal tract. Therefore, modifications were made to Consortium V to determine which microbiota provided functional benefits. Petition 870250102358, dated 07 / 11 / 2025, pp. 154 / 280 146 / 227 including, without limitation, consortium growth, oxalate metabolism and degradation, consortium engraftment and consortium survival, and which microbiotas were not necessary or harmed the patient receiving the consortia as treatment for the disease or impaired the function of the consortia as a whole (including, but not limited to, consortium growth, oxalate metabolism and degradation, consortium engraftment and consortium survival). Examples of such designed and investigated consortia are Consortia IX-XVI.

[0258] Of the Consortia IX-XVI that were designed and tested, Consortium IX was selected as the lead one for clinical development. The main changes made as variations of the consortia were made to modify the treatment of the disease, specifically a disease that causes or is caused by decreased ability or inability to effectively metabolize and degrade oxalate in the gastrointestinal tract, including the removal of the Citrobacter freundii strain because, through experimentation, it was determined to be a facultative anaerobe (see, for example, strain removal between consortia XIII and XV and between consortia XXIV and XIII and XII), replacement of a Bacteroides kribbi species with a cluster of different Bacteroides kribbi species (see, for example, strain replacements between consortia XV and XVI), replacement of a Blautia faecis species with a different Blautia faecis species (see, for example,strain replacements between consortia XV and XVI), strains that were determined to be duplicative strains based on whole genome sequencing clustering (see, for example, strain removals between consortia XVII and XVI), replacement of a Bifidobacterium adolescentis with an alternative Bifidobacterium adolescentis to improve growth in culture (see, for example, strain replacement between Consortia X and XII), replacement, Petition 870250102358, dated 07 / 11 / 2025, pages 155 / 280 147 / 227 of a Bifidobacterium pseudocatenulatum with an alternative Bifidobacterium pseudocatenulatum to improve growth in culture (see, for example, strain replacement between Consortia X and XII), replacement of a Bacteroides xylanisolvens with an alternative Bacteroides xylanisolvens to improve growth in culture (see, for example, strain replacement between Consortia X and XII), replacement of a Clostridium citroniae with an alternative Clostridium citroniae to improve growth in culture (see, for example, strain replacement between Consortia X and XII), replacement of a Blautia faecis with an alternative Blautia faecis to identify a Blautia strain that was able to grow sufficiently to produce a master cell bank (see, for example, strain replacement between Consortia X and XII), removal of Holdemanella biformis to eliminate the risk of phage because, although a phage was not detected in the co-culture,It was detected using bioinformatic methods (see, for example, strain replacement between Consortia X and XII) and removal of Faecalibacterium prasnitzii to eliminate the risk of phage because, although a phage was not detected in the co-culture, it was detected using bioinformatic methods (see, for example, strain replacement between Consortia X and XII). Example 2: Design and manufacture of pharmaceutical products

[0259] As demonstrated in Example 1, the consortia described in this document were designed to be a complex community of anaerobic microbiota that can grow and function in a gastrointestinal tract. However, prior methods known to those skilled in the art were not capable of fabricating such large consortia. Thus, novel fabrication methods were needed to cultivate the microbiota into discrete groups (i.e., drug substances) to form a final drug product. Petition 870250102358, dated 07 / 11 / 2025, pp. 156 / 280 148 / 227

[0260] Conventionally, live biotherapeutic products (LBPs) are manufactured one strain at a time (i.e., single-strain manufacturing). Single-strain manufacturing requires scaling up the fermentation of each strain, followed by lyophilization to produce individual drug substances (each a “DS”). After that, the various DSs of individual lyophilized dyes are blended into a mixture and packaged into capsules or other suitable packaging / filler to form a final pharmaceutical product (a “DP”). While this works for small consortia, it is not feasible to grow more than 100 strains separately, make more than 100 DSs, and then blend more than 100 DSs into a stable DP. In addition to stability limitations, current technology would require one or more years to manufacture a single DP.Therefore, conventional manufacturing using current technology was not an option for a DP with more than 100 strains, and preferably more than 145 strains, as provided in Consortium IX.

[0261] As the consortia were designed and modified as described in Examples 1 and 2, fabrication methods were developed capable of fabricating consortia of more than 145 strains comprising more than 90 species and 4 or more of the 6 taxonomic phyla found in the human gastrointestinal tract microbiome. In addition, methods were developed to modify Consortium IX, which comprises approximately 99 species in the taxonomic phyla Bacteroidetes, Firmicutes, Actinobacteria, Proteobacteria, and Archaea. The methods developed and described in this document are mixed co-culture methods capable of stably cultivating more than 50 strains in a co-culture to generate DSs with more than 50 strains.

[0262] The strains were selected for co-culture based on growth rates and the manufacturing process was initially designed to add strains to the co-culture at different times throughout the manufacturing process in order to obtain the Petition 870250102358, dated 07 / 11 / 2025, pages 157 / 280 149 / 227 growth of each strain. This approach was termed “time-addition” manufacturing. The rationale behind this initial approach was to ensure that the strains revived in the gastrointestinal tract to increase grafting efficacy (i.e., to allow grafting before the strains were excreted). Reanimation and grafting of lyophilized strains require preserving the strains in an “active state” (i.e., active growth state). However, this “time-addition” manufacturing approach was not successful because the growth rates of the strains in the consortia described in this document are highly variable, making it difficult to achieve exponential growth simultaneously for several strains in co-culture.Thus, it was determined that further experiments would be necessary to understand the unique growth kinetics of each strain, in order to enable the classification of strains based on growth rate and further modification of the bioreactor addition time. Kinetic growth assays were performed using HTP anaerobic growth kinetic assays on each individual strain in each of the Consortia IX-XVI at 8 different inoculation densities.

[0263] Although experimentation to understand the unique growth kinetics of each strain has proven useful with time-of-addition manufacturing, ultimately the highly variable nature of strain growth from a lyophilized powder to an active consortium in a bioreactor has proven undesirable for time-of-addition methods.

[0264] Thus, a second approach to co-culture was developed. Instead of applying different addition times, the second approach used the adjustment of the inoculation density for each strain in order to synchronize growth and control the strain distribution at the time of co-culture harvest (manufacturing the “inoculation density”). Using kinetics Petition 870250102358, dated 07 / 11 / 2025, pages 158 / 280 150 / 227 of the exclusive growth zones determined for each strain in the consortia, specifically in Consortia IX-XVI, growth zones were determined for each strain. By doing so, it was determined that co-culture was effective and possible if each strain was added to the culture at an initial time point based on inoculum density (i.e., number of cells per strain added to the co-culture), such that higher inoculum densities of certain strains resulted in a shorter growth lag time for those strains. Based on this, the higher inoculum density of slow-growing strains and the lower inoculum density of fast-growing strains resulted in a synchronized harvest time.As demonstrated by examples in Figures 1A and 1B, modifying the inoculation densities of individual strains allowed for control of strain distribution and improved strain recovery in co-cultures (i.e., uniform strain distribution and higher strain recovery are achieved by adjusting inoculum densities). Figure 1A shows an example of a co-culture of 21 fast-growing strains where only 4 of the 21 strains were not detected by metagenomics in the final product. However, it is important to note that even if a strain is not detected in the final product, it can still provide a community advantage by allowing for more efficient and robust growth of other detectable strains in the final product. Figure 1B shows an experiment modified in addition to that shown in Figure 1A, where the harvest time and strain detection were modified.As demonstrated, the different timing of growth and culture led to better distribution of the strains and detection of all 21 strains.

[0265] Further modification of the co-culture process was necessary to improve fermentation. For example, further modification was made to control the pH and obtain growth conditions based on the bioreactor vessel. Petition 870250102358, dated 07 / 11 / 2025, pages 159 / 280 151 / 227 (i.e., the type of container and the size of the container).

[0266] Using the methods developed and described in this document, Consortia IX-XVI were manufactured using only 7 DSs. An exemplary 7 DS Medicinal Product comprises: 3 monocultures of O. formigenes, the DS1 strains (e.g., listed in Table 1), the DS2 strains (e.g., listed in Table 1), the DS3 strains (e.g., listed in Table 1), the DS4 strains (e.g., listed in Table 1).

[0267] Using the methods developed and described in this document, the microbes listed in Table 2 (FB-003 or FB-003 Consortium) were manufactured using only 4 DSs. An exemplary 4 DS Medicinal Product comprises: the DS1 strains (e.g., listed in Table 1), the DS2 strains (e.g., listed in Table 1), the DS3 strains (e.g., listed in Table 1), and the DS4 strains (e.g., listed in Table 1).

[0268] To identify each DS without sequencing the complete genome of all strains and to ensure proper growth throughout the co-culture process, identifier strains were developed. For DS1, the identifier strains were Bacteroides thetaiotaomicron, Bifidobacterium pseudocatenulatum, and Megasphaera massiliensis. For DS2, the identifier strains were Bacteroides ovatus, Faecalibacterium prausnitzii, and Phascolarctobacterium faecium. For DS3, the identifier strains were Blautia wexlerae, Anaerostipes hadrus, and Clostridium bolteae. For DS4, the identifier strains were Holdemanella biformis, Parasutterella excrementihominis, and Dialister invisus.

[0269] As described in this document, the number of strains detected at the end of the co-culture may be lower than the number of strains added at the beginning of the culture. This may be a result of limited detection methods. Furthermore, although not all strains may be detected at the conclusion of the co-culture process, the inclusion of undetected strains may still be possible. Petition 870250102358, dated 07 / 11 / 2025, pages 160 / 280 152 / 227 is vital for the survival and spread of other strains that are detected.

[0270] In one experiment, DS1 consisted of 54 initial strains and 50 strains were detected at the end of the co-culture process; DS2 consisted of 47 initial strains and 39 strains were detected at the end of the co-culture process; DS3 consisted of 33 initial strains and 30 strains were detected at the end of the co-culture process; and DS4 consisted of 14 initial strains and 11 strains were detected at the end of the co-culture process.

[0271] This achievement in strain detection was obtained through the development of a fermentation process that allowed the growth of various strains in co-culture. The variables investigated include the growth kinetics of each strain, the nutritional requirements of each strain, the competition for nutritional sources in each DS, the selection of the initial inoculum concentration to obtain growth, and the strain distribution in each DS. For example, growth curves were performed and used to define the DS buckets, as well as the composition of the initial inoculum. This is shown in Figures 2A and 2B. Figure 2A shows the strain segregation design in 4 DS buckets based on slow-growing and fast-growing strains. Figure 2B shows the initial inoculum seed design for fast-growing and very fast-growing strains.By using 5 iterations of the strain segregation and inoculum seed design methods, DS1, for example, managed to increase its yield rate from approximately 35 / 54 strains detected at the conclusion of the co-culture process to 50 / 54 strains detected at the conclusion of the co-culture process.

[0272] Further experimentation was needed to successfully manufacture DSs on a large scale. For example, experiments were conducted on sterilization procedures and raw materials used in the media, gas solubility in the bioreactor (i.e., in the fermenter), shear stress Petition 870250102358, dated 07 / 11 / 2025, pp. 161 / 280 153 / 227 caused by the impeller and gas dispersion in the bioreactor and the mass transfer and mixing times. Each of these factors is necessary to develop a process that can successfully produce a complex consortium, such as any of the Consortia described in this document. For example, through experiments, it was determined that nitrogen spraying led to greater shear and affected gas solubility. Thus, experiments were conducted to adjust the sprayer speed, sprayer location, and replace the sprayer with gas overlay. The data showed that gas overlay was the only approach that provided a successful co-culture of DSs. For example, data from different spraying conditions only allowed the detection of up to 36 of the 54 strains of DS1, while gas overlay allowed the detection of 11 more species at the end of the co-culture (i.e., 47 / 54 strains).

[0273] The next step in the manufacturing process that needed to be developed was a method for storing the final product in order to preserve the stability and activity of the strains. Freezing and lyophilization methods were investigated to determine what would preserve the activity and viability of the strains for each DS.

[0274] To determine whether lyophilization would be better than freezing for preserving the activity and viability of the strains in each DS, it was necessary to develop lyophilization processes, as none were known on the market for the complexity of the DSs and consortia presented here. The main variables that were investigated to develop the lyophilization process for each DS included, but are not limited to: broth formulation or alternative microbiota suspension medium, methods to avoid oxygen contamination during the lyophilization process, excipient:broth ratio, parameters for freezing the microbiota suspension before freezing. Petition 870250102358, dated 07 / 11 / 2025, pages 162 / 280 154 / 227 lyophilization, cycle parameters for lyophilization, sterilization requirements, methods for reviving microbiota after lyophilized storage, buffers for reviving microbiota and storage of lyophilized DS.

[0275] For example, plates covered with high-throughput aluminum foil were used as one of the test options for storing lyophilized DS. It was assumed that this would work because the aluminum foil covering should prevent exposure to oxygen. However, it was determined that the plates covered with aluminum foil did not, in fact, prevent oxygen contamination because there was no way to partially seal the plate. Another storage method investigated was that of glass and plastic tray vials with multiplexed stoppers. The theoretical advantage of this approach was considered to be the ability to perform high-throughput screening without the need to individually stopper each vial, as the multiplexed stoppers can be placed on the vials in a single step. However, this method proved ineffective as oxygen contamination occurred upon removal of the multiplexed stoppers.After exploring other options for methods of preserving the freeze-dried product, it was determined that individual glass vials with individual lids allowed for long-term storage without oxygen contamination.

[0276] Through a second example, it was necessary to determine the correct formulation for the freeze-drying buffer / medium. The following lyophilization agents were investigated to determine the correct formulation for each DS: sorbitol, maltodextrin, OPS Diagnostics buffer, sucrose, inulin, alginate, mannitol, trehalose, and skim milk. For example, Figure 3A shows examples of different DS2 viability based on different lyophilization agents, and Figure 3B shows examples of different DS1 viability based on different lyophilization agents. The addition of reducing agents, including, among others Petition 870250102358, dated 07 / 11 / 2025, pages 163 / 280 155 / 227 others, cysteine ​​HCL and riboflavin, were also investigated, as shown in Figure 4A (DS2) and Figure 4B (DS1). Other lyophilization formulations tested include 8% maltodextrin + 0.5% inulin + RA, 5% sucrose + 10% glycerol + 0.3% inulin + RA, 7% trehalose + 8% maltodextrin + RA, 3% sucrose + 5% maltodextrin + 0.5% inulin + RA, 5% maltodextrin + OPS Diag + 0.5% inulin + RA and 5% maltodextrin + 10% glycerol + 0.3% inulin + RA.

[0277] Based on freeze-thaw and freeze-drying experiments, the data suggest that the selected dose is 10 to 12% solids. However, additional experiments were conducted to determine if a lower dose would be possible. An exemplary experiment in DS2 is shown in Figure 5A and a second exemplary experiment is shown in Figure 5B.

[0278] Next, assays were performed to determine the success rates of cell revitalization. Cell revitalization was performed using the YCFAC medium of the Anaerobic systems and dilution schemes were conducted using a 100-fold dilution for the lyophilized powder (e.g., 50 mg (0.05 g) of powder were diluted in 5.0 ml of YCFAC medium). Revivescence was then detected using flow cytometry and the Coulter Counter.

[0279] The experiments performed here and the data generated determined that the lyophilized material produced a comparable colonization of strains in mice. Example 3: Synthetic consortia

[0280] Isolation and Processing. Isolation of bacterial strains to create synthetic consortia: bacterial strains to create consortia were isolated from samples of healthy human feces collected under anaerobic conditions, homogenized, and then the bacterial species of each sample were identified using genome sequencing. Petition 870250102358, dated 07 / 11 / 2025, pp. 164 / 280 156 / 227 complete (WGS). From there, the bacterial strains and their abundance were identified.

[0281] Stool samples were then processed and bacterial strains were isolated for culture in appropriate culture media (e.g., BHI, blood agar). Isolation of oxalate degraders and specific strains to metabolize pathways related to HE was prioritized along with fastidious and unique strains and strains associated with a healthy gut microbiome. After culture, the strains were purified and sequenced using metagenomics. From the cultured and isolated strains, communities were created to treat enteric hyperoxaluria based on the notion that our bacteria fill critical functional niches in the gut, support normal GI physiology, support the engraftment of special strains such as O. formigenes, and degrade oxalate.

[0282] Diversity of synthetic consortia: each consortium described in this document contains unique species and strains to encompass various metabolic phenotypes (e.g., bile acid metabolism, short-chain fatty acid synthesis, oxalate degradation). A core set of 31 bacterial strains was similar across the synthetic consortia, and each community had its unique signature, as indicated in the Venn diagram. The number of species present in each consortium ranged from 40 to 103 species, and the number of strains ranged from 75 to 195, as shown in Figures 6A and 6B. The species and strains comprised varying proportions of diversity at the phylum level, where the proportion of Bacteroidetes to Firmicutes ranged from 51% to 96%, indicating that the overall composition varied. Example 4: The production of threonine auxotrophic microorganisms

[0283] Some microorganisms are auxotrophic. This means that the microorganism does not have the ability to synthesize Petition 870250102358, dated 07 / 11 / 2025, pages 165 / 280 157 / 227 a specific organic compound necessary for its growth. One of these organic compounds that certain microorganisms are unable to synthesize is threonine. Furthermore, although some microorganisms are not per se threonine auxotrophs, they are inefficient threonine producers, which hinders effective growth in commonly used growth media.

[0284] N-acetylgalactosamine (GalNAc) is an amino sugar derived from galactose that is generally the first monosaccharide that connects serine or threonine in specific forms of protein O-glycosylation. While it is possible to supplement certain small-batch growth media with GalNAc for the growth of threonine auxotrophs without the addition of threonine, this supplementation is not preferred for large-batch manufacturing because GalNAc is expensive and large quantities are needed for the effective growth of microorganisms requiring this galactose derivative. Furthermore, certain media, such as YCFAC, are unable to effectively grow certain threonine auxotrophs even in the presence of GalNAc.

[0285] Thus, a method is needed to improve the expansion and growth of inefficient threonine producers for the effective growth of these microorganisms.

[0286] One of the microorganisms included in the consortia described in this document is Akkermansia muciniphilia. Akkermansia lacks the ability to synthesize its own threonine and therefore lacks the ability to expand and grow effectively in a culture that does not have a source of GalNAc (or a primary source that can be metabolized into GalNAc). Furthermore, GalNAc is the preferred carbon source for Akkermansia, and therefore known methods for effective Akkermansia growth and fabrication include the addition of GalNAc to the growth medium.

[0287] Thus, the experiments were designed to identify new methods of cultivating Akkermansia in large Petition 870250102358, dated 07 / 11 / 2025, pages 166 / 280 158 / 227 batches without large amounts of GalNAc. Specifically, three different growth media were tested: YCFAC + GalNAc, YCFAC + GalNAc + Threonine, and YCFAC + Threonine. Since BHI is an animal-derived medium containing threonine, BHI medium was used as a positive control (specifically BHI medium + GalNAc + Hemin + Vitamin K). As GalNAc is the preferred carbon source of Akkermansia, it was expected that it would be necessary in all media to allow for the expansion and growth of the microorganism; however, the expected question was the amount of GalNAc needed, not whether GalNAc was needed if threonine was also added. Surprisingly, it was determined that: 1) YCFAC + 0.5 g / l GalNAc did not support the growth of Akkermansia; 2) YCFAC + 0.5 g / l GalNAc + 10 mM threonine supported growth; and 3) YCFAC + 10 mM threonine alone supported the growth of Akkermansia.In these experiments, a seed culture containing 0.5 g / l of GalNAc in YCFAC was used to initiate cell growth before being transferred to a large fermenter for growth and expansion with the three media described above.

[0288] However, some of the consortia described in this document include more than 100 different microorganisms, with Akkermansia being just one of those 100 or so different microorganisms. Furthermore, the manufacturing methods described in this document allow for the growth and manufacturing of multiple microorganisms in a single large batch culture (e.g., in a fermenter). The question then became how to cultivate Akkermansia in a large co-culture when it is the only microorganism that is a threonine auxotroph with a preferred carbon source of GalNAc. Therefore, an experiment was designed to determine if it was possible to start a seed culture with only Akkermansia and then combine it with a second seed culture of multiple microorganisms for large batch expansion. Petition 870250102358, dated 07 / 11 / 2025, pp. 167 / 280 159 / 227

[0289] This experiment comprised: 1) a seed culture was first grown to allow Akkermansia to begin growing in a small 10 ml culture (i.e., a seed culture) before expansion in a large batch fermenter, 2) simultaneously with the Akkermansia seed culture, a second 100 ml seed culture of all other microorganisms in the medicinal substance was grown separately, 3) the 100 ml seed coculture and the 10 m...

Claims

CLAIMS 1. A method for preventing, reducing and / or treating dysbiosis in a subject, characterized in that it comprises administering an effective amount of a microbial consortium or a pharmaceutical composition thereof comprising a) Clostridium citroniae, Bacteroides salyersiae, Blautia obeum, Parabacteroides merdae, Parabacteroides distasonis, Anaerostipes hadrus, Lachnospiraceae sp. FBI00033, Eubacterium eligens, Bifidobacterium dentium, Blautia wexlerae, Fusicatenibacter saccharivorans, Bacteroides nordii, Dorea formicigenerans, Dorea longicatena, Bacteroides stercorirosoris, Bifidobacterium longum, Bacteroides kribbi, Lachnospiraceae sp.FBI00071, Bacteroides thetaiotaomicron, Clostridium clostridioforme, Clostridium scindens, Roseburia hominis, Clostridium fessum, Coprococcus comes, Blautia faecis, Hungatella hathewayi, Bacteroides stercoris, Collinsella aerofaciens, Hungatella effluvii, Bifidobacterium adolescentis, Bifidobacterium catenulatum, Lactobacillus rogosae, Bacteroides faecis, Bacteroides finegoldii, Clostridiaceae sp. FBI00191, Ruminococcus faecis, Lachnoclostridium pacaense, Clostridium bolteae, Longicatena caecimuris, Eggerthella lenta, Blautia massiliensis, Bacteroides xylanisolvens, Bacteroides vulgatus, Megasphaera massiliensis, Butyricimonas faecihominis, Eisenbergiella tayi, Acidaminococcus intestini, Emergence timonensis, Bifidobacterium pseudocatenulatum, Eubacterium hallii, Anaerofustis stercorihominis, Eubacterium ventriosum, Blautia hydrogenotrophica and Lachnospiraceae sp.FBI00290 or a functional equivalent thereof; or b) FBI00001, FBI00002, FBI00010, FBI00013, FBI00029, FBI00032, FBI00033, FBI00034, FBI00043, FBI00044, FBI00048, FBI00050, FBI00051, FBI00057, FBI00059, FBI00060, FBI00070, FBI00071, FBI00076, FBI00079, FBI00087, FBI00093, FBI00102, FBI00109, FBI00117, FBI00120, FBI00125, FBI00127, FBI00128, FBI00145, FBI00162, FBI00174, FBI00184, FBI00190, FBI00191, FBI00194, FBI00198, FBI00199, FBI00200, FBI00201, FBI00205, FBI00206, FBI00211, FBI00220, FBI00221, FBI00236, FBI00245, Petition 870250081422, dated 10 / 09 / 2025, page 21 / 434 2 / 32 FBI00248, FBI00251, FBI00254, FBI00267, FBI00278, FBI00288 and FBI00290, or a functional equivalent thereof.

2. Method, in accordance with a reivindicação 1, characterized by the fact that o consórcio microbialo ou uma composizione farmacêutica do mesmo comprehensi ainda: a) Acutalibacter timonensis, Alistipes onderdonkii, Bacteroides uniformis, Eubacterium rectale, Alistipes timonensis, Bacteroides kribbi, Coprococcus eutactus, Bilophila wadsworthia, Bacteroides caccae, Alistipes shahii, Parasutterella excrementihominis, Paraprevotella clara, Sutterella wadsworthensis, Sutterella massiliensis, Porphyromonas asaccharolytica, Ruminococcus bromii, Monoglobus pectinilyticus, Ruminococcaceae sp. FBI00097, Gordonibacter pamelaeae, Bacteroides uniformis, Gordonibacter pamelaeae, Bacteroides fragilis, Phascolarctobacterium faecium, Monoglobus pectinolyticus, Clostridium aldenense, Ruthenibacterium lactatiformans, Bacteroides ovatus, Bifidobacterium bifidum, Anaerotruncus massiliensis, Clostridium aldenense, Sutterella wadsworthensis, Catabacter hongkongensis, Alistipes senegalensis,Ruminococcaceae sp. FBI00233, Alistipes shahii, Dielma fastidiosa, Eubacterium siraeum, Faecalibacterium prausnitzii, Turicibacter sanguinis, Eubacterium rectale, Bacteroides caccae, Methanobrevibacter smithii, Barnesiella intestinihominis, Alistipes onderdonkii and Methanobrevibacter smithii, or a functional equivalent thereof; b) Bifidobacterium adolescentis, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Bacteroides thetaiotaomicron, Coprococcus comes, Fusicatenibacter saccharivorans, Eggerthella lenta, Eubacterium eligens, Bacteroides xylanisolvens, Lactobacillus rogosae, Clostridium citroniae, Collinsella aerofaciens, Blautia obeum, Eggerthella lenta, Blautia wexlerae, Lachnoclostridium pacaense, Bacteroides vulgatus, Parabacteroides merdae, Dorea formicigenerans, Ruminococcus faecis, Roseburia hominis, Anaerostipes hadrus, Bifidobacterium adolescentis, Bifidobacterium pseudocatenulatum, Clostridium bolteae, Eisenbergiella tayi, Dorea longicatena, Eggerthella lenta,Bacteroides stercoris, Hungatella hathewayi and Bacteroides xylanisolvens, or a functional equivalent thereof; and / or Petition 870250081422, dated 09 / 10 / 2025, page 22 / 434 3 / 32 c) Alistipes putredinis, Dialister succinatiphilus, Akkermansia muciniphila, Ruminococcus bromii, Dialister invisus, Bacteroides massiliensis, Bilophila wadsworthia, Holdemanella biformis, Parasutterella excrementihominis, Alistipes sp. FBI00180, Bacteroides coprocola, Alistipes sp. FBI00238, Alistipes putredinis, Eubacterium xylanophilum, and Senegalmassilia anaerobia or a functional equivalent thereof., 3. Method according to claim 1, characterized in that the microbial consortium or a pharmaceutical composition thereof further comprises: a) FBI00004, FBI00012, FBI00015, FBI00018, FBI00019, FBI00021, FBI00038, FBI00040, FBI00046, FBI00061, FBI00066, FBI00075, FBI00077, FBI00080, FBI00081, FBI00085, FBI00092, FBI00097, FBI00099, FBI00112, FBI00132, FBI00137, FBI00140, FBI00149, FBI00151, FBI00176, FBI00189, FBI00197, FBI00208, FBI00212, FBI00224, FBI00226, FBI00229, FBI00233, FBI00235, FBI00237, FBI00243, FBI00244, FBI00258, FBI00260, FBI00263, FBI00270, FBI00273, FBI00277 and FBI00292, or a functional equivalent thereof; b) FBI00009, FBI00011, FBI00016, FBI00020, FBI00025, FBI00027, FBI00030, FBI00047, FBI00052, FBI00053, FBI00056, FBI00062, FBI00078, FBI00096, FBI00104, FBI00110, FBI00111, FBI00113, FBI00115, FBI00116, FBI00123, FBI00124, FBI00126, FBI00135, FBI00147, FBI00159, FBI00167, FBI00170, FBI00232, FBI00255 and FBI00271, or a functional equivalent thereof;and / or c) FBI00022, FBI00049, FBI00068, FBI00069, FBI00152, FBI00165, FBI00171, FBI00175, FBI00177, FBI00180, FBI00182, FBI00238, FBI00269, FBI00274 and FBI00281, or a functional equivalent thereof.

4. Method according to claim 2 or 3, characterized in that the microbial consortium or a pharmaceutical composition thereof further comprises a first strain of Oxalobacter formigenes or FBI00067.

5. Method, according to claim 4, characterized by the fact that the microbial consortium or a pharmaceutical composition thereof further comprises a second strain of Oxalobacter formigenes or FBI00133.

6. Method according to claim 5, characterized in that the microbial consortium or a pharmaceutical composition thereof further comprises a third strain of Oxalobacter formigenes or FBI00289.

7. Method, in accordance with a reivindicação 1, characterized by the fate de que o consórcio microbialo ou uma composizione farmacêutica do mesmo comprehensi: a) Clostridium citroniae, Bacteroides salyersiae, Blautia obeum, Parabacteroides merdae, Parabacteroides distasonis, Anaerostipes hadrus, Lachnospiraceae sp. FBI00033, Eubacterium eligens, Bifidobacterium dentium, Blautia wexlerae, Fusicatenibacter saccharivorans, Bacteroides nordii, Dorea formicigenerans, Dorea longicatena, Bacteroides stercorirosoris, Bifidobacterium longum, Bacteroides kribbi, Lachnospiraceae sp. FBI00071, Bacteroides thetaiotaomicron, Clostridium clostridioforme, Clostridium scindens, Roseburia hominis, Clostridium fessum, Coprococcus comes, Blautia faecis, Hungatella hathewayi, Bacteroides stercoris, Collinsella aerofaciens, Hungatella effluvii, Bifidobacterium adolescentis, Bifidobacterium catenulatum, Lactobacillus rogosae, Bacteroides faecis, Bacteroides finegoldii, Clostridiaceae sp. FBI00191, Ruminococcus faecis,Lachnoclostridium pacaense, Clostridium bolteae, Longicatena caecimuris, Eggerthella lenta, Blautia massiliensis, Bacteroides xylanisolvens, Bacteroides vulgatus, Megasphaera massiliensis, Butyricimonas faecihominis, Eisenbergiella tayi, Acidaminococcus intestini, Emergence timonensis, Bifidobacterium pseudocatenulatum, Eubacterium hallii, Anaerofustis stercorihominis, Eubacterium ventriosum, Blautia hydrogenotrophica and Lachnospiraceae sp. FBI00290 or a functional equivalent thereof; b) Acutalibacter timonensis, Alistipes onderdonkii, Bacteroides uniformis, Eubacterium rectale, Alistipes timonensis, Bacteroides kribbi, Coprococcus eutactus, Bilophila wadsworthia, Bacteroides caccae, Alistipes shahii, Parasutterella excrementihominis, Paraprevotella clara, Sutterella wadsworthensis, Sutterella massiliensis, Porphyromonas asaccharolytica, Ruminococcus bromii, Monoglobus pectinolyticus, Ruminococcaceae sp. FBI00097,Gordonibacter pamelaeae, Bacteroides uniformis, Gordonibacter pamelaeae, Bacteroides fragilis, Phascolarctobacterium faecium, Monoglobus pectinolyticus, Clostridium aldenense, Ruthenibacterium lactatiformans, Bacteroides ovatus, Bifidobacterium bifidum, Anaerotruncus massiliensis, Clostridium aldenense, Sutterella wadsworthensis, Catabacter hongkongensis, Alistipes senegalensis, Ruminococcaceae sp. FBI00233, Alistipes shahii, Dielma fastidiosa, Eubacterium siraeum, Faecalibacterium prausnitzii, Turicibacter sanguinis, Eubacterium rectale, Bacteroides caccae, Methanobrevibacter smithii, Barnesiella intestinihominis, Alistipes onderdonkii and Methanobrevibacter smithii, or a functional equivalent thereof; c) Bifidobacterium adolescentis, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Bacteroides thetaiotaomicron, Coprococcus comes, Fusicatenibacter saccharivorans, Eggerthella lenta, Eubacterium eligens, Bacteroides xylanisolvens, Lactobacillus rogosae, Clostridium citroniae,Collinsella aerofaciens, Blautia obeum, Eggerthella lenta, Blautia wexlerae, Lachnoclostridium pacaense, Bacteroides vulgatus, Parabacteroides merdae, Dorea formicigenerans, Ruminococcus faecis, Roseburia hominis, Anaerostipes hadrus, Bifidobacterium adolescentis, Bifidobacterium pseudocatenulatum, Clostridium bolteae, Eisenbergiella tayi, Dorea longicatena, Eggerthella lenta, Bacteroides stercoris, Hungatella hathewayi and Bacteroides xylanisolvens, or a functional equivalent thereof; and) Alistipes putredinis, Dialister succinatiphilus, Akkermansia muciniphila, Ruminococcus bromii, Dialister invisus, Bacteroides massiliensis, Bilophila wadsworthia, Holdemanella biformis, Parasutterella excrementihominis, Alistipes sp. FBI00180, Bacteroides coprocola, Alistipes sp. FBI00238, Alistipes putredinis, Eubacterium xylanophilum, e Senegalimassilia anaerobia ou um equivalent funcional do mesmo., 8. Method according to claim 1, characterized in that the microbial consortium or a pharmaceutical composition thereof comprises: Petition 870250081422, dated 10 / 09 / 2025, p. 25 / 434 6 / 32 a) FBI00001, FBI00002, FBI00010, FBI00013, FBI00029, FBI00032, FBI00033, FBI00034, FBI00043, FBI00044, FBI00048, FBI00050, FBI00051, FBI00057, FBI00059, FBI00060, FBI00070, FBI00071, FBI00076, FBI00079, FBI00087, FBI00093, FBI00102, FBI00109, FBI00117, FBI00120, FBI00125, FBI00127, FBI00128, FBI00145, FBI00162, FBI00174, FBI00184, FBI00190, FBI00191, FBI00194, FBI00198, FBI00199, FBI00200, FBI00201, FBI00205, FBI00206, FBI00211, FBI00220, FBI00221, FBI00236, FBI00245, FBI00248, FBI00251, FBI00254, FBI00267, FBI00278, FBI00288 and FBI00290, or a functional equivalent thereof;b) FBI00004, FBI00012, FBI00015, FBI00018, FBI00019, FBI00021, FBI00038, FBI00040, FBI00046, FBI00061, FBI00066, FBI00075, FBI00077, FBI00080, FBI00081, FBI00085, FBI00092, FBI00097, FBI00099, FBI00112, FBI00132, FBI00137, FBI00140, FBI00149, FBI00151, FBI00176, FBI00189, FBI00197, FBI00208, FBI00212, FBI00224, FBI00226, FBI00229, FBI00233, FBI00235, FBI00237, FBI00243, FBI00244, FBI00258, FBI00260, FBI00263, FBI00270, FBI00273, FBI00277 e FBI00292, ou um equivalente funcional do mesmo; c) FBI00009, FBI00011, FBI00016, FBI00020, FBI00025, FBI00027, FBI00030, FBI00047, FBI00052, FBI00053, FBI00056, FBI00062, FBI00078, FBI00096, FBI00104, FBI00110, FBI00111, FBI00113, FBI00115, FBI00116, FBI00123, FBI00124, FBI00126, FBI00135, FBI00147, FBI00159, FBI00167, FBI00170, FBI00232, FBI00255 e FBI00271, ou um equivalente funcional do mesmo;ed) FBI00022, FBI00049, FBI00068, FBI00069, FBI00152, FBI00165, FBI00171, FBI00175, FBI00177, FBI00180, FBI00182, FBI00238, FBI00269, FBI00274 and FBI00281, or a functional equivalent thereof.

9. Method according to claim 7, characterized in that the microbial consortium or a pharmaceutical composition thereof further comprises a first strain of Oxalobacter formigenes or FBI00067, a second strain of Oxalobacter formigenes or FBI00133 and a third strain of Petition 870250081422, dated 10 / 09 / 2025, page 26 / 434 7 / 32 Oxalobacter formigenes or FBI00289.

10. Method according to claim 8, characterized in that the microbial consortium or a pharmaceutical composition thereof further comprises a first strain of Oxalobacter formigenes or FBI00067, a second strain of Oxalobacter formigenes or FBI00133 and a third strain of Oxalobacter formigenes or FBI00289.

11. Method according to claim 1, characterized in that the microbial consortium or a pharmaceutical composition thereof is FB-001 or a functional equivalent thereof.

12. Method according to claim 1, characterized in that the microbial consortium or a pharmaceutical composition thereof is FB-003 or a functional equivalent thereof.

13. A method, according to any one of claims 1 to 12, characterized in that the microbial consortium or a pharmaceutical composition thereof increases the microbial diversity of the gastrointestinal tract.

14. A method according to any one of claims 1 to 13, characterized in that the microbial consortium or a pharmaceutical composition thereof increases short-chain fatty acids (SCFAs).

15. A method according to any one of claims 1 to 14, characterized in that the microbial consortium or a pharmaceutical composition thereof increases secondary bile acids.

16. A method, according to any one of claims 1 to 15, characterized in that the microbial consortium or a pharmaceutical composition thereof reduces bacterial pathogens in the gastrointestinal tract of the subject.

17. A method according to any one of claims 1 to 16, characterized in that the microbial consortium or a pharmaceutical composition thereof comprises between about 5 χ 109 and about 5 χ 1012 viable cells.

18. Method, according to any of the claims 1 Petition 870250081422, dated 10 / 09 / 2025, pp. 27 / 434 8 / 32 to 16, characterized in that the microbial consortium or a pharmaceutical composition thereof comprises between about 5 χ 109 and about 5 χ 1010 viable cells.

19. Method, according to any one of claims 1 to 16, characterized in that the microbial consortium or a pharmaceutical composition thereof comprises between about 5 χ 1010 and about 5 χ 1011 viable cells.

20. A method according to any one of claims 1 to 16, characterized in that the microbial consortium or a pharmaceutical composition thereof comprises between about 5 χ 1011 and about 5 χ 1012 viable cells.

21. A method according to any one of claims 1 to 20, characterized in that the microbial consortium or a pharmaceutical composition thereof comprises up to about 1011 viable cells.

22. A method, according to any one of claims 1 to 20, characterized in that the microbial consortium or a pharmaceutical composition thereof comprises up to about 1012 viable cells.

23. Method according to claim 1, wherein the method is characterized in that it comprises administering a loading dose and one or more maintenance doses.

24. Method according to claim 23, characterized in that the loading dose is administered for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days or 10 days.

25. Method according to claim 23 or 24, characterized in that the loading dose is administered for 2 to 3 days, 3 to 5 days, 4 to 6 days, or 5 to 7 days.

26. Method, according to any one of claims 23 to 25, characterized in that one or more maintenance doses are administered for at least 21 days after the last loading dose.

27. Method, according to any of the claims 1 Petition 870250081422, dated 10 / 09 / 2025, pp. 28 / 434 9 / 32 to 26, characterized in that it further comprises administering an antibacterial agent, an antiviral agent, an antifungal agent, an anti-inflammatory agent, an immunosuppressive agent and / or a prebiotic.

28. Method according to claim 27, characterized in that the antibacterial agent is selected from the group consisting of ciprofloxacin, levaquine, floxin, tequin, avelox, norflox, cephalexin, cefuroxime, cefadroxil, cefazolin, cephalothin, cefaclor, cefamandole, cefoxitin, cefprozil, ceftobiprole, amoxicillin, ampicillin, penicillin V, dicloxacillin, carbenicillin, vancomycin and methicillin, tetracycline, minocycline, oxytetracycline, doxycycline, ertapenem, doripenem, imipenem / cilastatin and meropenem.

29. Method according to claim 27, characterized in that the antiviral agent is selected from the group consisting of abacavir, acyclovir, adefovir, amprenavir, atazanavir, cidofovir, darunavir, delavirdine, didanosine, docosanol, efavirenz, elvitegravir, emtricitabine, enfuvirtide, etravirine, famciclovir, foscamet, fomivirsen, ganciclovir, indinavir, idoxuridine, lamivudine, lopinavir, maraviroc, mk-2048, nelfinavir, nevirapine, nirmatelvir, penciclovir, raltegravir, rilpivirine, ritonavir, saquinavir, stavudine, tenofovir, trifluridine, valacyclovir, valganciclovir, vidarabine, ibacitabine, amantadine, oseltamivir, rimantadine, tipranavir, zalcitabine, zanamivir and zidovudine.

30. Method according to claim 27, characterized in that the antifungal agent is selected from the group consisting of miconazole, ketoconazole, clotrimazole, econazole, omoconazole, bifonazole, butoconazole, fenticonazole, isoconazole, oxiconazole, sertaconazole, sulconazole, tioconazole, fluconazole, itraconazole, isavuconazole, ravuconazole, posaconazole, voriconazok, terconazole, albaconazole, abafungin, terbinafine, naftifine, butenafine, anidulafungin, caspofungin, micafungin, poligodial, benzoic acid, ciclopirox, tolnaftate, undecylenic acid, flucytosine or 5-fluorocytosine, griseofulvin and haloprogin.

31. Method according to claim 27, characterized in that the anti-inflammatory and / or immunosuppressive agent is selected from the group consisting of cyclophosphamide, mycophenolate mofetil, corticosteroids, mesalazine, mesalamine, sulfasalazine, sulfasalazine derivatives, cyclosporine A, mercaptopurine, azathiopurine, prednisone, methotrexate, antihistamines, glucocorticoids, epinephrine, theophylline, cromolyn sodium, antileukotrienes, anticholinergics, monoclonal anti-IgE, immunomodulatory peptides, small immunomodulatory molecules, immunomodulatory cytokines, immunomodulatory antibodies and vaccines.

32. Method according to claim 27, characterized in that the prebiotic is selected from the group consisting of amino acids, biotin, fructooligosaccharides, galactooligosaccharides, inulin, lactulose, mannanoligosaccharides, inulin enriched with oligofructose, oligofructose, oligodextrose, tagatose, trans-galactooligosaccharide and xylooligosaccharides.

33. A method, according to any one of claims 1 to 32, characterized in that the microbial consortium or its pharmaceutical composition is present in a food product.

34. Method for restoring the microbiome and / or recovering a healthy microbiome in a subject, characterized in that it comprises administering an effective amount of a microbial consortium or a pharmaceutical composition thereof comprising a) Clostridium citroniae, Bacteroides salyersiae, Blautia obeum, Parabacteroides merdae, Parabacteroides distasonis, Anaerostipes hadrus, Lachnospiraceae sp. FBI00033, Eubacterium eligens, Bifidobacterium dentium, Blautia wexlerae, Fusicatenibacter saccharivorans, Bacteroides nordii, Dorea formicigenerans, Dorea longicatena, Bacteroides stercorirosoris, Bifidobacterium longum, Bacteroides kribbi, Lachnospiraceae sp.FBI00071, Bacteroides thetaiotaomicron, Clostridium clostridioforme, Clostridium scindens, Roseburia hominis, Clostridium fessum, Coprococcus comes, Blautia faecis, Hungatella hathewayi, Bacteroides stercoris, Collinsella aerofaciens, Hungatella effluvii, Bifidobacterium adolescentis, Bifidobacterium catenulatum, Lactobacillus rogosae, Bacteroides faecis, Bacteroides finegoldii, Clostridiaceae sp. FBI00191, Ruminococcus faecis, Lachnoclostridium pacaense, Clostridium bolteae, Longicatena Petition 870250081422, of 10 / 09 / 2025, p. 30 / 434 11 / 32 caecimuris, Eggerthella lenta, Blautia massiliensis, Bacteroides xylanisolvens, Bacteroides vulgatus, Megasphaera massiliensis, Butyricimonas faecihominis, Eisenbergiella tayi, Acidaminococcus intestini, Emergence timonensis, Bifidobacterium pseudocatenulatum, Eubacterium hallii, Anaerofustis stercorihominis, Eubacterium ventriosum, Blautia hydrogenotrophica and Lachnospiraceae sp.FBI00290 ou um equivalente funcional do mesmo; ou b) FBI00001, FBI00002, FBI00010, FBI00013, FBI00029, FBI00032, FBI00033, FBI00034, FBI00043, FBI00044, FBI00048, FBI00050, FBI00051, FBI00057, FBI00059, FBI00060, FBI00070, FBI00071, FBI00076, FBI00079, FBI00087, FBI00093, FBI00102, FBI00109, FBI00117, FBI00120, FBI00125, FBI00127, FBI00128, FBI00145, FBI00162, FBI00174, FBI00184, FBI00190, FBI00191, FBI00194, FBI00198, FBI00199, FBI00200, FBI00201, FBI00205, FBI00206, FBI00211, FBI00220, FBI00221, FBI00236, FBI00245, FBI00248, FBI00251, FBI00254, FBI00267, FBI00278, FBI00288 e FBI00290, ou um equivalente funcional do mesmo.

35. Method, in accordance with a reivindicação 34, characterized by the fate of the microbial consortium or uma composition farmacêutica do mesmo comprehensi ainda: a) Acutalibacter timonensis, Alistipes onderdonkii, Bacteroides uniformis, Eubacterium rectale, Alistipes timonensis, Bacteroides kribbi, Coprococcus eutactus, Bilophila wadsworthia, Bacteroides caccae, Alistipes shahii, Parasutterella excrementihominis, Paraprevotella clara, Sutterella wadsworthensis, Sutterella massiliensis, Porphyromonas asaccharolytica, Ruminococcus bromii, Monoglobus pectinilyticus, Ruminococcaceae sp. FBI00097, Gordonibacter pamelaeae, Bacteroides uniformis, Gordonibacter pamelaeae, Bacteroides fragilis, Phascolarctobacterium faecium, Monoglobus pectinolyticus, Clostridium aldenense, Ruthenibacterium lactatiformans, Bacteroides ovatus, Bifidobacterium bifidum, Anaerotruncus massiliensis, Clostridium aldenense, Sutterella wadsworthensis, Catabacter hongkongensis, Alistipes senegalensis,Ruminococcaceae sp. FBI00233, Alistipes shahii, Dielma fastidiosa, Eubacterium siraeum, Faecalibacterium prausnitzii, Petition 870250081422, of 10 / 09 / 2025, pág. 31 / 434 12 / 32 Turicibacter sanguinis, Eubacterium rectale, Bacteroides caccae, Methanobrevibacter smithii, Barnesiella intestinihominis, Alistipes onderdonkii e Methanobrevibacter smithii, ou um equivalente funcional do mesmo; b) Bifidobacterium adolescentis, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Bacteroides thetaiotaomicron, Coprococcus comes, Fusicatenibacter saccharivorans, Eggerthella lenta, Eubacterium eligens, Bacteroides xylanisolvens, Lactobacillus rogosae, Clostridium citroniae, Collinsella aerofaciens, Blautia obeum, Eggerthella lenta, Blautia wexlerae, Lachnoclostridium pacaense, Bacteroides vulgatus, Parabacteroides merdae, Dorea formicigenerans, Ruminococcus faecis, Roseburia hominis, Anaerostipes hadrus, Bifidobacterium adolescentis, Bifidobacterium pseudocatenulatum, Clostridium bolteae,Eisenbergiella tayi, Dorea longicatena, Eggerthella lenta, Bacteroides stercoris, Hungatella hathewayi and Bacteroides xylanisolvens, or a functional equivalent thereof; and / or c) Alistipes putredinis, Dialister succinatiphilus, Akkermansia muciniphila, Ruminococcus bromii, Dialister invisus, Bacteroides massiliensis, Bilophila wadsworthia, Holdemanella biformis, Parasutterella excrementihominis, Alistipes sp. FBI00180, Bacteroides coprocola, Alistipes sp. FBI00238, Alistipes putredinis, Eubacterium xylanophilum, and Senegalmassilia anaerobia or a functional equivalent thereof., 36. Method according to claim 34, characterized in that the microbial consortium or a pharmaceutical composition thereof further comprises: a) FBI00004, FBI00012, FBI00015, FBI00018, FBI00019, FBI00021, FBI00038, FBI00040, FBI00046, FBI00061, FBI00066, FBI00075, FBI00077, FBI00080, FBI00081, FBI00085, FBI00092, FBI00097, FBI00099, FBI00112, FBI00132, FBI00137, FBI00140, FBI00149, FBI00151, FBI00176, FBI00189, FBI00197, FBI00208, FBI00212, FBI00224, FBI00226, FBI00229, FBI00233, FBI00235, FBI00237, FBI00243, FBI00244, FBI00258, FBI00260, FBI00263, FBI00270, FBI00273, FBI00277 and FBI00292, or a functional equivalent thereof; Petition 870250081422, dated 10 / 09 / 2025, p.32 / 434 13 / 32 b) FBI00009, FBI00011, FBI00016, FBI00020, FBI00025, FBI00027, FBI00030, FBI00047, FBI00052, FBI00053, FBI00056, FBI00062, FBI00078, FBI00096, FBI00104, FBI00110, FBI00111, FBI00113, FBI00115, FBI00116, FBI00123, FBI00124, FBI00126, FBI00135, FBI00147, FBI00159, FBI00167, FBI00170, FBI00232, FBI00255 and FBI00271, or a functional equivalent thereof; and / or c) FBI00022, FBI00049, FBI00068, FBI00069, FBI00152, FBI00165, FBI00171, FBI00175, FBI00177, FBI00180, FBI00182, FBI00238, FBI00269, FBI00274 and FBI00281, or a functional equivalent thereof.

37. Method according to claim 35 or 36, characterized in that the microbial consortium or a pharmaceutical composition thereof further comprises a first strain of Oxalobacter formigenes or FBI00067.

38. Method according to claim 37, characterized in that the microbial consortium or a pharmaceutical composition thereof further comprises a second strain of Oxalobacter formigenes or FBI00133.

39. Method according to claim 38, characterized in that the microbial consortium or a pharmaceutical composition thereof further comprises a third strain of Oxalobacter formigenes or FBI00289.

40. Method, de accordo com a reivindicação 34, characterized by pelo fato de que o consórcio microbialo ou uma composición farmacêutica do mesmo comprehensi: a) Clostridium citroniae, Bacteroides salyersiae, Blautia obeum, Parabacteroides merdae, Parabacteroides distasonis, Anaerostipes hadrus, Lachnospiraceae sp. FBI00033, Eubacterium eligens, Bifidobacterium dentium, Blautia wexlerae, Fusicatenibacter saccharivorans, Bacteroides nordii, Dorea formicigenerans, Dorea longicatena, Bacteroides stercorirosoris, Bifidobacterium longum, Bacteroides kribbi, Lachnospiraceae sp. FBI00071, Bacteroides thetaiotaomicron, Clostridium clostridioforme, Clostridium scindens, Roseburia hominis, Clostridium fessum, Coprococcus comes, Blautia faecis, Hungatella Petition 870250081422, of 10 / 09 / 2025, p.33 / 434 14 / 32 hathewayi, Bacteroides stercoris, Collinsella aerofaciens, Hungatella effluvii, Bifidobacterium adolescentis, Bifidobacterium catenulatum, Lactobacillus rogosae, Bacteroides faecis, Bacteroides finegoldii, Clostridiaceae sp. FBI00191, Ruminococcus faecis, Lachnoclostridium pacaense, Clostridium bolteae, Longicatena caecimuris, Eggerthella lenta, Blautia massiliensis, Bacteroides xylanisolvens, Bacteroides vulgatus, Megasphaera massiliensis, Butyricimonas faecihominis, Eisenbergiella tayi, Acidaminococcus intestini, Emergencia timonensis, Bifidobacterium pseudocatenulatum, Eubacterium hallii, Anaerofustis stercorihominis, Eubacterium ventriosum, Blautia hydrogenotrophica and Lachnospiraceae sp.FBI00290 or a functional equivalent thereof; b) Acutalibacter timonensis, Alistipes onderdonkii, Bacteroides uniformis, Eubacterium rectale, Alistipes timonensis, Bacteroides kribbi, Coprococcus eutactus, Bilophila wadsworthia, Bacteroides caccae, Alistipes shahii, Parasutterella excrementihominis, Paraprevotella clara, Sutterella wadsworthensis, Sutterella massiliensis, Porphyromonas asaccharolytica, Ruminococcus bromii, Monoglobus pectinolyticus, Ruminococcaceae sp. FBI00097, Gordonibacter pamelaeae, Bacteroides uniformis, Gordonibacter pamelaeae, Bacteroides fragilis, Phascolarctobacterium faecium, Monoglobus pectinolyticus, Clostridium aldenense, Ruthenibacterium lactatiformans, Bacteroides ovatus, Bifidobacterium bifidum, Anaerotruncus massiliensis, Clostridium aldenense, Sutterella wadsworthensis, Catabacter hongkongensis, Alistipes senegalensis, Ruminococcaceae sp.FBI00233, Alistipes shahii, Dielma fastidiosa, Eubacterium siraeum, Faecalibacterium prausnitzii, Turicibacter sanguinis, Eubacterium rectale, Bacteroides caccae, Methanobrevibacter smithii, Barnesiella intestinihominis, Alistipes onderdonkii and Methanobrevibacter smithii, or a functional equivalent thereof; c) Bifidobacterium adolescentis, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Bacteroides thetaiotaomicron, Coprococcus comes, Fusicatenibacter saccharivorans, Eggerthella lenta, Eubacterium eligens, Bacteroides xylanisolvens, Lactobacillus rogosae, Clostridium citoniae, Collinsella aerofaciens, Blautia obeum, Eggerthella lenta, Blautia wexlerae, Lachnoclostridium Petition 870250081422, of 09 / 10 / 2025, p.34 / 434 15 / 32 pacaense, Bacteroides vulgatus, Parabacteroides merdae, Dorea formicigenerans, Ruminococcus faecis, Roseburia hominis, Anaerostipes hadrus, Bifidobacterium adolescentis, Bifidobacterium pseudocatenulatum, Clostridium bolteae, Eisenbergiella tayi, Dorea longicatena, Eggerthella lenta, Bacteroides stercoris, Hungatella hathewayi and Bacteroides xylanisolvens, or a functional equivalent thereof; and) Alistipes putredinis, Dialister succinatiphilus, Akkermansia muciniphila, Ruminococcus bromii, Dialister invisus, Bacteroides massiliensis, Bilophila wadsworthia, Holdemanella biformis, Parasutterella excrementihominis, Alistipes sp. FBI00180, Bacteroides coprocola, Alistipes sp. FBI00238, Alistipes putredinis, Eubacterium xylanophilum, and Senegalmassilia anaerobia or a functional equivalent thereof.

41. Method according to claim 34, characterized in that the microbial consortium or a pharmaceutical composition thereof comprises: a) FBI00001, FBI00002, FBI00010, FBI00013, FBI00029, FBI00032, FBI00033, FBI00034, FBI00043, FBI00044, FBI00048, FBI00050, FBI00051, FBI00057, FBI00059, FBI00060, FBI00070, FBI00071, FBI00076, FBI00079, FBI00087, FBI00093, FBI00102, FBI00109, FBI00117, FBI00120, FBI00125, FBI00127, FBI00128, FBI00145, FBI00162, FBI00174, FBI00184, FBI00190, FBI00191, FBI00194, FBI00198, FBI00199, FBI00200, FBI00201, FBI00205, FBI00206, FBI00211, FBI00220, FBI00221, FBI00236, FBI00245, FBI00248, FBI00251, FBI00254, FBI00267, FBI00278, FBI00288 and FBI00290, or a functional equivalent thereof;b) FBI00004, FBI00012, FBI00015, FBI00018, FBI00019, FBI00021, FBI00038, FBI00040, FBI00046, FBI00061, FBI00066, FBI00075, FBI00077, FBI00080, FBI00081, FBI00085, FBI00092, FBI00097, FBI00099, FBI00112, FBI00132, FBI00137, FBI00140, FBI00149, FBI00151, FBI00176, FBI00189, FBI00197, FBI00208, FBI00212, FBI00224, FBI00226, FBI00229, FBI00233, FBI00235, FBI00237, FBI00243, FBI00244, FBI00258, FBI00260, FBI00263, FBI00270, FBI00273, FBI00277 and FBI00292, or a functional equivalent Petition 870250081422, dated 10 / 09 / 2025, pp. 35 / 434 16 / 32 thereof; c) FBI00009, FBI00011, FBI00016, FBI00020, FBI00025, FBI00027, FBI00030, FBI00047, FBI00052, FBI00053, FBI00056, FBI00062, FBI00078, FBI00096, FBI00104, FBI00110, FBI00111, FBI00113, FBI00115, FBI00116, FBI00123, FBI00124, FBI00126, FBI00135, FBI00147, FBI00159, FBI00167, FBI00170, FBI00232, FBI00255 and FBI00271, or a functional equivalent thereof;ed) FBI00022, FBI00049, FBI00068, FBI00069, FBI00152, FBI00165, FBI00171, FBI00175, FBI00177, FBI00180, FBI00182, FBI00238, FBI00269, FBI00274 and FBI00281, or a functional equivalent thereof.

42. Method according to claim 40, characterized in that the microbial consortium or a pharmaceutical composition thereof further comprises a first strain of Oxalobacter formigenes or FBI00067, a second strain of Oxalobacter formigenes or FBI00133 and a third strain of Oxalobacter formigenes or FBI00289.

43. Method according to claim 41, characterized in that the microbial consortium or a pharmaceutical composition thereof further comprises a first strain of Oxalobacter formigenes or FBI00067, a second strain of Oxalobacter formigenes or FBI00133 and a third strain of Oxalobacter formigenes or FBI00289.

44. Method according to claim 34, characterized in that the microbial consortium or a pharmaceutical composition thereof is FB-001 or a functional equivalent thereof.

45. Method according to claim 34, characterized in that the microbial consortium or a pharmaceutical composition thereof is FB-003 or a functional equivalent thereof.

46. ​​A method, according to any one of claims 34 to 45, characterized in that the microbial consortium or a pharmaceutical composition thereof increases the microbial diversity of the gastrointestinal tract.

47. Method, according to any of the claims 34 Petition 870250081422, dated 10 / 09 / 2025, pp. 36 / 434 17 / 32 to 46, characterized in that the microbial consortium or a pharmaceutical composition thereof increases short-chain fatty acids (SCFAs).

48. A method according to any one of claims 34 to 47, characterized in that the microbial consortium or a pharmaceutical composition thereof increases secondary bile acids.

49. A method, according to any one of claims 34 to 48, characterized in that the microbial consortium or a pharmaceutical composition thereof reduces bacterial pathogens in the gastrointestinal tract of the subject.

50. A method according to any one of claims 34 to 49, characterized in that the microbial consortium or a pharmaceutical composition thereof comprises between about 5 χ 109 and about 5 χ 1012 viable cells.

51. A method according to any one of claims 34 to 50, characterized in that the microbial consortium or a pharmaceutical composition thereof comprises between about 5 χ 109 and about 5 χ 1010 viable cells.

52. A method according to any one of claims 34 to 51, characterized in that the microbial consortium or a pharmaceutical composition thereof comprises between about 5 χ 1010 and about 5 χ 1011 viable cells.

53. A method according to any one of claims 34 to 52, characterized in that the microbial consortium or a pharmaceutical composition thereof comprises between about 5 χ 1011 and about 5 χ 1012 viable cells.

54. A method according to any one of claims 34 to 53, characterized in that the microbial consortium or a pharmaceutical composition thereof comprises up to about 1011 viable cells.

55. Method, according to any one of claims 34 to 53, characterized in that the microbial consortium or a pharmaceutical composition thereof comprises up to about 1012 viable cells.

56. Method according to claim 34, wherein the method is characterized in that it comprises administering a loading dose and one or more maintenance doses.

57. Method according to claim 56, characterized in that the loading dose is administered for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days or 10 days.

58. Method according to claim 56 or 57, characterized in that the loading dose is administered for 2 to 3 days, 3 to 5 days, 4 to 6 days, or 5 to 7 days.

59. Method, according to any one of claims 56 to 58, characterized in that one or more maintenance doses are administered for at least 21 days after the last loading dose.

60. A method according to any one of claims 34 to 59, characterized in that it further comprises administering an antibacterial agent, an antiviral agent, an antifungal agent, an anti-inflammatory agent, an immunosuppressive agent and / or a prebiotic.

61. Method according to claim 60, characterized in that the antibacterial agent is selected from the group consisting of ciprofloxacin, levaquine, floxin, tequin, avelox, norflox, cephalexin, cefuroxime, cefadroxil, cefazolin, cephalothin, cefaclor, cefamandole, cefoxitin, cefprozil, ceftobiprole, amoxicillin, ampicillin, penicillin V, dicloxacillin, carbenicillin, vancomycin and methicillin, tetracycline, minocycline, oxytetracycline, doxycycline, ertapenem, doripenem, imipenem / cilastatin and meropenem.

62. Method according to claim 60, characterized in that the antiviral agent is selected from the group consisting of abacavir, acyclovir, adefovir, amprenavir, atazanavir, cidofovir, darunavir, delavirdine, didanosine, docosanol, efavirenz, elvitegravir, emtricitabine, enfuvitide, etravirine, famciclovir, foscamet, fomivirsen, ganciclovir, indinavir, idoxuridine, lamivudine, lopinavir, maraviroc, mk-2048, nelfinavir, nevirapine, nirmatelvir, penciclovir, Petition 870250081422, dated 10 / 09 / 2025, p. 38 / 434 19 / 32 raltegravir, rilpivirine, ritonavir, saquinavir, stavudine, tenofovir, trifluridine, valaciclovir, valganciclovir, vidarabine, ibacitabine, amantadine, oseltamivir, rimantidine, tipranavir, zalcitabine, zanamivir and zidovudine.

63. Method according to claim 60, characterized in that the antifungal agent is selected from the group consisting of miconazole, ketoconazole, clotrimazole, econazole, omoconazole, bifonazole, butoconazole, fenticonazole, isoconazole, oxiconazole, sertaconazole, sulconazole, tioconazole, fluconazole, itraconazole, isavuconazole, ravuconazole, posaconazole, voriconazok, terconazole, albaconazole, abafungin, terbinafine, naftifine, butenafine, anidulafungin, caspofungin, micafungin, poligodial, benzoic acid, ciclopirox, tolnaftate, undecylenic acid, flucytosine or 5-fluorocytosine, griseofulvin and haloprogin.

64. Method according to claim 60, characterized in that the anti-inflammatory and / or immunosuppressive agent is selected from the group consisting of cyclophosphamide, mycophenolate mofetil, corticosteroids, mesalazine, mesalamine, sulfasalazine, sulfasalazine derivatives, cyclosporine A, mercaptopurine, azathiopurine, prednisone, methotrexate, antihistamines, glucocorticoids, epinephrine, theophylline, cromolyn sodium, antileukotrienes, anticholinergics, anti-monoclonal IgE, immunomodulatory peptides, small immunomodulatory molecules, immunomodulatory cytokines, immunomodulatory antibodies and vaccines.

65. Method according to claim 60, characterized in that the prebiotic is selected from the group consisting of amino acids, biotin, fructooligosaccharides, galactooligosaccharides, inulin, lactulose, mannanoligosaccharides, inulin enriched with oligofructose, oligofructose, oligodextrose, tagatose, trans-galactooligosaccharide and xylooligosaccharides.

66. A method according to any one of claims 34 to 65, characterized in that the microbial consortium or pharmaceutical composition thereof is present in a food product.

67. Method for treating a disease in a subject characterized by the fact that it comprises administering an effective amount of a microbial consortium or a pharmaceutical composition thereof comprising a) Clostridium citroniae, Bacteroides salyersiae, Blautia obeum, Parabacteroides merdae, Parabacteroides distasonis, Anaerostipes hadrus, Lachnospiraceae sp. FBI00033, Eubacterium eligens, Bifidobacterium dentium, Blautia wexlerae, Fusicatenibacter saccharivorans, Bacteroides nordii, Dorea formicigenerans, Dorea longicatena, Bacteroides stercorirosoris, Bifidobacterium longum, Bacteroides kribbi, Lachnospiraceae sp.FBI00071, Bacteroides thetaiotaomicron, Clostridium clostridioforme, Clostridium scindens, Roseburia hominis, Clostridium fessum, Coprococcus comes, Blautia faecis, Hungatella hathewayi, Bacteroides stercoris, Collinsella aerofaciens, Hungatella effluvii, Bifidobacterium adolescentis, Bifidobacterium catenulatum, Lactobacillus rogosae, Bacteroides faecis, Bacteroides finegoldii, Clostridiaceae sp. FBI00191, Ruminococcus faecis, Lachnoclostridium pacaense, Clostridium bolteae, Longicatena caecimuris, Eggerthella lenta, Blautia massiliensis, Bacteroides xylanisolvens, Bacteroides vulgatus, Megasphaera massiliensis, Butyricimonas faecihominis, Eisenbergiella tayi, Acidaminococcus intestini, Emergence timonensis, Bifidobacterium pseudocatenulatum, Eubacterium hallii, Anaerofustis stercorihominis, Eubacterium ventriosum, Blautia hydrogenotrophica and Lachnospiraceae sp.FBI00290 or a functional equivalent thereof; or b) FBI00001, FBI00002, FBI00010, FBI00013, FBI00029, FBI00032, FBI00033, FBI00034, FBI00043, FBI00044, FBI00048, FBI00050, FBI00051, FBI00057, FBI00059, FBI00060, FBI00070, FBI00071, FBI00076, FBI00079, FBI00087, FBI00093, FBI00102, FBI00109, FBI00117, FBI00120, FBI00125, FBI00127, FBI00128, FBI00145, FBI00162, FBI00174, FBI00184, FBI00190, FBI00191, FBI00194, FBI00198, FBI00199, FBI00200, FBI00201, FBI00205, FBI00206, FBI00211, FBI00220, FBI00221, FBI00236, FBI00245, FBI00248, FBI00251, FBI00254, FBI00267, FBI00278, FBI00288 and FBI00290, or a functional equivalent thereof; wherein the disease is irritable bowel syndrome, diarrhea, constipation, celiac disease and leaky gut syndrome, ulcerative colitis or Crohn's disease. Petition 870250081422, dated 10 / 09 / 2025, pp. 40 / 434 21 / 32 68. Method, in accordance with a reivindicação 67, characterized by the fate of que o microbial consorcio ou uma composizione farmacêutica do mesmo comprehensi ainda: a) Acutalibacter timonensis, Alistipes onderdonkii, Bacteroides uniformis, Eubacterium rectale, Alistipes timonensis, Bacteroides kribbi, Coprococcus eutactus, Bilophila wadsworthia, Bacteroides caccae, Alistipes shahii, Parasutterella excrementihominis, Paraprevotella clara, Sutterella wadsworthensis, Sutterella massiliensis, Porphyromonas asaccharolytica, Ruminococcus bromii, Monoglobus pectinilyticus, Ruminococcaceae sp. FBI00097, Gordonibacter pamelaeae, Bacteroides uniformis, Gordonibacter pamelaeae, Bacteroides fragilis, Phascolarctobacterium faecium, Monoglobus pectinolyticus, Clostridium aldenense, Ruthenibacterium lactatiformans, Bacteroides ovatus, Bifidobacterium bifidum, Anaerotruncus massiliensis, Clostridium aldenense, Sutterella wadsworthensis, Catabacter hongkongensis, Alistipes senegalensis,Ruminococcaceae sp. FBI00233, Alistipes shahii, Dielma fastidiosa, Eubacterium siraeum, Faecalibacterium prausnitzii, Turicibacter sanguinis, Eubacterium rectale, Bacteroides caccae, Methanobrevibacter smithii, Barnesiella intestinihominis, Alistipes onderdonkii and Methanobrevibacter smithii, or a functional equivalent thereof; b) Bifidobacterium adolescentis, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Bacteroides thetaiotaomicron, Coprococcus comes, Fusicatenibacter saccharivorans, Eggerthella lenta, Eubacterium eligens, Bacteroides xylanisolvens, Lactobacillus rogosae, Clostridium citroniae, Collinsella aerofaciens, Blautia obeum, Eggerthella lenta, Blautia wexlerae, Lachnoclostridium pacaense, Bacteroides vulgatus, Parabacteroides merdae, Dorea formicigenerans, Ruminococcus faecis, Roseburia hominis, Anaerostipes hadrus, Bifidobacterium adolescentis, Bifidobacterium pseudocatenulatum, Clostridium bolteae, Eisenbergiella tayi, Dorea longicatena, Eggerthella lenta,Bacteroides stercoris, Hungatella hathewayi and Bacteroides xylanisolvens, or a functional equivalent thereof; and / or c) Alistipes putredinis, Dialister succinatiphilus, Akkermansia muciniphila, Ruminococcus bromii, Dialister invisus, Bacteroides massiliensis, Bilophila wadsworthia, Holdemanella biformis, Parasutterella excrementihominis, Alistipes sp. FBI00180, Bacteroides coprocola, Alistipes sp. FBI00238, Alistipes putredinis, Eubacterium xylanophilum, and Senegalmassilia anaerobia or a functional equivalent thereof., 69. Method according to claim 67, characterized in that the microbial consortium or a pharmaceutical composition thereof further comprises: a) FBI00004, FBI00012, FBI00015, FBI00018, FBI00019, FBI00021, FBI00038, FBI00040, FBI00046, FBI00061, FBI00066, FBI00075, FBI00077, FBI00080, FBI00081, FBI00085, FBI00092, FBI00097, FBI00099, FBI00112, FBI00132, FBI00137, FBI00140, FBI00149, FBI00151, FBI00176, FBI00189, FBI00197, FBI00208, FBI00212, FBI00224, FBI00226, FBI00229, FBI00233, FBI00235, FBI00237, FBI00243, FBI00244, FBI00258, FBI00260, FBI00263, FBI00270, FBI00273, FBI00277 and FBI00292, or a functional equivalent thereof; b) FBI00009, FBI00011, FBI00016, FBI00020, FBI00025, FBI00027, FBI00030, FBI00047, FBI00052, FBI00053, FBI00056, FBI00062, FBI00078, FBI00096, FBI00104, FBI00110, FBI00111, FBI00113, FBI00115, FBI00116, FBI00123, FBI00124, FBI00126, FBI00135, FBI00147, FBI00159, FBI00167, FBI00170, FBI00232, FBI00255 and FBI00271, or a functional equivalent thereof;and / or c) FBI00022, FBI00049, FBI00068, FBI00069, FBI00152, FBI00165, FBI00171, FBI00175, FBI00177, FBI00180, FBI00182, FBI00238, FBI00269, FBI00274 and FBI00281, or a functional equivalent thereof.

70. Method according to claim 68 or 69, characterized in that the microbial consortium or a pharmaceutical composition thereof further comprises a first strain of Oxalobacter formigenes or FBI00067.

71. Method, according to claim 70, characterized in Petition 870250081422, dated 10 / 09 / 2025, page 42 / 434 23 / 32 by the fact that the microbial consortium or a pharmaceutical composition thereof further comprises a second strain of Oxalobacter formigenes or FBI00133.

72. Method according to claim 71, characterized in that the microbial consortium or a pharmaceutical composition thereof further comprises a third strain of Oxalobacter formigenes or FBI00289.

73. Method, de accordo com a reivindicação 67, characterized pelo fato de que o consórcio microbialo ou uma composizione farmacêutica do mesmo comprehensi: a) Clostridium citroniae, Bacteroides salyersiae, Blautia obeum, Parabacteroides merdae, Parabacteroides distasonis, Anaerostipes hadrus, Lachnospiraceae sp. FBI00033, Eubacterium eligens, Bifidobacterium dentium, Blautia wexlerae, Fusicatenibacter saccharivorans, Bacteroides nordii, Dorea formicigenerans, Dorea longicatena, Bacteroides stercorirosoris, Bifidobacterium longum, Bacteroides kribbi, Lachnospiraceae sp. FBI00071, Bacteroides thetaiotaomicron, Clostridium clostridioforme, Clostridium scindens, Roseburia hominis, Clostridium fessum, Coprococcus comes, Blautia faecis, Hungatella hathewayi, Bacteroides stercoris, Collinsella aerofaciens, Hungatella effluvii, Bifidobacterium adolescentis, Bifidobacterium catenulatum, Lactobacillus rogosae, Bacteroides faecis, Bacteroides finegoldii, Clostridiaceae sp. FBI00191,Ruminococcus faecis, Lachnoclostridium pacaense, Clostridium bolteae, Longicatena caecimuris, Eggerthella lenta, Blautia massiliensis, Bacteroides xylanisolvens, Bacteroides vulgatus, Megasphaera massiliensis, Butyricimonas faecihominis, Eisenbergiella tayi, Acidaminococcus intestini, Emergence timonensis, Bifidobacterium pseudocatenulatum, Eubacterium hallii, Anaerofustis stercorihominis, Eubacterium ventriosum, Blautia hydrogenotrophica and Lachnospiraceae sp. FBI00290 or a functional equivalent thereof; b) Acutalibacter timonensis, Alistipes onderdonkii, Bacteroides uniformis, Eubacterium rectale, Alistipes timonensis, Bacteroides kribbi, Coprococcus eutactus, Bilophila wadsworthia, Bacteroides caccae, Alistipes shahii, Parasutterella excrementihominis, Paraprevotella clara, Sutterella wadsworthensis, Sutterella massiliensis, Porphyromonas asaccharolytica, Ruminococcus bromii, Monoglobus pectinolyticus,Ruminococcaceae sp. FBI00097, Gordonibacter pamelaeae, Bacteroides uniformis, Gordonibacter pamelaeae, Bacteroides fragilis, Phascolarctobacterium faecium, Monoglobus pectinolyticus, Clostridium aldenense, Ruthenibacterium lactatiformans, Bacteroides ovatus, Bifidobacterium bifidum, Anaerotruncus massiliensis, Clostridium aldenense, Sutterella wadsworthensis, Catabacter hongkongensis, Alistipes senegalensis, Ruminococcaceae sp. FBI00233, Alistipes shahii, Dielma fastidiosa, Eubacterium siraeum, Faecalibacterium prausnitzii, Turicibacter sanguinis, Eubacterium rectale, Bacteroides caccae, Methanobrevibacter smithii, Barnesiella intestinihominis, Alistipes onderdonkii and Methanobrevibacter smithii, or a functional equivalent thereof; c) Bifidobacterium adolescentis, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Bacteroides thetaiotaomicron, Coprococcus comes, Fusicatenibacter saccharivorans, Eggerthella lenta, Eubacterium eligens, Bacteroides xylanisolvens,Lactobacillus rogosae, Clostridium citoniae, Collinsella aerofaciens, Blautia obeum, Eggerthella lenta, Blautia wexlerae, Lachnoclostridium pacaense, Bacteroides vulgatus, Parabacteroides merdae, Dorea formicigenerans, Ruminococcus faecis, Roseburia hominis, Anaerostipes hadrus, Bifidobacterium adolescentis, Bifidobacterium pseudocatenulatum, Clostridium bolteae, Eisenbergiella tayi, Dorea longicatena, Eggerthella lenta, Bacteroides stercoris, Hungatella hathewayi and Bacteroides xylanisolvens, or a functional equivalent thereof; and) Alistipes putredinis, Dialister succinatiphilus, Akkermansia muciniphila, Ruminococcus bromii, Dialister invisus, Bacteroides massiliensis, Bilophila wadsworthia, Holdemanella biformis, Parasutterella excrementihominis, Alistipes sp. FBI00180, Bacteroides coprocola, Alistipes sp. FBI00238, Alistipes putredinis, Eubacterium xylanophilum, e Senegalimassilia anaerobia ou um equivalent funcional do mesmo., 74. Method according to claim 67, characterized in that the microbial consortium or a pharmaceutical composition thereof comprises: Petition 870250081422, dated 10 / 09 / 2025, p. 44 / 434 25 / 32 a) FBI00001, FBI00002, FBI00010, FBI00013, FBI00029, FBI00032, FBI00033, FBI00034, FBI00043, FBI00044, FBI00048, FBI00050, FBI00051, FBI00057, FBI00059, FBI00060, FBI00070, FBI00071, FBI00076, FBI00079, FBI00087, FBI00093, FBI00102, FBI00109, FBI00117, FBI00120, FBI00125, FBI00127, FBI00128, FBI00145, FBI00162, FBI00174, FBI00184, FBI00190, FBI00191, FBI00194, FBI00198, FBI00199, FBI00200, FBI00201, FBI00205, FBI00206, FBI00211, FBI00220, FBI00221, FBI00236, FBI00245, FBI00248, FBI00251, FBI00254, FBI00267, FBI00278, FBI00288 and FBI00290, or a functional equivalent thereof;b) FBI00004, FBI00012, FBI00015, FBI00018, FBI00019, FBI00021, FBI00038, FBI00040, FBI00046, FBI00061, FBI00066, FBI00075, FBI00077, FBI00080, FBI00081, FBI00085, FBI00092, FBI00097, FBI00099, FBI00112, FBI00132, FBI00137, FBI00140, FBI00149, FBI00151, FBI00176, FBI00189, FBI00197, FBI00208, FBI00212, FBI00224, FBI00226, FBI00229, FBI00233, FBI00235, FBI00237, FBI00243, FBI00244, FBI00258, FBI00260, FBI00263, FBI00270, FBI00273, FBI00277 e FBI00292, ou um equivalente funcional do mesmo; c) FBI00009, FBI00011, FBI00016, FBI00020, FBI00025, FBI00027, FBI00030, FBI00047, FBI00052, FBI00053, FBI00056, FBI00062, FBI00078, FBI00096, FBI00104, FBI00110, FBI00111, FBI00113, FBI00115, FBI00116, FBI00123, FBI00124, FBI00126, FBI00135, FBI00147, FBI00159, FBI00167, FBI00170, FBI00232, FBI00255 e FBI00271, ou um equivalente funcional do mesmo;ed) FBI00022, FBI00049, FBI00068, FBI00069, FBI00152, FBI00165, FBI00171, FBI00175, FBI00177, FBI00180, FBI00182, FBI00238, FBI00269, FBI00274 and FBI00281, or a functional equivalent thereof.

75. Method according to claim 73, characterized in that the microbial consortium or a pharmaceutical composition thereof further comprises a first strain of Oxalobacter formigenes or FBI00067, a second strain of Oxalobacter formigenes or FBI00133 and a third strain of Petition 870250081422, dated 10 / 09 / 2025, page 45 / 434 26 / 32 Oxalobacter formigenes or FBI00289.

76. Method according to claim 74, characterized in that the microbial consortium or a pharmaceutical composition thereof further comprises a first strain of Oxalobacter formigenes or FBI00067, a second strain of Oxalobacter formigenes or FBI00133 and a third strain of Oxalobacter formigenes or FBI00289.

77. Method according to claim 67, characterized in that the microbial consortium or a pharmaceutical composition thereof is FB-001 or a functional equivalent thereof.

78. Method according to claim 67, characterized in that the microbial consortium or a pharmaceutical composition thereof is FB-003 or a functional equivalent thereof.

79. A method, according to any one of claims 67 to 78, characterized in that the microbial consortium or a pharmaceutical composition thereof increases the microbial diversity of the gastrointestinal tract.

80. A method according to any one of claims 67 to 79, characterized in that the microbial consortium or a pharmaceutical composition thereof increases short-chain fatty acids (SCFAs).

81. A method according to any one of claims 67 to 80, characterized in that the microbial consortium or a pharmaceutical composition thereof increases secondary bile acids.

82. A method, according to any one of claims 67 to 81, characterized in that the microbial consortium or a pharmaceutical composition thereof reduces bacterial pathogens in the gastrointestinal tract of the subject.

83. Method, according to any one of claims 67 to 82, characterized in that the microbial consortium or a pharmaceutical composition thereof comprises between about 5 χ 109 and about 5 χ 1012 viable cells.

84. Method, according to any of the claims 67 Petition 870250081422, dated 10 / 09 / 2025, pp. 46 / 434 27 / 32 to 83, characterized in that the microbial consortium or a pharmaceutical composition thereof comprises between about 5 χ 109 and about 5 χ 1010 viable cells.

85. A method according to any one of claims 67 to 84, characterized in that the microbial consortium or a pharmaceutical composition thereof comprises between about 5 χ 1010 and about 5 χ 1011 viable cells.

86. Method, according to any one of claims 67 to 85, characterized in that the microbial consortium or a pharmaceutical composition thereof comprises between about 5 χ 1011 and about 5 χ 1012 viable cells.

87. A method according to any one of claims 67 to 86, characterized in that the microbial consortium or a pharmaceutical composition thereof comprises up to about 1011 viable cells.

88. A method according to any one of claims 67 to 86, characterized in that the microbial consortium or a pharmaceutical composition thereof comprises up to about 1012 viable cells.

89. Method according to claim 67, wherein the method is characterized in that it comprises administering a loading dose and one or more maintenance doses.

90. Method according to claim 89, characterized in that the loading dose is administered for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days or 10 days.

91. Method according to claim 89 or 90, characterized in that the loading dose is administered for 2 to 3 days, 3 to 5 days, 4 to 6 days, or 5 to 7 days.

92. Method, according to any one of claims 67 to 91, characterized in that one or more maintenance doses are administered for at least 21 days after the last loading dose.

93. Method, according to any of the claims 67 Petition 870250081422, dated 10 / 09 / 2025, pp. 47 / 434 28 / 32 to 92, characterized in that it further comprises administering an antibacterial agent, an antiviral agent, an antifungal agent, an anti-inflammatory agent, an immunosuppressive agent and / or a prebiotic.

94. Method according to claim 93, characterized in that the antibacterial agent is selected from the group consisting of ciprofloxacin, levaquine, floxin, tequin, avelox, norflox, cephalexin, cefuroxime, cefadroxil, cefazolin, cephalothin, cefaclor, cefamandole, cefoxitin, cefprozil, ceftobiprole, amoxicillin, ampicillin, penicillin V, dicloxacillin, carbenicillin, vancomycin and methicillin, tetracycline, minocycline, oxytetracycline, doxycycline, ertapenem, doripenem, imipenem / cilastatin and meropenem.

95. Method according to claim 93, characterized in that the antiviral agent is selected from the group consisting of abacavir, acyclovir, adefovir, amprenavir, atazanavir, cidofovir, darunavir, delavirdine, didanosine, docosanol, efavirenz, elvitegravir, emtricitabine, enfuvirtide, etravirine, famciclovir, foscamet, fomivirsen, ganciclovir, indinavir, idoxuridine, lamivudine, lopinavir, maraviroc, mk-2048, nelfinavir, nevirapine, nirmatelvir, penciclovir, raltegravir, rilpivirine, ritonavir, saquinavir, stavudine, tenofovir, trifluridine, valacyclovir, valganciclovir, vidarabine, ibacitabine, amantadine, oseltamivir, rimantadine, tipranavir, zalcitabine, zanamivir and zidovudine.

96. Method according to claim 93, characterized in that the antifungal agent is selected from the group consisting of miconazole, ketoconazole, clotrimazole, econazole, omoconazole, bifonazole, butoconazole, fenticonazole, isoconazole, oxiconazole, sertaconazole, sulconazole, tioconazole, fluconazole, itraconazole, isavuconazole, ravuconazole, posaconazole, voriconazok, terconazole, albaconazole, abafungin, terbinafine, naftifine, butenafine, anidulafungin, caspofungin, micafungin, poligodial, benzoic acid, ciclopirox, tolnaftate, undecylenic acid, flucytosine or 5-fluorocytosine, griseofulvin and haloprogin.

97. Method according to claim 93, characterized in that the anti-inflammatory and / or immunosuppressive agent is selected from the group consisting of cyclophosphamide, mycophenolate mofetil, corticosteroids, mesalazine, mesalamine, sulfasalazine, sulfasalazine derivatives, cyclosporine A, mercaptopurine, azathiopurine, prednisone, methotrexate, antihistamines, glucocorticoids, epinephrine, theophylline, cromolyn sodium, antileukotrienes, anticholinergics, monoclonal anti-IgE, immunomodulatory peptides, small immunomodulatory molecules, immunomodulatory cytokines, immunomodulatory antibodies and vaccines.

98. Method according to claim 93, characterized in that the prebiotic is selected from the group consisting of amino acids, biotin, fructooligosaccharides, galactooligosaccharides, inulin, lactulose, mannanoligosaccharides, inulin enriched with oligofructose, oligofructose, oligodextrose, tagatose, trans-galactooligosaccharide and xylooligosaccharides.

99. A method according to any one of claims 67 to 98, characterized in that the microbial consortium or pharmaceutical composition thereof is present in a food product.

100. Method, according to any one of claims 67 to 99, characterized in that it further comprises diagnosing IBD in the subject prior to administration of the microbial consortium or pharmaceutical composition thereof.

101. Method for reducing dysbiosis in a subject, wherein the method is characterized by the fact that it comprises administering to a patient a therapeutically effective amount of a pharmaceutical composition comprising consortia to reduce dysbiosis of the gastrointestinal tract in the patient.

102. Method, according to claim 101, characterized in that the reduction of dysbiosis comprises grafting of microbes from the Consortia, increased microbial diversity of the gastrointestinal tract, increased short-chain fatty acids (SCFAs), increased secondary bile acids and / or decreased bacterial pathogens.

103. Method, according to claim 101 or 102, characterized in that the Consortia are FB-001 or a functional equivalent. Petition 870250081422, dated 10 / 09 / 2025, pp. 49 / 434 30 / 32 thereof.

104. Method according to claim 101 or 102, characterized in that the Consortia are FB-003 or a functional equivalent thereof.

105. Method for restoring the microbiome in a patient, wherein the method is characterized by the fact that it comprises administering to the patient a therapeutically effective amount of a pharmaceutical composition comprising Consortia.

106. Method, according to claim 105, characterized in that the microbiome restoration comprises the grafting of microbes from the Consortia, increased microbial diversity of the gastrointestinal tract, increased short-chain fatty acids (SCFAs), increased secondary bile acids and / or decreased bacterial pathogens.

107. Method according to claim 105 or 106, characterized in that the Consortia are FB-001 or a functional equivalent thereof.

108. Method according to claim 105 or 106, characterized in that the Consortia are FB-003 or a functional equivalent thereof.

109. A method for increasing the recovery of a healthy microbiome in a patient after a dysbiosis-inducing event, wherein the method is characterized by the fact that it comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising Consortia.

110. Method, according to claim 109, characterized in that the recovery of a healthy microbiome comprises the grafting of microbes from the Consortia, an increase in microbial diversity of the gastrointestinal tract, an increase in short-chain fatty acids (SCFAs), an increase in secondary bile acids and / or a decrease in bacterial pathogens.

111. Method according to claim 109 or 110, Petition 870250081422, dated 10 / 09 / 2025, pp. 50 / 434 31 / 32 characterized in that the Consortia are FB-001 or a functional equivalent thereof.

112. Method, according to claim 109 or 110, characterized in that the Consortia are FB-003 or a functional equivalent thereof.

113. A method, according to any one of claims 109 to 112, characterized in that the dysbiosis-inducing event is treatment with one or more antibiotics, an infectious disease, or an underlying disease.

114. Method according to claim 113, characterized in that the underlying disease is IBD, colitis, ulcerative colitis or Crohn's disease.

115. Composition for treating or reducing the severity of at least one symptom of a gastrointestinal disease, disorder or condition associated with dysbiosis in a patient, wherein the composition is characterized by the fact that it comprises consortia in an amount effective to populate and optionally graft into a gastrointestinal tract in the patient.

116. Composition according to claim 115, characterized in that the gastrointestinal disease is selected from the group consisting of IBD, colitis, ulcerative colitis and Crohn's disease.

117. Composition, according to any one of claims 115 and 116, characterized in that dysbiosis is associated with a decrease in microbial diversity of the gastrointestinal tract, a decrease in short-chain fatty acids (SCFAs), a decrease in secondary bile acids and / or an increase in bacterial pathogens.

118. Method, according to any one of claims 115 to 117, characterized in that the Consortia are FB-001 or a functional equivalent thereof.

119. Method, according to any one of claims 115 to 117, characterized in that the Consortia are FB-003 or a functional equivalent thereof. Petition 870250081422, dated 10 / 09 / 2025, p. 51 / 434 32 / 32 120. A method for treating or reducing the severity of at least one symptom of a gastrointestinal disease associated with dysbiosis, characterized by the fact that it comprises administering an effective amount of a pharmaceutical composition comprising consortia.

121. Method according to claim 120, characterized in that the Consortia are FB-001 or a functional equivalent thereof.

122. Method according to claim 120, characterized in that the Consortia are FB-003 or a functional equivalent thereof.

123. Composition characterized by the fact that it comprises FB-003 or a functional equivalent thereof.

124. A method characterized by the fact that it is for producing FB003 or a functional equivalent thereof.

125. Method for treating IBD, colitis, ulcerative colitis or Crohn's disease characterized by the fact that it is through the administration of consortia.

126. Method according to claim 125, characterized in that the Consortia are FB-003 or FB-001.

127. Method for reducing symptoms associated with IBD, colitis, ulcerative colitis or Crohn's disease, characterized in that it is by administering Consortia.

128. Method according to claim 127, characterized in that the Consortia are FB-003 or FB-001.

129. Any method or composition described herein.

Images